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To my wife Poonam, 
 
Who had the patience to live 7000 miles away from me 
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1. INTRODUCTION 
1.1 Role of C/EBPa  in myelopoiesis 
 
The past two decades have witnessed significant advances in our 
understanding of the cellular physiology and molecular regulation of 
hematopoiesis and myelopoiesis.  The transcription factors involved in 
hematopoiesis and myelopoiesis are depicted in models 1 and 2.(Zhu 
and Emerson, 2002)  
 
C/EBPa is one of the most important transcription factors which are 
involved in granulocytic differentiation.  It belongs to 
CCAAT/enhancer binding proteins (C/EBPs) family of transcription 
factors that all contain a highly conserved basic-leucine zipper domain 
at the carboxyl terminus, which is involved in dimerisation and DNA 
binding.  The genes for six C/EBP members have been cloned to date 
from several species and have been given systematic nomenclature in 
which members are designated as C/EBP followed by a Greek letter 
indicating the chronological order of their discovery (C/EBPa-
z).(Akira et al., 1990; Poli et al., 1990; Descombes et al., 1990; Chang 
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et al., 1990; Roman et al., 1990; Cao et al., 1991; Williams et al., 1991; 
Ron and Habener, 1992; Ramji and Foka, 2002) 
 
 
 
 
 
 
Model 1: Transcriptional regulation of early hematopoietic stem cell development. 
HSCs, as one progeny of hemangioblasts or hemogenic endothelium, are faced with the 
cell fate choice either to self-renew or to differentiate into committed common lymphoid 
or common myeloid hematopoietic precursors.  The transcription factors involved in 
each development direction are depicted. 
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Model 2: Transcriptional regulation of common myeloid precursor (CMP) 
commitment.  CMPs differentiate into either common precursors for granulocytic and 
monocytic lineages (GMPs) or common precursors for both erythroid and 
megakaryocytic lineages (EMPs).  A separate, possible, pathway leading to eosinophils 
is depicted by dotted line.  Dual expression of PU.1 and GATA-1 leads HSCs to 
CMPs, but then dominant expression of PU.1 is restricted to GMPs, while unopposed 
GATA-1 expression directs differentiation to EMPs. 
 
 
The transcription factor C/EBPa plays a pivotal role during 
differentiation in various cell types, including adipocytes and 
hepatocytes, lung and ovary cells.(Cao et al., 1991; Lin and Lane, 
1994; Scott et al., 1992; Flodby et al., 1996; Zhang et al., 1997; 
Radomska et al., 1998; Umek et al., 1991)  In hematopoiesis, C/EBPa 
is expressed in myeloid cells.(Scott et al., 1992; Radomska et al., 
1998)  It has been previously demonstrated that the expression of 
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C/EBPa correlates with the commitment of multipotential precursors 
to the myeloid lineage, and is specifically upregulated during 
neutrophilic differentiation.(Scott et al., 1992; Radomska et al., 1998)  
Furthermore, conditional expression of C/EBPa  is sufficient to induce 
neutrophilic differentiation (Radomska et al., 1998; Wang et al., 1999) 
and can block the monocytic differentiation program in bipotential 
myeloid precursors (model 3).(Radomska et al., 1998)  
expression vector
C/EBPa
Zn
U937 cells
promoter C/EBPa
Conditional expression of C/EBPa is sufficient for induction 
of granulocytic differentiation of bipotential U937 cells
U937 with inducible C/EBPa
- Zn + Zn
Radomska H et al., MCB 1998
 
 
Model 3: Overexpression of C/EBPa leads to granulocytic differentiation. 
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In addition, it has been reported that mice with targeted disruption of 
C/EBPa gene demonstrate a selective block in differentiation of 
neutrophils while all the other blood cell types are present in normal 
proportions.  C/EBPa knockout mice do not express granulocyte 
colony-stimulating factor receptor (GCSFr) that is a critical target gene 
of C/EBPa.  As a result, multipotential myeloid progenitors from the 
mutant fetal liver are unable to respond to granulocyte colony-
stimulating factor (GCSF) signaling, although they are capable of 
forming granulocyte-macrophage and macrophage colonies in 
methylcellulose in response to other growth factors (model 4).(Zhang 
et al., 1997)  
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Absence of neutrophil development and 
G-CSF receptor expression in C/EBPa deficient mice
+/- -/-
C/EBPa
Zhang DE et al., PNAS 1997
C/EBPa
 
 
 
Model 4: Knockout mice of C/EBPa lack neutrophils and GCSFr expression. 
 
 
Some critical target genes of C/EBPa have been identified and studied 
which are summarized in the following paragraph.  C/EBPa protein 
activates the CD14 promoter and mediates TGF-b signaling during 
monocyte development.  CD14 is a monocyte/macrophage 
differentiation marker that is strongly upregulated during monocyte cell 
differentiation.  When myelomonoblastic U937 cells are treated with 
vitamin D3 and TGF-b, they differentiate toward monocytic cells.  
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And there is a specific increase in the DNA binding and the expression 
of C/EBPa and C/EBPb during U937 monocytic cell 
differentiation.(Zhang et al., 1997)   
 
C/EBPa, -b, and –d are also regulated during granulocyte lineage 
specification.  Ford et al. have shown that C/EBPa exists as multiple 
phosphorylated forms in the nucleus of both multipotential and 
granulocyte-committed hematopoietic progenitor cells.  C/EBPb is 
unphosphorylated and cytoplasmically localized in multipotential cells 
but exist as a phosphorylated nuclear enhancer-binding activity in 
granulocyte-committed cells.  GCSF-induced granulocytic 
differentiation of multipotential progenitor cells results in activation of 
C/EBPd expression and functional recruitment of C/EBPd and 
C/EBPb to the nucleus.  These results suggest that the C-EBP family 
members are critical regulators of myeloperoxidase gene expression 
and are consistent with a model in which a temporal exchange of 
C/EBP isoforms at the myeloperoxidase enhancer mediates the 
transition from a primed state in multipotential cells to a 
transcriptionally active configuration in promyelocytes.(Ford et al., 
1996)   
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Another target gene of C/EBPa in granulopoiesis is c-Myc.  Johansen 
et al. identified c-Myc as a C/EBPa negatively regulated gene. They 
mapped an E2F binding site in the c-Myc promoter as the cis-acting 
element critical for C/EBPa negative regulation.  The identification of 
c-Myc as a C/EBPa target gene is interesting, as it has been previously 
shown that down-regulation of c-Myc can induce myeloid 
differentiation.  In this study they show that stable expression of c-
Myc from an exogenous promoter not responsive to C/EBPa-
mediated down-regulation forces myeloblasts to remain in an 
undifferentiated state.  Therefore, C/EBPa negative regulation of c-
Myc is critical for allowing early myeloid precursors to enter a 
differentiation pathway. This is the first report to demonstrate that 
C/EBPa directly affects the level of c-Myc expression and, thus, the 
decision of myeloid blasts to enter into the granulocytic differentiation 
pathway.(Johansen et al., 2001) 
  
In 32D cl3 myeloblasts cell line the activation of C/EBPa-ER 
construct by estradiol was sufficient to induce terminal granulocytic 
differentiation and a G1 cell cycle arrest despite the continued presence 
of IL-3.  bcr-ablp210 prevented 32D cl3 cell differentiation, including 
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myeloperoxidase (MPO) RNA induction.  Inhibition of cell growth by 
C/EBPaWT-ER occurred even in 32D cl3 cells expressing bcr-ablp210 
or in Ba/F3 B-lymphoid cells, without induction of differentiation.  Cell 
cycle arrest was associated with elevated p27Kip1 levels.  PU.1 protein 
and mRNA levels were increased within 4 hours of C/EBPaWT-ER 
activation, in 32D cl3, 32D-bcr-ablp210, or Ba/F3 cells, and induction of 
PU.1 mRNA occurred even in the presence of cycloheximide, 
suggesting that induction of endogenous PU.1 RNA by C/EBPaWT-
ER results from direct transcriptional activation.  However, activation 
of PU.1-ER(T) in 32D cl3 cells induced MPO RNA but not cell cycle 
arrest or terminal differentiation.  Thus, in 32D cl3 myeloblasts, 
C/EBPa acts independent of G-CSF signals, directly upstream of 
PU.1, and upstream of p27Kip1 and additional factors to limit 
proliferation and induce granulocytic  differentiation.(Wang et al., 1999)   
In a recent study it has been shown that C/EBPs are required for 
granulopoiesis independent of their induction of the GCSFr.(Wang Qf 
and Friedman, 2002) 
Induction of granulocytic differentiation by C/EBPa seems to be by  2 
pathways.  In a cell line derived from the fetal liver of C/EBPa-
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deficient animals it has been shown that conditional expression of 
C/EBPa induces the C/EBP family members C/EBPb and C/EBPe 
and subsequently granulocytic differentiation.  Similar results were 
obtained when C/EBPa-/- cells were stimulated with the cytokines 
interleukin-3 and granulocyte-macrophage colony-stimulating factor, 
but not with all-trans retinoic acid, supporting a model of at least 2 
pathways leading to the differentiation of myeloid progenitors to 
granulocytes and implicating induction of other C/EBP family members 
in granulopoiesis.(Zhang et al., 2002) 
 
C/EBP family members are also involved in protein-protein interaction 
and thereby regulate myeloid specific promoters.  C/EBPa and 
GCSFr signals cooperate to induce the myeloperoxidase and 
neutrophil elastase genes(Wang et al., 2001), C/EBP and AML1 
synergistically activate the macrophage colony-stimulating factor 
receptor (MCSFr) promoter(Zhang et al., 1996), C/EBP, c-Myb, and 
PU.1 cooperate to regulate the neutrophil elastase 
promoter(Oelgeschlager et al., 1996), PU.1 and C/EBPa regulate the 
granulocyte colony-stimulating factor receptor (GCSFr) promoter in 
myeloid cells(Smith et al., 1996), and transcriptional coactivator ASC-
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2 functionally interact with C/EBPa in granulocytic differentiation of 
HL60 promyelocytic cells.(Hong et al., 2001) 
 
1.2 Disruption of C/EBPa  activity and expression in acute 
myeloid leukemia 
 
We recently reported that dominant-negative mutations of C/EBPa are 
found in patients with acute myeloid leukemia of subtypes M1 and M2.  
Heterozygous mutations were found in CEBPA gene in ten patients 
with acute myeloid leukemia (AML), five mutations in the amino 
terminus truncated the full-length protein, but did not affect a 30-kD 
protein initiated further downstream.  The mutant proteins block wild-
type C/EBPa DNA binding and transactivation of granulocyte target 
genes in a dominant-negative manner, and fails to induce granulocytic 
differentiation.  It is the first report of CEBPA gene mutations in 
human neoplasia, and such mutations are likely to induce the 
differentiation block found in AML.(Pabst et al., 2001a) 
Furthermore, AML1-ETO associates with C/EBPa, inhibits C/EBPa 
dependent transcription of myeloid cell specific rat defensin NP-3 
promoter, and blocks granulocytic differentiation.(Westendorf et al., 
1998)  We also demonstrated that the leukemic fusion protein AML1-
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ETO, found in patients with acute myeloid leukemia with translocation 
t(8;21), downregulates both C/EBPa expression and function in 
primary AML patient samples.(Pabst et al., 2001b)  
 
The hallmark of acute promyelocytic leukemia (APL) is the 
translocation t(15;17) resulting in PML-RARa fusion protein and a 
block in promyelocytic differentiation.  In primary human APL cells 
PML-RARa physically interacts with C/EBPa at diagnosis and 
relapse, but not after All-Trans-Retinoic-Acid (ATRA)-induced 
remission.  Similar results are observed in primary leukemic cells from 
transgenic mouse models of APL along with marked reduction of 
C/EBPa DNA binding.  Conditional expression of PML-RARa 
abrogates C/EBPa DNA binding, transactivation, and differentiation of 
myeloid cell lines in an ATRA-reversible manner.  These studies 
implicate disruption of C/EBPa DNA binding and function by physical 
interaction with PML-RARa as an additional mechanism contributing 
to the block in differentiation following expression of the fusion protein 
in APL (Tracey Lodie and Dan Tenen, pers. communication). 
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These studies point to the crucial role of C/EBPa in both normal 
myeloid differentiation and leukemogenesis.  However, how the 
transcriptional activity of C/EBPa is regulated both in normal 
myelopoiesis as well as in leukemogenesis, is not fully understood.   
 
In a recent review on transcriptional regulation of granulocyte and 
monocyte development, Friedman, A.D. has set the perspective for the 
future research in this field.  Many questions remain unanswered 
regarding the transcriptional regulation of granulocyte and monocyte 
development.  With respect to the cellular basis for initiating these 
lineages: What are the relative contributions of granulocyte/monocyte 
and B-cell/monocyte progenitors to mature blood elements; do some 
granulocyte or monocyte progenitors develop directly from pluripotent 
stem cells; how irreversible are commitment decisions?  With respect 
to gene regulation: Are there additional important transcriptional 
regulators of myeloid genes remaining to be uncovered via detailed 
investigation of promoters and distal enhancers; are there lineage-
restricted co-activators or co-repressors which participate in lineage 
specification?  With respect to key transcription factors, further 
clarification of the regulatory network is needed: Which factor or 
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factors specify each lineage and at what levels of expression; can 
family members act redundantly in this regard; what additional 
cooperative mechanisms operate among transcriptional regulators; 
what roles do cytokine receptor signaling and transcription factor 
modifications play in each commitment decision and in each step of 
lineage progression?  The answers to these questions will provide 
general lessons in developmental biology and insights into 
leukemogenesis and will enable applications in clinical hematology, 
oncology, and gene therapy.(Friedman, 2002) 
 
1.3 Ras signaling in leukemia and myeloid differentiation 
 
The Ras family of proteins are GTP-dependent molecular switches that 
are essential for cell growth and differentiation.(Mccormick, 1995; 
Gutkind, 1998)  Ras exerts its effect on cell growth mainly via ETS 
(Wasylyk et al., 1994) and AP-1 (Johnson et al., 1996) transcription 
factors.  For example, cells with a null mutation in the c-jun gene and 
expressing oncogenic Ras lack many characteristics of Ras 
transformation,(Johnson et al., 1993) and dominant negative mutants of 
ETS-1, ETS-2, or PU.1 containing only the DNA binding domain 
inhibit Ras activation of transcription and revert Ras-transformed 
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cells.(Wasylyk et al., 1994)  In particular, Ras has been demonstrated 
to play an important role in myeloid differentiation.  Macrophage 
differentiation and M-CSF-dependent survival are altered in transgenic 
mice that express dominant suppressors of Ras signaling,(Jin et al., 
1995) while a number of hematopoietic cell lines undergo spontaneous 
myeloid differentiation in response to expression of activated Ras.(Hibi 
et al., 1993; Maher et al., 1996)  In addition, M-CSF, granulocyte-
macrophage colony-stimulating factor, or interleukin-3-induced 
monocytopoiesis of CD34+ cells  is inhibited by N-Ras antisense 
oligonucleotides.(Skorski et al., 1992) 
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1.4 Aim of this research 
Since Ras signaling and the transcription factor C/EBPa both play 
important roles in myeloid differentiation, we wanted to know how 
C/EBPa is activated during granulocytic differentiation? We 
hypothesized that Ras might be involved in the activation of C/EBPa.  
Experiments were designed to test if Ras changes the DNA binding, 
expression level or post-translational modification of C/EBPa?  After 
finding that Ras phosphorylates C/EBPa, we designed experiments to 
map the site of phosphorylation in C/EBPa and to point mutate this 
site to check the relevance of this phosphorylation.  Then we wanted 
to discover the biological relevance of C/EBPa phosphorylation in 
myeloid cells by retroviral transduction of C/EBPa WT and 
C/EBPaS248A mutant and look for its effect on granulocytic 
differentiation. 
Here we demonstrate data which suggest a model where Ras signaling 
phosphorylates C/EBPa on serine 248 of the transactivation domain 
resulting in an enhancement of the ability of C/EBPa to transactivate 
the G-CSF receptor promoter, which contributes to the induction of 
granulocytic differentiation.  
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2.  MATERIALS AND METHODS 
2.1 Cell lines and cell culture 
 
Human kidney 293T cells and human kidney 293E1A cells (kindly 
provided by John Blenis, Harvard Medical School, Boston, MA) were 
maintained in Dulbecco's modified Eagle's medium supplemented with 
10% fetal calf serum (HyClone).  32D cl3 cells were maintained in 
phenol-red free Iscove’s Modified Dulbecco’s Medium with 10% 
heat-inactivated fetal bovine serum (HI-FBS), 1 ng/ml IL-3 (R&D 
Systems, Minneapolis, MN), and penicillin-streptomycin.  jCRE cells 
were maintained in Dulbecco’s Modified Eagle’s Medium with 10% 
heat-inactivated calf serum and pen/strep.  pBabePuro-
C/EBPa(S248A)-ER was introduced into jCRE cells using 
lipofectamine (Gibco, BRL, Gaithersburg, MD), and a pool of 
resistant cells was isolated using 2 mg/ml puromycin.  32D cl3 cells 
were co-cultured in the presence of 4 mg/ml Polybrene with jCRE-
S248A cells which had been irradiated to 3000 cGy.  After 48 hrs, the 
32D cl3 cells were placed in 96 well dishes with 2 mg/ml puromycin, 
and individual subclones were isolated.  Estradiol was employed at 1 
mM.  Morphology was assessed by Wright’s-Giemsa staining of 
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cytospins.  pBabePuro-C/EBPa(S248A)-ER was constructed by 
ligating an MluI/NcoI segment containing the mutant serine in place of 
the identical fragment in pBabePuro-C/EBPaWT-ER.  Total cellular 
extracts were subjected to Western blotting using antiserum 
recognizing human ERa (Santa Cruz Biotechnology, San Diego, CA) 
or murine actin (Sigma, St. Louis, MO). 
 
2.2 Reporter constructs and expression plasmids 
 
The human G-CSF receptor promoter ranging from bp -74 to +67 with 
respect to the major transcription start site (Smith et al., 1996) was 
subcloned in the firefly luciferase vector pXP2.(Nordeen, 1988) pTK 
driven by 2 C/EBP sites (p(C/EBP)2TK) is a dimer of the C/EBP site 
from the granulocyte colony-stimulating factor receptor promoter from 
bp -57 to bp –37 with respect to the major transcription start 
site,(Smith et al., 1996) subcloned into pTK81luc, a pXP2-based 
luciferase construct with a TATA box only as a minimal 
promoter.(Nordeen, 1988)  As an internal control plasmid for co-
transfection assays, the pRL-null construct driving a Renilla luciferase 
gene (Promega, Madison, WI) was used as described before.(Behre et 
al., 1997; Behre et al., 1999; Zhang et al., 1999)  The expression 
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plasmids pMSV-C/EBPa (rat), various deletion mutants of C/EBPa in 
pMSV, pMSV-C/EBP b, pMSV-C/EBPd, GAL4-C/EBPa area 1-9, 
GAL4-C/EBPa area 1-3, and GAL4-C/EBPa area 4-9 and a minimal 
promoter with GAL4 DNA binding sites were described 
previously.(Friedman and McKnight, 1990; Oelgeschlager et al., 1996)  
Human activated pMT3-Ha-Ras(L61)  was kindly provided by Larry 
Feig (Tufts University, Boston, MA).(Feig and Cooper, 1988; Feig, 
1988) 
  
To introduce a serine to alanine point mutation at serine 248 of rat 
C/EBPa we performed PCR site-directed mutagenesis.  pcDNA3-
C/EBPa was digested with NotI and the resulting small fragment of 
C/EBPa coding sequence was used as template DNA for all PCR 
reactions.  Four primers were synthesized to amplify two internal 
fragments from wild type C/EBPa: sense primer A (bp 693-716) and 
antisense primer B (bp 763-740) were used to amplify fragment AB 
(size 70 bp), sense primer C (bp 740-763) and antisense primer D (bp 
860-837) were used to amplify fragment CD (size 120 bp).  The point 
mutation at bp 742 was introduced in primer B (from A to C) and 
primer C (from T to G) which overlap with each other (bp 740-763), 
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so the resulting fragments will have the mutation incorporated during 
the PCR amplification.  The fragments AB and CD were purified from 
agarose gels using a Gel Extraction kit (Qiagen).  These 2 fragments 
were joined by elongation reaction using primers A and D to create a 
single fragment AD (size 167 bp) which would have the serine 248 
(TCG) mutated to alanine (GCG).  This fragment was then digested 
with SfiI and XcmI and subcloned into SfiI/XcmI digested wild type 
pcDNA3-C/EBPa.  The point mutation was confirmed by DNA 
sequencing and was used in subsequent experiments. 
 
2.3 Transient transfections using LipofectAMINE Plus and 
reporter assays for firefly and Renilla luciferase 
 
293T cells or 293E1A cells were transfected using LipofectAMINE 
Plus (Life Technologies) as described by the manufacturer.  Firefly 
luciferase activities from the constructs pG-CSFR, pXP2, pGal4-DBD, 
pTK and p(C/EBP)2TK and Renilla luciferase activity from the internal 
control plasmid pRL-null were determined 24 h after the initiation of the 
transfection protocols using the Dual-Luciferase Reporter Assay 
System (Promega).  Firefly luciferase activities were normalized to the 
Renilla luciferase values of pRL-null.   Results are given as means ± 
 24
S.E.M. of at least six independent experiments.  The following DNA 
concentrations of the reporter constructs and expression plasmids 
were used for LipofectAMINE Plus transfections: 0.1 µg of pG-
CSFR, pXP2, pGal4-DBD, pTK and p(C/EBP)2TK; 0.01 µg of the 
internal control plasmid pRL-null; 0.1 µg of the expression plasmids 
for C/EBPa and C/EBPa mutants and for Ras(L61), and the same 
concentrations of the empty expression vectors were used as controls, 
respectively.  In the transfections without cotransfection of Ras, the 
empty vector pMT3 was included instead of pMT3-Ras.  pRL-null 
was chosen as internal control plasmid, because it was not 
transactivated by Ras in 293T cells.(Behre et al., 1999; Behre et al., 
1997) 
 
2.4 Electrophoretic mobility shift assay 
 
Electrophoretic mobility shift assays were performed as described 
previously.(Behre et al., 1999; Zhang et al., 1999)  As a positive 
control for C/EBPa binding, a double-stranded C/EBPa probe from 
the human G-CSF receptor promoter (bp -57 to bp –37 with respect 
to the major transcription start site, as described before in Fig. 9 of 
reference (Smith et al., 1996) OligoA: AAG GTG TTG CAA TCC 
 25
CCA GC and OligoB: GCT GGG GAT TGC AAC ACC TT) was 
labeled with Klenow polymerase and [32P]dCTP (NEN Life Science 
Products) and incubated with 0.1 µg/µl of double-stranded poly(dI-
dC) (Sigma) with 1 µl of in vitro translated C/EBPa.  In some 
experiments, a 100-fold molar excess of the C/EBP probe was added 
as specific unlabeled competitor.  C/EBPa antibody (14AA) was used 
for Gel Supershift (Cat # SC61 X, Santa Cruz Biotechnology). 
 
2.5 In vivo labeling and phosphopeptide mapping 
 
To detect changes in the phosphorylation pattern of C/EBPa upon 
stimulation with activated Ras in vivo, 0.5 µg of pcDNA3-C/EBPa or 
pcDNA3-C/EBPaS248A either with or without 0.25 µg of activated 
Ras(L61), was transfected into 293T cells using LipofectAMINE Plus 
(Life Technologies).  3 h after transfection, cells were starved in serum-
free Dulbecco's modified Eagle's medium.  After 18 h, cells were 
placed into serum-free and phosphate-free Dulbecco's modified Eagle's 
medium (Life Technologies) for 30 min before they were metabolically 
labeled with [32P]orthophosphate (2.5 mCi/ml).  After 4 h, cells were 
lysed with radioimmunoprecipitation assay buffer containing 1% 
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Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 5 
mM EDTA, and 50 mM Tris (pH 8.0) and supplemented with 
aprotinin, phenylmethylsulfonyl fluoride, pepstatin A, leupeptin, 
antipain, and chymostatin as protease inhibitors (Sigma) and sodium 
pyrophosphate, sodium fluoride, and sodium vanadate as phosphatase 
inhibitors (Sigma).  In parallel plates, 0.3 µg of the G-CSF receptor 
promoter was co-transfected in 293T cells, and luciferase activities 
were determined to ensure that Ras signaling enhances the 
transactivation function of C/EBPa in the particular experiment used in 
in vivo labeling and subsequent phosphopeptide mapping. 
 
C/EBPa was isolated by immunoprecipitation from the lysates using a 
rabbit polyclonal antibody against C/EBPa (Santa Cruz), washed four 
times with radioimmunoprecipitation assay buffer, separated on 10% 
SDS-polyacrylamide gels, and transferred to nitrocellulose (Bio-Rad) 
for phosphopeptide mapping.  After transfer, the C/EBPa protein 
bands was excised.  To determine the phosphorylated protein residues 
of C/EBPa, C/EBPa  protein bands were digested with 1-chloro-3-
tosylamido-7-amino-2-heptanone-treated chymotrypsin (Worthington) 
and endoproteinase Glu-C (V8 protease) (Boehringer Mannheim) and 
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processed for phosphopeptide mapping as described 
previously.(Boyle et al., 1991) 
 
2.6 Western blot assay 
 
24 h after the start of transfection, cells were lysed with 
radioimmunoprecipitation assay buffer.  Equal amounts of total protein 
were separated on 10% SDS-polyacrylamide gels and transferred to 
Immobilon-P membrane (Millipore).  Membranes were incubated with 
anti-C/EBPa antibody (Santa Cruz Biotechnology) or b-tubulin 
antibody as an internal control (catalog no. 1111876; Boehringer 
Mannheim) for 60 min and then with Protein A-horseradish peroxidase 
conjugate (Amersham) for 45 min.  Signals were detected with ECL 
Western blotting detection reagents (Amersham).  In parallel plates, the 
G-CSF receptor promoter construct was co-transfected, and luciferase 
activities were determined to ensure that Ras enhances the 
transactivation function of C/EBPa  in the particular experiment used 
for Western blot analysis of C/EBPa expression and that the 
transfection efficacy was the same (less than 10% difference between 
plates) in the particular experiment. Differences in protein expression 
were quantitated by ImageQuant software (Molecular Dynamics).  
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C/EBPa antibody (14AA, SC61) was used for Western Blot and 
immunoprecipitation (Santa Cruz Biotechnology).  
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3.  RESULTS 
3.1 Ras enhances the ability of C/EBPa  to transactivate 
the G-CSF receptor promoter 
 
Since Ras and the regulation of the G-CSF receptor by C/EBPa are 
both important for myeloid development, we asked whether activated 
Ras enhances the ability of C/EBPa to transactivate the G-CSF 
receptor promoter.  293T cells were transfected with a plasmid 
containing the human G-CSF receptor promoter (Smith et al., 1996) 
cloned upstream of the luciferase reporter gene along with expression 
plasmids for C/EBPa and Ras, and reporter gene expression was 
determined 24 h post-transfection.  Transfection of a Ras expression 
construct significantly enhanced the ability of C/EBPa to transactivate 
the G-CSF receptor promoter (Fig. 1A).  The same effect was 
demonstrated in myeloid U937 cells as well (Fig. 1D).  Western blot 
analysis for C/EBPa expression demonstrated that activated Ras did 
not change the expression level of cotransfected C/EBPa (Fig. 1B).  
Thus, Ras signaling directly acts on the transactivation capacity of 
C/EBPa.  The cooperation of activated Ras with C/EBPa is therefore 
important for G-CSF receptor promoter activity. 
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Fig. 1. Ras signaling enhances the transcriptional activity of C/EBPa .  A) Ras 
enhances the ability of C/EBPa to transactivate the G-CSF receptor promoter.  293T 
cells were transfected with the human G-CSF receptor promoter or the human G-CSF 
receptor promoter with mutated C/EBP sites and with the expression plasmids pMSV-
C/EBPa (or empty vector pMSV) and pMT3-Ha-Ras(L61) (or empty vector pMT3).  
Luciferase activities were determined 24 h after transient transfection with 
LipofectAMINE Plus and normalized to the activities of the internal control plasmid 
pRL-null.  B) Western blot analysis for C/EBPa expression (and b-tubulin expression 
as loading control) for the experiment shown in Fig. 1A. 
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3.2 Ras enhances the ability of C/EBPa , but not of C/EBP b  or 
C/EBPd  to transactivate a minimal TK promoter driven by 
C/EBP DNA binding sites 
 
We next asked the following questions: (a) whether the binding of 
C/EBPa to DNA was necessary for its activation by Ras and (b) 
whether a C/EBPa binding site alone was sufficient for the Ras-
enhanced C/EBPa activation.  We observed enhanced C/EBPa 
transactivation mediated by activated Ras using a reporter construct 
containing two C/EBPa binding sites cloned upstream of a minimal TK 
promoter (p(C/EBP)TK) (Fig. 1C).  In control experiments, no effect 
of Ras on C/EBPa activity was observed when the minimal TK 
promoter without C/EBPa binding sites was used (Fig. 1C).  These 
data indicate that C/EBPa binding to DNA is necessary for its 
activation by Ras signaling and that C/EBPa binding sites are sufficient 
to mediate this  effect.  Interestingly, the activation of C/EBPa by Ras 
was specific for C/EBPa, because C/EBP b und C/EBPd were not 
activated functionally by Ras signaling in this assay (Fig. 1C). 
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Fig. 1. C)  Ras enhances the ability of C/EBPa , but not of C/EBP b  or C/EBPd  
to transactivate a minimal TK promoter driven by C/EBP DNA binding sites 
(p(C/EBP)2TK).  293T cells were transfected with p(C/EBP)TK or a minimal TK 
promoter without C/EBP sites (pTK) and with the expression plasmids pMSV-
C/EBPa, pMSV-C/EBP b , pMSV-C/EBPd, and/or pMT3-Ha-Ras(L61) or the 
respective empty vectors.  Luciferase activities were determined 24 h after transient 
transfection with LipofectAMINE Plus. 
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Fig. 1.  D) Ras enhances the ability of C/EBPa to transactivate a minimal TK promoter 
driven by C/EBP DNA binding sites (p(C/EBP)2TK) in myeloid U937 cells. 
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3.3 Ras enhances the transactivation function of a fusion 
protein containing a Gal4 DNA binding domain and a 
discrete region of the C/EBPa  transactivation domain 
 
To map the domain of C/EBPa activated by Ras signaling, we used a 
minimal promoter with GAL4 DNA binding sites and the expression 
plasmids GAL4-C/EBPa area 1-9, GAL4-C/EBPa area 1-3, and 
GAL4-C/EBPa area 4-9, using the previously described nomenclature 
(Smith et al., 1996) to refer to the areas of the C/EBPa transactivation 
domain (Fig. 2A and 2B).  Ras signaling activated a fusion protein 
containing the GAL4-DNA binding domain and the transactivation 
domains of C/EBPa (areas 1 to 9).  Areas 1-3 of C/EBPa were not 
activated by Ras, whereas areas 4-9 were still activated by Ras.  These 
data indicate that Ras signaling might act on areas 4-9 of the 
transactivation domain of C/EBPa. 
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Fig. 2. Ras signaling activates C/EBPa  via the C/EBPa  transactivation domain. 
A)  Ras enhances the transactivation function of a fusion protein containing a Gal4 DNA 
binding domain and areas 4-9 of the C/EBPa transactivation domain.  293E1A cells 
were transfected with a minimal promoter driven by GAL4 DNA binding sites and the 
expression plasmids GAL4-C/EBPa area 1-9, GAL4-C/EBPa area 1-3, GAL4-
C/EBPa area 4-9, and/or pMT3-Ha-Ras(L61).  B)  Model of the construct GAL4-
C/EBPa area 1-9 used in Fig. 2A. The transactivation domain of C/EBPa (area 1 to 9) 
is fused to the DNA binding domain of GAL4. 
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3.4 Ras does not change DNA binding of C/EBPa  
 
To further elucidate the mechanism by which Ras augments the 
transcriptional activity of C/EBPa, we performed experiments to 
determine whether the activation of C/EBPa by Ras was partly due to 
an increase of C/EBPa DNA binding.  An electrophoretic  mobility-
shift assay was performed using a bp -57 to bp -37 G-CSF receptor 
promoter fragment containing its C/EBPa  binding site.(Smith et al., 
1996)  A positive control, in vitro translated C/EBPa, specifically 
bound to this probe as expected (Fig. 2C).  Nuclear extracts from 
293T cells transfected with the expression plasmid of C/EBPa with or 
without cotransfection of Ras bound to the oligo as well, and most 
importantly, Ras signaling did not change the DNA binding of 
C/EBPa.  To rule out different C/EBPa protein contents of the 
nuclear extracts used, we performed a Western blot analysis for 
C/EBPa expression (Fig. 2D) which showed equal loading of 
C/EBPa.  These results indicate that binding of C/EBPa to the G-CSF 
receptor promoter DNA is not enhanced by Ras signaling. 
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Fig. 2. C)  Ras does not change DNA binding of C/EBPa .  A C/EBPa probe from 
the human G-CSF receptor promoter (bp -57 to bp –37 with respect to the major 
transcription start site, as described before in Fig. 9 of reference(Smith et al., 1996)) 
was used in an electrophoretic mobility shift assay of C/EBPa DNA binding.  As 
controls, probes were incubated with no added protein, 1 µl of in vitro translated 
C/EBPa), in vitro translated C/EBPa plus a 100-fold molar excess of self-unlabeled 
competitor, in vitro translated C/EBPa plus an antibody against C/EBPa for supershift 
(Santa Cruz), or in vitro translated C/EBPa plus a 100-fold molar excess of self-
unlabeled competitor plus an antibody against C/EBPa for supershift (Santa Cruz).  On 
the right site, with nuclear extracts from 293T cells transfected with the expression 
plasmids pMSV-C/EBPa and pMT3-Ha-Ras(L61).  D)  Western blot analysis for 
C/EBPa expression (and b-tubulin expression as loading control) for the experiment 
shown in Fig. 2C. 
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3.5 Ras activates C/EBPa  via area 9 of the C/EBPa  TAD  
 
To further localize the site of C/EBPa activated by Ras signaling and 
to fine map this site, we used various deletion mutants of C/EBPa 
(Fig. 3A, 3B).  C/EBPaD4-9 was minimally activated and C/EBPaD9 
was not activated by Ras.  All other mutants were activated at least 2-
fold by Ras.  These studies demonstrate that Ras acts on area 9 of 
C/EBPa.  
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Fig. 3. Ras signaling requires serine 248 of C/EBPa  to activate C/EBPa . A) 
Ras activates C/EBPa via area 9 of the C/EBPa transactivation domain.  293T cells 
were transfected with p(C/EBP)2TK and the expression plasmids pMSV-C/EBPa or 
various deletions mutants of C/EBPa and/or pMT3-Ha-Ras(L61).  B) Model of 
C/EBPa, with areas 1-9 containing the first and second transactivation domain (TAD1 
and TAD2) and the DNA binding domain of C/EBPa with the basic region and leucine 
zipper region. 
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3.6 Ras activates C/EBPa  wild type but not a S248A 
mutant 
 
Because Ras acts on area 9 of the transactivation domain of C/EBPa, 
we focused on this area for generating C/EBPa point mutants.  Area 9 
of C/EBPa is depicted in detail in Figure 4B.  There is only one 
potential phosphorylation consensus site in area 9, at serine 248.  We 
generated a point mutant of C/EBPa at serine 248 by mutation to 
alanine (C/EBPaS248A).  C/EBPa wild type and C/EBPaS248A both 
transactivated the G-CSF receptor promoter 20 fold.  While Ras 
signaling enhanced wild type C/EBPa transactivation capacity from 20 
fold to 60 fold, Ras only enhanced the transactivation capacity of the 
S248A mutant of C/EBPa from 20 to 29 fold (Fig. 3C).  These results 
suggest that Ras signaling might act on serine 248 of the C/EBPa 
transactivation domain to enhance C/EBPa transcriptional activity. 
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Fig. 3. C)  Ras activates C/EBPa wild type, but not a serine 248 to alanine mutant of 
C/EBPa. 293T cells were transfected with p(C/EBP)2TK and the expression plasmids 
pcDNA3-C/EBPa or pcDNA3-C/EBPaS248A and/or pMT3-Ha-Ras(L61). 
Luciferase activities were determined 24 h after transient transfection with 
LipofectAMINE Plus and normalized to the activities of the internal control plasmid 
pRL-null. 
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3.7 A PKC inhibitor blocks the activation of C/EBPa  by 
Ras 
 
Because serine 248 is a potential protein kinase C (PKC) consensus 
site (Fig. 4B), we asked whether a PKC inhibitor (Staurosporine at 20 
nM final concentration) could block the activation of C/EBPa by Ras 
signaling.  In fact, pretreatment of 293T cells with Staurosporine 
abolished the activation of C/EBPa by Ras signaling (Fig. 4A).  These 
results support the hypothesis that the PKC pathway could be involved 
in the Ras mediated activation of C/EBPa.  
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Fig. 4.  Activation of C/EBPa  by Ras signaling is PKC dependent.  A)  A PKC 
inhibitor blocks the activation of C/EBPa by Ras.  293T cells were transfected with 
p(C/EBP)2TK and the expression plasmids pMSV-C/EBPa and/or pMT3-Ha-
Ras(L61).  Cells were pretreated with a PKC inhibitor (staurosporine at 20 nM) or the 
vehicle.  Luciferase activities were determined 24 h after transient transfection with 
LipofectAMINE Plus and normalized to the activities of the internal control plasmid 
pRL-null. 
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Fig. 4. B)  Model of C/EBPa, with areas 1-9 containing the first and second 
transactivation domain (TAD1 and TAD2) and the DNA binding domain of C/EBPa 
with the basic region and leucine zipper region.  Area 9 is depicted in detail.  The amino 
acid sequence of area 9 contains only one potential phosphorylation site, serine 248, 
which represents a PKC consensus site. 
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3.8 Ras phosphorylates C/EBPa  at S248 in vivo 
 
Because our data suggest that Ras activates C/EBPa via 
phosphorylation on serine 248, we wanted to prove that Ras signaling, 
in fact, phosphorylates C/EBPa on serine 248 in vivo.  293T cells 
were transfected with p(C/EBP)2TK and with the expression plasmids 
for C/EBPa or C/EBPaS248A and/or activated Ras.   
Phosphopeptide mapping of cells transfected with C/EBPa, 
C/EBPaS248A, C/EBPa plus Ras, and C/EBPaS248A plus Ras was 
performed.  Ras signaling (Fig. 5C) enhanced a phosphorylation spot 
in the C/EBPa pattern (Fig. 5A) which was not visible in 
C/EBPaS248A (Fig. 5B) or C/EBPaS248A plus cotransfected Ras 
(Fig. 5D).  Thus, we conclude that Ras signaling phosphorylates 
C/EBPa on serine 248 in vivo.  
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Fig. 5.  Ras signaling phosphorylates C/EBPa  at serine 248 in vivo.  293T cells 
were transfected with p(C/EBP)2TK and the expression plasmids pcDNA3-C/EBPa 
or pcDNA3-C/EBPaS248A and/or pMT3-Ha-Ras(L61).  Phosphopeptide mapping 
of C/EBPa (A), C/EBPaS248A (B), C/EBPa plus Ras (C), and C/EBPaS248A plus 
Ras (D) was performed.  The arrow indicates a phosphopeptide present in C/EBPa 
WT cells and enhanced by Ras, but not present in C/EBPa S248A cells, even after Ras 
activation. 
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Fig. 5. E)  Model of how Ras enhances the ability of C/EBPa  to transactivate 
the G-CSF receptor promoter by phosphorylation on serine 248.  Our data 
suggest a model in which Ras signaling phosphorylates C/EBPa on serine 248 of the 
transactivation domain resulting in an enhancement of the ability of C/EBPa to 
transactivate the G-CSF receptor promoter.  We hypothesize that partly this 
enhancement could be mediated by recruitment of a co-activator (see discussion). Our 
data suggest that Ras signaling enhances the activity of C/EBPa to induce granulocytic 
differentiation by phosphorylation of serine 248. 
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3.9 Mutation of serine 248 to alanine obviates the ability of 
C/EBPa  to induce differentiation 
 
To determine the biological importance of serine 248, we linked 
C/EBPa(S248A) to the human Estradiol Receptor (ERa) ligand-
binding domain and isolated 32D cl3 cell lines expressing this protein.  
Two subclones with protein expression as high as that we previously 
achieved for C/EBPaWT-ER were obtained (Fig. 6A).  In 32D-
C/EBPa(S248A)-ER-1 cells, the full-length species reproducibly 
migrated faster than that found for clone 2 cells or for cells expressing 
the wild-type protein.  Smaller species, likely representing degradation 
products, and a larger species (arrow), likely representing a dimer 
formed via the leucine zipper, also ran faster than comparable bands in 
the other lanes.  Perhaps this difference in migration represents altered 
phosphorylation at serine 248 or at another residue.  It is not clear why 
this faster migration was only seen with one subclone, but may 
represent heterogeneity in the 32D cl3 cells themselves. 
 
To assess induction of differentiation by C/EBPa(S248A)-ER, each of 
the cell lines was placed in estradiol.  Morphologically, after 3 days the 
majority of 32D-C/EBPa(WT)-ER cells had differentiated  to 
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neutrophils (Fig. 6C, right panels), whereas little morphologic change 
was seen with 32D-C/EBPa(S248A)-ER-1 cells and clone 2 developed  
primary granules without nuclear maturation (Fig 6C, left and middle 
panels).  To further assess differentiation, RNAs prepared daily from 
cultures exposed to estradiol were subjected to Northern blotting for 
MPO, LF, and b-actin (Fig. 6B).  As reported previously, 
C/EBPaWT-ER rapidly induced MPO and induced LF after 48 hrs.  
In contrast, in 32D-C/EBPa(S248A)-ER-1 cells, neither MPO nor LF 
were induced, and in clone 2 cells MPO was induced in a delayed 
fashion and LF was not induced.  Mutation of serine 248 to alanine did 
not prevent the growth inhibitory properties of C/EBPaWT-ER in 32D 
cl3 cells (data not shown).  
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Fig. 6.  Mutation of serine 248 to alanine obviates the ability of C/EBPa  to 
induce differentiation.  A)  To determine the biological importance of serine 248, we 
linked C/EBPa(S248A) to the human Estradiol Receptor (ERa) ligand-binding domain 
and isolated 32D cl3 cell lines expressing this protein.  Two subclones with protein 
expression as high as that we previously achieved for C/EBPaWT-ER were obtained.  
B)  To further assess differentiation, RNAs prepared daily from cultures exposed to 
estradiol were subjected to Northern blotting for MPO, LF, and b-actin.  As reported 
previously, C/EBPaWT-ER rapidly induced MPO and induced LF after 48 hrs.  In 
contrast, in 32D-C/EBPa(S248A)-ER-1 cells, neither MPO nor LF were induced, and 
in clone 2 cells MPO was induced in a delayed fashion and LF was not induced. 
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Fig. 6. C)  To assess induction of differentiation by C/EBPa(S248A)-ER, each of the 
cell lines was placed in estradiol.  Morphologically, after 3 days the majority of 32D-
C/EBPa(WT)-ER cells had differentiated  to neutrophils (right panels), whereas little 
morphologic change was seen with 32D-C/EBPa(S248A)-ER-1 cells and clone 2 
developed  primary granules without nuclear maturation (left and middle panels). 
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4.  DISCUSSION 
 
As Ras signaling and the transcription factor C/EBPa play important 
roles in myeloid differentiation, we hypothesized that Ras might be 
involved in the activation of C/EBPa.  Here we demonstrate that Ras 
signaling phosphorylates C/EBPa on serine 248 of the transactivation 
domain resulting in an enhancement of its transactivation capacity.  
 
These data link the Ras pathway, which is involved in myelopoiesis 
(Crespo and Leon, 2000) and acute myeloid leukemia(Schaich et al., 
2001; Zuber et al., 2000) to the differentiation inducing C/EBPa 
pathway.  Thus, activated Ras enhances the ability of C/EBPa to 
transactivate the G-CSF receptor promoter and a minimal TK 
promoter containing C/EBP DNA binding sites from 10 fold to 40 fold 
(Fig. 1).  The major role of phosphorylation sites in the activation and 
deactivation of C/EBP family members has already been described by 
other groups.  Ford et al. suggested that C/EBPa exists in multiple 
phosphorylated forms in the nucleus of both multipotential and 
granulocytic-committed cells. (Ford et al., 1996)  Furthermore, it has 
been shown that C/EBPb is expressed in both phosphorylated and 
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unphosphorylated forms in blasts from patients with acute myeloid 
leukemia.(Iida et al., 2000) In terms of C/EBPb, a regulation by the 
Ras signal transduction pathway and Ras-induced phosphorylation of 
C/EBPb on threonine-235 is already known.(Nakajima et al., 1993)   
Furthermore, the MAP kinases ERK1 and ERK2 have been reported to 
mediate interferon-gamma responsiveness of C/EBPb.(Hu et al., 
2001) 
 
Regarding C/EBPa, Mahoney et al. reported that phosphorylation of 
C/EBPa in vitro by protein kinase C attenuates its site-selective DNA 
binding.(Mahoney et al., 1992)  Subsequently, Pan et al. could identify 
a specific increase in DNA binding and the expression of C/EBPa and 
C/EBPb during U937 monocytic cell differentiation, and related this to 
the transforming growth factor b signaling pathway.(Pan et al., 1999)  
Our data do not relate the effect of Ras signaling to the DNA binding 
domain or DNA binding capacity of C/EBPa.  Ras signaling acts on 
the C/EBPa transactivation domain, because it enhances 4 fold the 
transactivation function of a fusion protein containing a Gal4 DNA 
binding domain and the C/EBPa transactivation domain (Fig. 2A), and 
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does not change the C/EBPa DNA binding capacity (Fig. 2C).  In 
fact, Ras acts on serine 248 of the C/EBPa transactivation domain, 
because it does not enhance the 10-fold transactivation exhibited by a 
C/EBPa mutant with a deletion of area 9 (Fig. 3A) or a serine 248 to 
alanine point mutant in area 9 (Fig. 3C).  Thus, we conclude that the 
Ras pathway acts on the transactivation functions of C/EBPa, via 
serine 248.  
 
Ross et al. reported recently on other important phosphorylation sites 
in the transactivation domain of C/EBPa.(Ross et al., 1999; Ross et 
al., 2000)  The insulin pathway activates GSK3 kinase which in turns 
phosphorylates C/EBPa on threonines 222 and 226.(Ross et al., 1999)  
This activation of C/EBPa is blocked by the Wnt signaling 
pathway.(Ross et al., 2000)  Wnt signaling maintains preadipocytes in 
an undifferentiated state through inhibition of the adipogenic 
transcription factors C/EBPa and peroxisome proliferator- activated 
receptor gamma (PPARg).  When Wnt signaling in preadipocytes is 
prevented by overexpression of axin or dominant-negative TCF4, 
these cells differentiate into adipocytes.(Ross et al., 2000)   Our data in 
293T cells point to serine 248 as the major Ras-dependent 
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phosphorylation site of C/EBPa.  Serine 248 of C/EBPa is a PKC 
consensus site, and a PKC inhibitor blocks the activation of C/EBPa 
by Ras (Fig. 4A).  However, staurosporine is not completely specific 
for PKC.  Therefore, we have not excluded other kinases being 
responsible for the activation of C/EBPa by Ras.  
 
The serine to alanine mutant of C/EBPa did not completely eliminate 
the activation of C/EBPa by Ras (Fig. 3C) whereas deletion of region 
9 did (Fig. 3A).  Perhaps a transcriptional co-activator binds optimally 
to C/EBPa when serine 248 is phosphorylated (Fig. 5E), but can still 
bind weakly to the S248A mutant.  In this model the effect of Ras on 
C/EBPa transactivation is at least partly indirect, via a co-activator. 
This model is supported by the ability of Ras to induce basal activity 
of p(C/EBP)TK; on the other hand our observation that Ras increases 
phosphorylation of a C/EBPa peptide, but not of the same peptide 
from C/EBPaS248A suggests a more direct effect on C/EBPa by Ras 
(Fig. 5E).  Because Ross et al. had reported that serine 230 was also 
phosphorylated by insulin signaling in vivo, but not by GSK3,(Ross et 
al., 1999; Ross et al., 2000) it is also possible that phosphorylation of 
serine 230 might account for additional effects of Ras on C/EBPa.  
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However, we could not observe any loss of enhancement of 
transactivation capacity of C/EBPa by Ras signaling using the serine 
230 to alanine mutant of C/EBPa (data not shown, mutants kindly 
provided by Dr. MacDougald, Ann Arbor).  However, the very likely 
additional Ras-dependent phosphorylation sites in C/EBPa besides 
serine 248 (Fig. 5A-D) still need to be mapped and to be tested 
functionally.  Our current studies to identify interacting proteins and 
interacting phosphoproteins of C/EBPa using proteomics techniques 
(2D-gel electrophoresis of C/EBPa interacting proteins and 
phosphoproteins and identification of those proteins by mass 
spectrometry) might also contribute to answer the question whether the 
effect of Ras signaling on serine 248 of C/EBPa requires a co-
activator binding to serine 248 or not.  
 
Mutation of serine 248 to alanine had marked biologic consequences in 
32D cl3 cells, obviating the ability of C/EBPa to induce differentiation 
(Fig. 6).  Whether this represents a defect in Ras-dependent 
phosphorylation of this serine and consequent alteration of trans-
activating properties in myeloid cells or whether it represents a more 
indirect effect in which a  Ras-dependent pathway interacts with serine 
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248 or with another site in C/EBPa affected by mutation of serine 248 
to alanine remains to be determined. 
 
Further studies need to address the biological significance of serine 
248 of C/EBPa by testing the serine to alanine 248 C/EBPa mutant in 
biological assays of C/EBPa function such as in rescue assays in 
C/EBPa knock-out mice.  Of note, G-CSF, but not IL-3, signals 
cooperate with C/EBPa to induce myeloid genes in Ba/F3 lymphoid 
cells.(Wang et al., 2001)  Because impairment of C/EBPa function can 
contribute to the pathogenesis of acute myeloid leukemia,(Pabst et al., 
2001a; Pabst et al., 2001b) it needs to be addressed whether serine 248 
of C/EBPa is mutated in patients with acute myeloid leukemia and/or 
whether inactivating Ras mutations in acute myeloid leukemia might 
lead to a loss of C/EBPa function.  
 
In a nutshell, our data suggest so far that Ras signaling phosphorylates 
C/EBPa on serine 248 of the transactivation domain resulting in an 
enhancement of the ability of C/EBPa to transactivate the G-CSF 
receptor promoter.  Furthermore, our data suggest a model where Ras 
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signaling enhances the activity of C/EBPa to induce granulocytic 
differentiation by phosphorylation of serine 248. 
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5.  SUMMARY 
The transcription factor C/EBPa regulates early steps of normal 
granulocyte differentiation since mice with a disruption of the C/EBPa 
gene do not express detectable levels of the G-CSF receptor and 
produce no neutrophils.  We have recently shown that C/EBPa 
function is also impaired in acute myeloid leukemias.  However, how 
the transcriptional activity of C/EBPa is regulated both in myelopoiesis 
and leukemogenesis, is not fully understood.  The current study 
demonstrates that activated Ras enhances the ability of C/EBPa to 
transactivate the G-CSF receptor promoter and a minimal promoter 
containing only C/EBP DNA binding sites.  Ras signaling activates 
C/EBPa via the transactivation domain, because it enhances the 
transactivation function of a fusion protein containing a Gal4 DNA 
binding domain and the C/EBPa transactivation domain, and does not 
change C/EBPa DNA binding.  Ras acts on serine 248 of the C/EBPa 
transactivation domain, as it does not enhance the transactivation 
function of a C/EBPa serine 248 to alanine point mutant.  Interestingly, 
serine 248 of C/EBPa is a PKC consensus site, and a PKC inhibitor 
blocks the activation of C/EBPa by Ras.  Ras signaling 
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phosphorylates C/EBPa on serine 248 in vivo.  Finally, mutation of 
serine 248 to alanine obviates the ability of C/EBPa to induce 
granulocytic differentiation.  These data suggest a model where Ras 
signaling enhances the activity of C/EBPa to induce granulocytic 
differentiation by phosphorylation of serine 248.  
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6.  ZUSAMMENFASSUNG 
 
Der Transkriptionsfaktor C/EBPa reguliert frühe Schritte in der 
Differenzierung hämatopoetischer Vorläuferzellen zu Granulozyten. Bei 
C/EBPa knockout Mäusen ist der G-CSF-Rezeptor nicht nachweisbar. 
Diese Mäuse haben auch keine neutrophilen Granulozyten. Die Störung 
der Funktion von C/EBPa bei Patienten mit akuten myeloischen 
Leukämien ist bekannt. Es ist jedoch bislang weder die Regulation der 
Effekte des Proteins C/EBPa auf die Myelopoese noch auf die 
Leukämogenese zufriedenstellend beschrieben worden. Die vorliegende 
Arbeit zeigt, daß aktiviertes Ras die Fähigkeit des 
Transkriptionsfaktors C/EBPa, den Promoter des G-CSF Rezeptors 
sowie einen Promoter, der nur die DNA bindenden Stellen enthält, zu 
transaktivieren, verstärkt. Die Ras-Signaltransduktion ändert die 
Bindung von C/EBPa an die DNA nicht und verstärkt die Fähigkeit der 
Transaktivierung der beschriebenen Promotoren durch ein 
Fusionsprotein aus einer Gal4 DNA bindenden Domäne und der 
Transaktivierungsdomäne von C/EBPa. Also verstärkt Ras die 
transkriptionelle Aktivität von C/EBPa in seiner 
Transaktivierungsdomäne. In der vorliegenden Arbeit wurde die 
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Aminosäure, an der Ras C/EBPa aktiviert, bestimmt. Eine 
Punktmutation, die die Aminosäure Serin 248 in C/EBPa zu Alanin 
mutierte, führte zu einem Verlust der beschriebenen verstärkenden 
Funktion des Protoonkogens Ras auf die transkriptionelle Aktivität von 
C/EBPa. Die Aminosäure Serin 248 stellt eine PKC-Konsensus-Stelle 
dar. Ein Inhibitor der Proteinkinase C konnte die durch Ras induzierte 
Aktivierung von C/EBPa hemmen. Ras-Signaltransduktion führt in 
vivo zu Phosphorylierung von C/EBPa. Ferner führte die Mutation 
von Serin 248 zu Alanin zu einem Verlust der Fähigkeit C/EBPas, 
Differenzierung von Vorläuferzellen zu Granulozyten zu induzieren. Die 
vorliegenden Daten unterstützen ein Modell, in dem Ras-
Signaltransduktion die Kapazität C/EBPas, die Differenzierung zu der 
granulozytischen Reihe zu induzieren, durch Phosphorylierung an Serin 
248 verstärkt. 
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The transcription factor C/EBP regulates early steps
of normal granulocyte differentiation since mice with a
disruption of the C/EBP gene do not express detectable
levels of the granulocyte colony-stimulating factor re-
ceptor and produce no neutrophils. We have recently
shown that C/EBP function is also impaired in acute
myeloid leukemias. However, how the transcriptional
activity of C/EBP is regulated both in myelopoiesis and
leukemogenesis is not fully understood. The current
study demonstrates that activated Ras enhances the
ability of C/EBP to transactivate the granulocyte colo-
ny-stimulating factor receptor promoter and a minimal
promoter containing only C/EBP DNA binding sites. Ras
signaling activates C/EBP via the transactivation do-
main because it enhances the transactivation function
of a fusion protein containing a Gal4 DNA binding do-
main and the C/EBP transactivation domain and does
not change C/EBP DNA binding. Ras acts on serine 248
of the C/EBP transactivation domain, because it does
not enhance the transactivation function of a C/EBP
serine 248 to alanine point mutant. Interestingly, serine
248 of C/EBP is a protein kinase C (PKC) consensus
site, and a PKC inhibitor blocks the activation of
C/EBP by Ras. Ras signaling leads to phosphorylation
of C/EBP in vivo. Finally, mutation of serine 248 to
alanine obviates the ability of C/EBP to induce granu-
locytic differentiation. These data suggest a model
where Ras signaling enhances the activity of C/EBP to
induce granulocytic differentiation by phosphorylation
of serine 248.
The transcription factor C/EBP plays a pivotal role during
differentiation in various cell types, including adipocytes and
hepatocytes and lung and ovary cells (1–7). In hematopoiesis,
C/EBP is expressed in myeloid cells (3, 6). We have previously
demonstrated that the expression of C/EBP correlates with the
commitment of multipotential precursors to the myeloid lineage
and is specifically up-regulated during neutrophilic differentia-
tion (3, 6). Furthermore, conditional expression of C/EBP is
sufficient to induce neutrophilic differentiation (6) and can block
the monocytic differentiation program by inactivating transcrip-
tion factor PU.1 (8). In addition, no mature neutrophils are ob-
served in C/EBP knockout mice, whereas all the other blood cell
types are present in normal proportions (5). One mechanism of
how C/EBP may inhibit cell growth might be the direct repres-
sion of E2F-DP-mediated transcription (9).
We recently reported that dominant-negative mutations of
C/EBP are found in patients with acute myeloid leukemia
(AML) of subtypes M1 and M2 (10). Furthermore, we also
demonstrated that the leukemic fusion protein AML1-ETO,
found in patients with acute myeloid leukemia with transloca-
tion t (8, 21), down-regulates both C/EBP expression and
function in primary AML patient samples (11). These studies
point to the crucial role of C/EBP in both normal myeloid
differentiation and leukemogenesis. However, how the tran-
scriptional activity of C/EBP is regulated both in normal
myelopoiesis as well as in leukemogenesis is not fully
understood.
The Ras family of proteins are GTP-dependent molecular
switches that are essential for cell growth and differentiation (12,
13). Ras exerts its effect on cell growth mainly via ETS (14) and
AP-1 (15) transcription factors. For example, cells with a null
mutation in the c-jun gene and expressing oncogenic Ras lack
many characteristics of Ras transformation (15), and dominant
negative mutants of ETS-1, ETS-2, or PU.1 containing only the
DNA binding domain inhibit Ras activation of transcription and
revert Ras-transformed cells (14). In particular, Ras has been
demonstrated to play an important role in myeloid differentia-
tion. Macrophage differentiation and macrophage-colony-
stimulating factor-dependent survival are altered in transgenic
mice that express dominant suppressors of Ras signaling (16),
whereas a number of hematopoietic cell lines undergo spontane-
ous myeloid differentiation in response to expression of activated
Ras (17, 18). In addition, macrophage-colony-stimulating factor,
granulocyte-macrophage colony-stimulating factor, or interleu-
kin-3-induced monocytopoiesis of CD34 cells is inhibited by
N-Ras antisense oligonucleotides (19).
Because Ras signaling and the transcription factor C/EBP
both play important roles in myeloid differentiation, we hy-
pothesized that Ras might be involved in the activation of
C/EBP. Here we demonstrate data that suggest a model
where Ras signaling phosphorylates C/EBP on serine 248 of
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the transactivation domain, resulting in an enhancement of the
ability of C/EBP to transactivate the G-CSF1 receptor pro-
moter, which contributes to the induction of granulocytic
differentiation.
EXPERIMENTAL PROCEDURES
Cell Lines and Cell Culture—Human kidney 293T cells and human
kidney 293E1A cells (kindly provided by John Blenis, Harvard Medical
School, Boston, MA) were maintained in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal calf serum (HyClone). 32D cl3
cells were maintained in phenol-red free Iscove’s modified Dulbecco’s
medium with 10% heat-inactivated fetal bovine serum, 1 ng/ml inter-
leukin-3 (R&D Systems, Minneapolis, MN), and penicillin-streptomy-
cin. CRE cells were maintained in Dulbecco’s modified Eagle’s medium
with 10% heat-inactivated calf serum and penicillin-streptomycin. p-
BabePuro-C/EBP(S248A)-ER was introduced into CRE cells using
LipofectAMINE (Invitrogen), and a pool of resistant cells was isolated
using 2 g/ml puromycin. 32D cl3 cells were co-cultured in the presence
of 4 g/ml Polybrene with CRE-S248A cells that had been irradiated.
After 48 h, the 32D cl3 cells were placed in 96-well dishes with 2 g/ml
puromycin, and individual subclones were isolated. Estradiol was em-
ployed at 1 M. Morphology was assessed by Wright’s-Giemsa staining
of cytospins. pBabePuro-C/EBP(S48A)-ER was constructed by ligating
an MluI/NcoI segment containing the mutant serine in place of the
identical fragment in pBabePuro-C/EBPWT-ER. Total cellular ex-
tracts were subjected to Western blotting using antiserum recognizing
human ER (Santa Cruz Biotechnology, San Diego, CA) or murine actin
(Sigma).
Reporter Constructs and Expression Plasmids—The human G-CSF
receptor promoter ranging from bp 74 to 67 with respect to the
major transcription start site (20) was subcloned in the firefly luciferase
vector pXP2 (21). pTK driven by 2 C/EBP sites (p(C/EBP)2TK) is a
dimer of the C/EBP site from the granulocyte colony-stimulating factor
receptor promoter from bp 57 to bp 37 with respect to the major
transcription start site (20), subcloned into pTK81luc, a pXP2-based
luciferase construct with a TATA box only as a minimal promoter (21).
As an internal control plasmid for co-transfection assays, the pRL-null
construct driving a Renilla luciferase gene (Promega, Madison, WI) was
used as described before (22–24). The expression plasmids pMSV-C/
EBP (rat), various deletions mutants of C/EBP in pMSV, pMSV-C/
EBP, pMSV-C/EBP, GAL4-C/EBP area 1–9, GAL4-C/EBP area
1–3, and GAL4-C/EBP area 4–9, and a minimal promoter with GAL4
DNA binding sites were described previously (25, 26). Human activated
pMT3-Ha-Ras(L61) was kindly provided by Larry Feig (Tufts Univer-
sity, Boston, MA) (27, 28). A serine to alanine point mutation at serine
248 of rat C/EBP was introduced by site-directed mutagenesis.
Transient Transfections Using LipofectAMINE Plus and Reporter
Assays for Firefly and Renilla Luciferase—293T cells or 293E1A cells
were transfected using LipofectAMINE Plus (Invitrogen) as described
by the manufacturer. Firefly luciferase activities from the constructs
pG-CSFR, pXP2, pGal4-DBD, pTK, and p(C/EBP)2TK and Renilla lu-
ciferase activity from the internal control plasmid pRL-null were deter-
mined 24 h after the initiation of the transfection protocols using the
dual-luciferase reporter assay system (Promega). Firefly luciferase ac-
tivities were normalized to the Renilla luciferase values of pRL-null.
Results are given as the means  S.E. of at least six independent
experiments. The DNA concentrations of the reporter constructs and
expression plasmids used for LipofectAMINE Plus transfections were
0.1 g of pG-CSFR, pXP2, pGal4-DBD, pTK, and p(C/EBP)2TK, 0.01 g
of the internal control plasmid pRL-null, 0.1 g of the expression
plasmids for C/EBP and C/EBP mutants and for Ras(L61); the same
concentrations of the empty expression vectors were used as controls,
respectively. In the transfections without cotransfection of Ras, the
empty vector pMT3 was included instead of pMT3-Ras. pRL-null was
chosen as the internal control plasmid, because it was not transacti-
vated by Ras in 293T cells (22, 23).
Electrophoretic Mobility Shift Assay—Electrophoretic mobility shift
assays were performed as described previously (22, 24). As a positive
control for C/EBP binding, a double-stranded C/EBP probe from the
human G-CSF receptor promoter (bp 57 to 37 with respect to the
major transcription start site, as described before in Fig. 9 of Ref. 20;
OligoA (AAG GTG TTG CAA TCC CCA GC) and OligoB (GCT GGG
GAT TGC AAC ACC TT)) was labeled with Klenow polymerase and
[32P]dCTP (PerkinElmer Life Sciences) and incubated with 0.1 g/l
double-stranded poly(dI-dC) (Sigma) with 1 l of in vitro translated
C/EBP. In some experiments, a 100-fold molar excess of the C/EBP
probe was added as specific unlabeled competitor. C/EBP antibody
(14AA) was used for gel supershift (Cat #SC61 X, Santa Cruz
Biotechnology).
In Vivo Labeling and Phosphopeptide Mapping—To detect changes
in the phosphorylation pattern of C/EBP upon stimulation with acti-
vated Ras in vivo, 0.5 g of pcDNA3-C/EBP or pcDNA3-C/EBPS248A
either with or without 0.25 g of activated Ras(L61), was transfected
into 293T cells using LipofectAMINE Plus (Invitrogen). 3 h after trans-
fection, cells were starved in serum-free Dulbecco’s modified Eagle’s
medium. After 18 h, cells were placed into serum-free and phosphate-
free Dulbecco’s modified Eagle’s medium (Invitrogen) for 30 min before
they were metabolically labeled with [32P]orthophosphate (2.5 mCi/ml).
After 4 h, cells were lysed with radioimmunoprecipitation assay buffer
containing 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 0.15
M NaCl, 5 mM EDTA, and 50 mM Tris (pH 8.0) and supplemented with
aprotinin, phenylmethylsulfonyl fluoride, pepstatin A, leupeptin, anti-
pain, and chymostatin as protease inhibitors (Sigma) and sodium py-
rophosphate, sodium fluoride, and sodium vanadate as phosphatase
inhibitors (Sigma). In parallel plates, 0.3 g of the G-CSF receptor
promoter was co-transfected in 293T cells, and luciferase activities were
determined to ensure that Ras signaling enhances the transactivation
function of C/EBP in the particular experiment used in in vivo labeling
and subsequent phosphopeptide mapping.
C/EBP was isolated by immunoprecipitation from the lysates using
a rabbit polyclonal antibody against C/EBP (Santa Cruz), washed four
times with radioimmunoprecipitation assay buffer, separated on 10%
SDS-polyacrylamide gels, and transferred to nitrocellulose (Bio-Rad)
for phosphopeptide mapping. After transfer, the C/EBP protein bands
was excised. To determine the phosphorylated protein residues of
C/EBP, C/EBP protein bands were digested with 1-chloro-3-tosyl-
amido-7-amino-2-heptanone-treated chymotrypsin (Worthington) and
endoproteinase Glu-C (V8 protease) (Roche Molecular Biochemicals)
and processed for phosphopeptide mapping as described previously (29).
Western Blot—24 h after the start of transfection, cells were lysed
with radioimmunoprecipitation assay buffer. Equal amounts of total
protein were separated on 10% SDS-polyacrylamide gels and trans-
ferred to Immobilon-P membrane (Millipore). Membranes were incu-
bated with anti-C/EBP antibody (Santa Cruz Biotechnology) or -tu-
bulin antibody as an internal control (catalog #1111876; Roche
Molecular Biochemicals) for 60 min and then with protein A-horserad-
ish peroxidase conjugate (Amersham Biosciences) for 45 min. Signals
were detected with ECL Western blotting detection reagents (Amer-
sham Biosciences). In parallel plates, the G-CSF receptor promoter
construct was co-transfected, and luciferase activities were determined
to ensure that Ras enhances the transactivation function of C/EBP in
the particular experiment used for Western blot analysis of C/EBP
expression and that the transfection efficacy was the same (less than
10% difference between plates) in the particular experiment. Differ-
ences in protein expression were quantitated by ImageQuant software
(Molecular Dynamics). C/EBP antibody (14AA, SC61) was used for
Western blot and immunoprecipitation (Santa Cruz Biotechnology).
RESULTS
Ras Enhances the Ability of C/EBP to Transactivate the
G-CSF Receptor Promoter—Because Ras and the regulation of
the G-CSF receptor by C/EBP are both important for myeloid
development, we asked whether activated Ras enhances the
ability of C/EBP to transactivate the G-CSF receptor pro-
moter. 293T cells were transfected with a plasmid containing
the human G-CSF receptor promoter (20) cloned upstream of
the luciferase reporter gene along with expression plasmids for
C/EBP and Ras, and reporter gene expression was determined
24 h post-transfection. Transfection of a Ras expression con-
struct significantly enhanced the ability of C/EBP to transac-
tivate the G-CSF receptor promoter (Fig. 1A). The same effect
was demonstrated in myeloid U937 cells as well (Fig. 1D).
Western blot analysis for C/EBP expression demonstrated
that activated Ras did not change the expression level of co-
transfected C/EBP (Fig. 1B). Thus, Ras signaling directly acts
on the transactivation capacity of C/EBP. The cooperation of
1 The abbreviations used are: G-CSF, granulocyte colony-stimulating
factor; TK, thymidine kinase; PKC, protein kinase C: MPO, myeloper-
oxidase; LF, lactoferrin.
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activated Ras with C/EBP is therefore important for G-CSF
receptor promoter activity.
Ras Enhances the Ability of C/EBP but Not of C/EBP  or
C/EBP to Transactivate a Minimal TK Promoter Driven by
C/EBP DNA Binding Sites—We next asked the questions of (a)
whether the binding of C/EBP to DNA was necessary for its
activation by Ras and (b) whether a C/EBP binding site alone
was sufficient for the Ras-enhanced C/EBP activation. We
observed enhanced C/EBP transactivation mediated by acti-
vated Ras using a reporter construct containing two C/EBP
binding sites cloned upstream of a minimal TK promoter (p(C/
EBP)TK) (Fig. 1C). In control experiments, no effect of Ras on
C/EBP activity was observed when the minimal TK promoter
without C/EBP binding sites was used (Fig. 1C). These data
indicate that C/EBP binding to DNA is necessary for its acti-
vation by Ras signaling and that C/EBP binding sites are
sufficient to mediate this effect. Interestingly, the activation of
C/EBP by Ras was specific for C/EBP, because C/EBP and
C/EBP were not activated functionally by Ras signaling in this
assay (Fig. 1C).
Ras Enhances the Transactivation Function of a Fusion Pro-
tein Containing a Gal4 DNA Binding Domain and a Discrete
Region of the C/EBP Transactivation Domain—To map the
domain of C/EBP activated by Ras signaling, we used a min-
imal promoter with GAL4 DNA binding sites and the expres-
sion plasmids GAL4-C/EBP area 1–9, GAL4-C/EBP area
1–3, and GAL4-C/EBP area 4–9 using the previously de-
scribed nomenclature (25) to refer to the areas of the C/EBP
transactivation domain (Fig. 2, A and B). Ras signaling acti-
vated a fusion protein containing the GAL4-DNA binding do-
main and the transactivation domains of C/EBP (areas 1–9).
Areas 1–3 of C/EBP were not activated by Ras, whereas areas
4–9 were still activated by Ras. These data indicate that Ras
signaling might act on areas 4–9 of the transactivation domain
of C/EBP.
Ras Does Not Change DNA Binding of C/EBP—To further
elucidate the mechanism by which Ras augments the tran-
scriptional activity of C/EBP, we performed experiments to
determine whether the activation of C/EBP by Ras was partly
due to an increase of C/EBP DNA binding. An electrophoretic
mobility shift assay was performed using a bp 57 to 37
G-CSF receptor promoter fragment containing its C/EBP
binding site (20). A positive control, in vitro translated C/EBP,
specifically bound to this probe as expected (Fig. 2C). Nuclear
extracts from 293T cells transfected with the expression plas-
mid of C/EBP with or without cotransfection of Ras bound to
the oligo as well, and most importantly, Ras signaling did not
change the DNA binding of C/EBP. To rule out different
C/EBP protein contents of the nuclear extracts used, we per-
formed a Western blot analysis for C/EBP expression (Fig.
2D), which showed equal loading of C/EBP. These results
indicate that binding of C/EBP to the G-CSF receptor pro-
moter DNA is not enhanced by Ras signaling.
Ras Activates C/EBP via Area 9 of the C/EBP TAD—To
further localize the site of C/EBP activated by Ras signaling
and to fine-map this site, we used various deletion mutants of
C/EBP (Fig. 3, A and B). C/EBP4–9 was minimally acti-
vated, and C/EBP9 was not activated by Ras. All other
mutants were activated at least 2-fold by Ras. These studies
demonstrate that Ras acts on area 9 of C/EBP.
Ras Activates C/EBP Wild Type but Not a S248A Mutant—
Because Ras acts on area 9 of the transactivation domain of
C/EBP, we focused on this area for generating C/EBP point
mutants. Area 9 of C/EBP is depicted in detail in Fig. 4B.
There is only one potential phosphorylation consensus site in
area 9, at serine 248. We generated a point mutant of C/EBP
at serine 248 by mutation to alanine (C/EBPS248A). C/EBP
wild type and C/EBPS248A both transactivated the G-CSF
receptor promoter 20-fold. Although Ras signaling enhanced
FIG. 1. Ras signaling enhances the transcriptional activity of
C/EBP. A, Ras enhances the ability of C/EBP to transactivate the
G-CSF receptor (CSFR) promoter. 293T cells were transfected with the
human G-CSF receptor promoter or the human G-CSF receptor pro-
moter with mutated C/EBP sites and with the expression plasmids
pMSV-C/EBP (or empty vector pMSV) and pMT3-Ha-Ras(L61) (or
empty vector pMT3). Luciferase activities were determined 24 h after
transient transfection with LipofectAMINE Plus and normalized to the
activities of the internal control plasmid pRL-null. B, Western blot
analysis for C/EBP expression (and -tubulin expression as loading
control) for the experiment shown in A. C, Ras enhances the ability of
C/EBP, but not of C/EBP  or C/EBP to transactivate a minimal TK
promoter driven by C/EBP DNA binding sites (p(C/EBP)2TK). 293T
cells were transfected with p(C/EBP)TK or a minimal TK promoter
without C/EBP sites (pTK) and with the expression plasmids pMSV-C/
EBP, pMSV-C/EBP , pMSV-C/EBP, and/or pMT3-Ha-Ras(L61) or
the respective empty vectors. D, Ras enhances the ability of C/EBP to
transactivate a minimal TK promoter driven by C/EBP DNA binding
sites (p(C/EBP)2TK) in myeloid U937 cells.
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wild type C/EBP transactivation capacity from 20- to 60-fold,
Ras only enhanced the transactivation capacity of the S248A
mutant of C/EBP from 20- to 29-fold (Fig. 3C). These results
suggest that Ras signaling might act on serine 248 of the
C/EBP transactivation domain to enhance C/EBP transcrip-
tional activity.
A Protein Kinase C (PKC) Inhibitor Blocks the Activation of
C/EBP by Ras—Because serine 248 is a potential PKC con-
sensus site (Fig. 4B), we asked whether a PKC inhibitor (stau-
rosporine at 20 nM final concentration) could block the activa-
tion of C/EBP by Ras signaling. In fact, pretreatment of 293T
cells with staurosporine abolished the activation of C/EBP by
Ras signaling (Fig. 4A). These results support the hypothesis
that the PKC pathway could be involved in the Ras-mediated
activation of C/EBP.
Ras Phosphorylates C/EBP in Vivo—Because our data sug-
gest that Ras activates C/EBP via phosphorylation on serine
248, we wanted to prove that Ras signaling in fact phosphoryl-
ates C/EBP on serine 248 in vivo. 293T cells were transfected
with p(C/EBP)2TK and with the expression plasmids for
C/EBP or C/EBPS248A and/or activated Ras. Phosphopep-
tide mapping of cells transfected with C/EBP, C/EBPS248A,
C/EBP plus Ras, and C/EBPS248A plus Ras was performed.
Ras signaling (Fig. 5C) enhanced a phosphorylation spot in the
C/EBP pattern (Fig. 5A) that was not visible in C/EBPS248A
(Fig. 5B) or C/EBPS248A plus cotransfected Ras (Fig. 5D).
Thus, we conclude that Ras signaling phosphorylates C/EBP
on serine 248 in vivo.
Mutation of Serine 248 to Alanine Obviates the Ability of
C/EBP to Induce Differentiation—To determine the biological
importance of serine 248, we linked C/EBP(S248A) to the hu-
man estradiol receptor (ER) ligand binding domain and isolated
32D cl3 cell lines expressing this protein. Two subclones with
protein expression as high as that we previously achieved for
C/EBPWT-ER were obtained (Fig. 6A). In 32D-C/EBP(S248A)-
ER-1 cells, the full-length species reproducibly migrated faster
than that found for clone 2 cells or for cells expressing the wild
FIG. 2. Ras signaling activates C/EBP via the C/EBP trans-
activation domain. A, Ras enhances the transactivation function of a
fusion protein containing a Gal4 DNA binding domain and areas 4–9 of
the C/EBP transactivation domain. 293E1A cells were transfected
with a minimal promoter driven by GAL4 DNA binding sites and the
expression plasmids GAL4-C/EBP area 1–9, GAL4-C/EBP area 1–3,
GAL4-C/EBP area 4–9, and/or pMT3-Ha-Ras(L61). B, model of the
construct GAL4-C/EBP area 1–9 used in A. The transactivation do-
main of C/EBP (area 1–9) is fused to the DNA binding domain of
GAL4. C, Ras does not change DNA binding of C/EBP. A C/EBP
probe from the human G-CSF receptor promoter (bp 57 to –37 with
respect to the major transcription start site, as described before in Fig.
9 of Ref. 20) was used in an electrophoretic mobility shift assay of
C/EBP DNA binding. As controls, probes were incubated with no
added protein, 1 l of in vitro translated (i.v.t.) C/EBP, in vitro trans-
lated C/EBP plus a 100-fold molar excess of self-unlabeled competitor,
in vitro translated C/EBP plus an antibody against C/EBP for super-
shift (Santa Cruz), or in vitro translated C/EBP plus a 100-fold molar
excess of self-unlabeled competitor plus an antibody against C/EBP for
supershift. Right panel, as described for the left panel, with nuclear
extracts from 293T cells transfected with the expression plasmids
pMSV-C/EBP and pMT3-Ha-Ras(L61). D, Western blot analysis for
C/EBP expression (and -tubulin expression as loading control) for the
experiment shown in C.
FIG. 3. Ras signaling requires serine 248 of C/EBP to acti-
vate C/EBP. A, Ras activates C/EBP via area 9 of the C/EBP
transactivation domain. 293T cells were transfected with p(C/
EBP)2TK and the expression plasmids pMSV-C/EBP or various
deletions mutants of C/EBP and/or pMT3-Ha-Ras(L61). B, model of
C/EBP, with areas 1–9 containing the first and second transactiva-
tion domain (TAD1 and TAD2) and the DNA binding domain (DBD) of
C/EBP with the basic region and leucine zipper region. C, Ras
activates C/EBP wild type but not a serine 248 to alanine mutant of
C/EBP. 293T cells were transfected with p(C/EBP)2TK and the
expression plasmids pcDNA3-C/EBP or pcDNA3-C/EBPS248A
and/or pMT3-Ha-Ras(L61) WT, wild type.
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type protein. Smaller species, likely representing degradation
products, and a larger species (Fig. 6A, arrow), likely represent-
ing a dimer formed via the leucine zipper, also ran faster than
comparable bands in the other lanes. Perhaps this difference in
migration represents altered phosphorylation at serine 248 or at
another residue. It is not clear why this faster migration was only
seen with one subclone but may represent heterogeneity in the
32D cl3 cells themselves.
To assess induction of differentiation by C/EBP(S248A)-ER,
each of the cell lines was placed in estradiol. Morphologically,
after 3 days, the majority of 32D-C/EBP(WT)-ER cells had
differentiated to neutrophils (Fig. 6B, left panels), whereas
little morphologic change was seen with 32D-C/EBP(S248A)-
ER-1 cells and clone 2 developed primary granules without
nuclear maturation (Fig 6B, middle and right panels). To fur-
ther assess differentiation, RNAs prepared daily from cultures
exposed to estradiol were subjected to Northern blotting for
MPO, LF, and -actin (Fig. 6C). As reported previously,
C/EBPWT-ER rapidly induced MPO and induced LF after
48 h. In contrast, in 32D-C/EBP(S248A)-ER-1 cells, neither
MPO nor LF were induced, and in clone 2 cells, MPO was
induced in a delayed fashion and LF was not induced. Mutation
of serine 248 to alanine did not prevent the growth inhibitory
properties of C/EBPWT-ER in 32D cl3 cells (data not shown).
DISCUSSION
Because Ras signaling and the transcription factor C/EBP
play important roles in myeloid differentiation, we hypothe-
sized that Ras might be involved in the activation of C/EBP.
Here we demonstrate that Ras signaling phosphorylates
C/EBP on serine 248 of the transactivation domain, resulting
in an enhancement of its transactivation capacity.
These data link the Ras pathway, which is involved in my-
elopoiesis (30) and acute myeloid leukemia (31, 32), to the
differentiation-inducing C/EBP pathway. Thus, activated Ras
enhances the ability of C/EBP to transactivate the G-CSF
receptor promoter and a minimal TK promoter containing
C/EBP DNA binding sites from 10- to 40-fold (Fig. 1). The major
role of phosphorylation sites in the activation and deactivation
of C/EBP family members has already been described by other
groups. Ford et al. (33) suggest that C/EBP exists in multiple
phosphorylated forms in the nucleus of both multipotential and
granulocytic-committed cells (33). Furthermore, it has been
shown that C/EBP is expressed in both phosphorylated and
unphosphorylated forms in blasts from patients with acute
myeloid leukemia (34). In terms of C/EBP, a regulation by the
Ras signal transduction pathway and Ras-induced phosphoryl-
ation of C/EBP on threonine-235 is already known (35). Fur-
thermore, the mitogen-activated protein kinases ERK1 and
ERK2 have been reported to mediate interferon- responsive-
ness of C/EBP (36).
FIG. 4. Activation of C/EBP by Ras signaling is PKC-depend-
ent. A, a PKC inhibitor blocks the activation of C/EBP by Ras. 293T
cells were transfected with p(C/EBP)2TK and the expression plasmids
pMSV-C/EBP and/or pMT3-Ha-Ras(L61). Cells were pretreated with a
PKC inhibitor (staurosporine at 20 nM) or the vehicle. Luciferase activ-
ities were determined 24 h after transient transfection with Lipo-
fectAMINE Plus and normalized to the activities of the internal control
plasmid pRL-null. B, model of C/EBP, with areas 1–9 containing the
first and second transactivation domain (TAD1 and TAD2) and the
DNA binding domain (DBD) of C/EBP with the basic region and
leucine zipper region. Area 9 is depicted in detail. The amino acid
sequence of area 9 contains only one potential phosphorylation site,
serine 248, which represents a PKC consensus site.
FIG. 5. Ras signaling phosphorylates C/EBP at serine 248 in
vivo. 293T cells were transfected with p(C/EBP)2TK and the expression
plasmids pcDNA3-C/EBP or pcDNA3-C/EBPS248A and/or pMT3-
Ha-Ras(L61). Phosphopeptide mapping of C/EBP (A), C/EBPS248A
(B), C/EBP plus Ras (C), and C/EBPS248A plus Ras (D) was per-
formed. The arrow indicates a phosphopeptide present in C/EBP wild
type (WT) cells and enhanced by Ras but not present in C/EBP S248A
cells, even after Ras activation. E, model of how Ras enhances the
ability of C/EBP to transactivate the G-CSF receptor promoter by
phosphorylation on serine 248. Our data suggest a model in which Ras
signaling phosphorylates C/EBP on serine 248 of the transactivation
domain (TAD), resulting in an enhancement of the ability of C/EBP to
transactivate the G-CSF receptor promoter. We hypothesize that this
enhancement could partly be mediated by recruitment of a co-activator
(see “Discussion”). Our data suggest that Ras signaling enhances the
activity of C/EBP to induce granulocytic differentiation by phospho-
rylation of serine 248.
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Regarding C/EBP, Mahoney et al. (37) report that phospho-
rylation of C/EBP in vitro by protein kinase C attenuates its
site-selective DNA binding . Subsequently, Pan et al. (38) could
identify a specific increase in DNA binding and the expression
of C/EBP and C/EBP during U937 monocytic cell differenti-
ation and related this to the transforming growth factor -sig-
naling pathway. Our data do not relate the effect of Ras sig-
naling to the DNA binding domain or DNA binding capacity of
C/EBP. Ras signaling acts on the C/EBP transactivation
domain, because it enhances 4-fold the transactivation function
of a fusion protein containing a Gal4 DNA binding domain and
the C/EBP transactivation domain (Fig. 2A) and does not
change the C/EBP DNA binding capacity (Fig. 2C). In fact,
Ras acts on serine 248 of the C/EBP transactivation domain,
because it does not enhance the 10-fold transactivation exhib-
ited by a C/EBP mutant with a deletion of area 9 (Fig. 3A) or
a serine 248 to alanine point mutant in area 9 (Fig. 3C). Thus,
we conclude that the Ras pathway acts on the transactivation
functions of C/EBP via serine 248.
Ross et al. (39, 40) report on other important phosphorylation
sites in the transactivation domain of C/EBP. Thus, GSK3
kinase phosphorylates C/EBP on threonines 222 and 226 (39).
Furthermore, Wnt signaling maintains preadipocytes in an
undifferentiated state and the adipogenic transcription factors
C/EBP and peroxisome proliferator-activated receptor  are
not expressed. When Wnt signaling in preadipocytes is pre-
vented by overexpression of axin or dominant-negative TCF4,
these cells differentiate into adipocytes (40). Our data in 293T
cells point to serine 248 as the major Ras-dependent phospho-
rylation site of C/EBP. Serine 248 of C/EBP is a PKC con-
sensus site, and a PKC inhibitor blocks the activation of
C/EBP by Ras (Fig. 4A). However, staurosporine is not com-
pletely specific for PKC. Therefore, we have not excluded other
kinases as responsible for the activation of C/EBP by Ras.
The serine to alanine mutant of C/EBP did not completely
eliminate the activation of C/EBP by Ras (Fig. 3C), whereas
deletion of region 9 did (Fig. 3A). Perhaps a transcriptional
co-activator binds optimally to C/EBP when serine 248 is
phosphorylated (Fig. 5E) but can still bind weakly to the S248A
mutant. In this model the effect of Ras on C/EBP transacti-
vation is at least partly indirect via a co-activator. This model
is supported by the ability of Ras to induce basal activity of
p(C/EBP)TK; on the other hand, our observation that Ras in-
creases phosphorylation of a C/EBP peptide but not of the
same peptide from C/EBPS248A suggests a more direct effect
on C/EBP by Ras (Fig. 5E). It is also possible that phospho-
rylation of serine 230 (39) might account for additional effects
of Ras on C/EBP. However, we could not observe any loss of
enhancement of transactivation capacity of C/EBP by Ras
signaling using the serine 230 to alanine mutant of C/EBP
(data not shown; the mutants were kindly provided by Dr.
MacDougald, Ann Arbor, MI). However, the very likely addi-
tional Ras-dependent phosphorylation sites in C/EBP besides
serine 248 (Fig. 5, A–D) still need to be mapped and to be tested
functionally. Our current studies to identify interacting pro-
teins of C/EBP using proteomics techniques (two-dimensional
gel electrophoresis and mass spectrometry) might also contrib-
ute to answering the question of whether the effect of Ras
signaling on serine 248 of C/EBP requires a co-activator bind-
ing to serine 248 or not.
Mutation of serine 248 to alanine had marked biologic con-
sequences in 32D cl3 cells, obviating the ability of C/EBP to
induce differentiation (Fig. 6). Whether this represents a defect
in Ras-dependent phosphorylation of this serine and conse-
quent alteration of trans-activating properties in myeloid cells
or whether it represents a more indirect effect in which a
Ras-dependent pathway interacts with serine 248 or with an-
other site in C/EBP affected by mutation of serine 248 to
alanine remains to be determined.
Further studies need to address the biological significance of
serine 248 of C/EBP by testing the serine to alanine 248
C/EBP mutant in biological assays of C/EBP function such
as in rescue assays in C/EBP knock-out mice. Of note, G-CSF,
but not interleukin-3, signals cooperate with C/EBP to induce
myeloid genes in Ba/F3 lymphoid cells (41). Because impair-
ment of C/EBP function can contribute to the pathogenesis of
acute myeloid leukemia (10, 11), whether serine 248 of C/EBP
is mutated in patients with acute myeloid leukemia and/or
whether inactivating Ras mutations in acute myeloid leukemia
might lead to a loss of C/EBP function needs to be addressed.
In summary, our data suggest that Ras signaling phospho-
rylates C/EBP on serine 248 of the transactivation domain,
resulting in an enhancement of the ability of C/EBP to trans-
FIG. 6. Mutation of serine 248 to alanine obviates the ability of
C/EBP to induce differentiation. To determine the biological im-
portance of serine 248, we linked C/EBP(S248A) to the human estra-
diol receptor (ER) ligand binding domain and isolated 32D cl3 cell
lines expressing this protein. Two subclones with protein expression as
high as that we previously achieved for C/EBPWT-ER were obtained
(A). To assess induction of differentiation by C/EBP(S248A)-ER, each
of the cell lines was placed in estradiol. Morphologically, after 3 days
the majority of 32D-C/EBP(WT)-ER cells had differentiated to neutro-
phils (B, left panels), whereas little morphologic change was seen with
32D-C/EBP(S248A)-ER-1 cells, and clone 2 developed primary gran-
ules without nuclear maturation (B, middle and right panels). To fur-
ther assess differentiation, RNAs prepared daily from cultures exposed
to estradiol were subjected to Northern blotting for MPO, LF, and
-actin (C). As reported previously, C/EBPWT-ER rapidly induced
MPO and induced LF after 48 h. In contrast, in 32D-C/EBP(S248A)-
ER-1 cells, neither MPO nor LF were induced, and in clone 2 cells, MPO
was induced in a delayed fashion and LF was not induced. WT, wild
type.
Ras Activates C/EBP26298
activate the G-CSF receptor promoter. Furthermore, our data
suggest a model where Ras signaling enhances the activity of
C/EBP to induce granulocytic differentiation by phosphoryla-
tion of serine 248.
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Recent results indicate that interactions of transcription factors with other
nuclear proteins play an important role in stem cell development, lineage
commitment and differentiation in the haematopoietic system, and the
pathogenesis of myeloid leukaemias. High-throughput proteomics by mass
spectrometric analysis of gel-separated proteins can identify multi-protein
complexes and changes in the expression of multiple proteins simultaneously.
This review describes an application of proteomic methods (2D gel electro-
phoresis (GE) and mass spectrometry (MS)), which can be used to identify reg-
ulated protein targets of transcription factors important in myeloid
differentiation and leukaemia. This global high-throughput functional pro-
teomics approach could lead to new insights into the network of protein–
protein interactions and target proteins involved in myeloid stem cell devel-
opment and leukaemia as well as provide new targets for rational pathogen-
esis-based therapies of leukaemia and cancer.
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1. Introduction
Recent data from different laboratories indicate that interactions of transcription
factors with other nuclear proteins plays not only an important role in lineage com-
mitment and differentiation in the haematopoietic system but also in the pathogen-
esis of acute myeloid leukaemia (AML) [1-10]. AML is characterised by a block in
myeloid differentiation and altered proliferation and cell death [11]. Genetic
approaches have already identified many cytogenetic abnormalities with correspond-
ing fusion genes or mutations in AML [12]. However, little is known on how these
genetic aberrations encoding fusion proteins lead to the biology of AML. Functional
genomics aims to identify the target genes of fusion proteins in AML. One of those
approaches is functional proteomics, which aims to identify the targets of a fusion
protein on a protein, rather than mRNA, level [13-16].
In this respect the generation and use of faithful mouse models of various leukae-
mias has been instrumental, not only in unravelling the pathogenetic mechanisms of
these diseases, but also in developing novel therapeutic targets that are currently
being tested in patients [17]. Progress in understanding the biology and mechanisms
of disease can be enhanced by the proteomic analysis of leukaemia. Since the term
‘proteome’ was introduced in 1995 [18], proteomic analysis has gained considerable
interest and is presently used as a tool in drug discovery in various contexts, includ-
ing [19]:
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• determining biochemical processes involved in disease
• monitoring cellular processes
• characterising protein expression levels
Proteomic analysis would further elucidate the underlying
protein networks involved in disease pathogenesis. Proteomics
can provide details of:
• changes in protein expression
• differential modifications involved in signalling
• interacting network groups of leukaemic fusion proteins and
transcription factors important in myeloid differentiation
This review describes an application of 2D gel electrophoresis
(GE) and mass spectrometry (MS) which has potential in the
identification of regulated protein targets (interacting proteins
and proteins altered in expression) of leukaemic fusion pro-
teins and transcription factors important in myeloid differen-
tiation. It also demonstrates the utility of this discovery-based
global strategy in elucidating novel pathways.
2. Review
The transcription factors C/EBPα and PU.1 are responsible
for the normal myeloid differentiation of stem cells to mono-
cytes and granulocytes, a process which is blocked in AML
(Figure 1) [1,2]. Recent results indicate that interactions of tran-
scription factors with other nuclear proteins play an impor-
tant role not only in normal differentiation of the
haematopoietic system, but also in the pathogenesis of mye-
loid leukaemias (Figure 1) [3-10]. In contrast to PU.1, the tran-
scription factor C/EBPα is crucial for the differentiation of
granulocytes. Data indicates that C/EBPα is activated by the
Ras signalling pathway via phosphorylation on ser248 [10].
Dominant negative mutations of C/EBPα have been found in
some patients with AML [8] but not in those with the t(8;21)
translocation. However, AML1-ETO positive AML blasts had
undetectable C/EBPα protein levels. AML1-ETO can bind to
C/EBPα, suppress its transcriptional activity and thereby
interfere with the autoregulation of the C/EBPα promoter,
leading to suppressed C/EBPα expression [9]. In summary,
protein–protein interactions of transcription factors are
important for normal myeloid development as well as leu-
kaemogenesis.
High-throughput proteomics by mass spectrometric study
of gel separated proteins can identify multi-protein complexes
and changes in the expression of multiple proteins simultane-
ously [13-16]. Changes in the post-translational modifications
of proteins leading to differential signalling patterns could be
determined by this proteomic approach. The authors suggest
that the functional studies on transcription factor interactions
described above should be extended to a whole proteome
(proteomic) approach to transcription factor interactions to
identify all protein expression changes caused by the overex-
pression of a transcription factor or a leukaemic fusion pro-
tein such as AML1-ETO, in a cell line overexpressing AML1-
ETO (target proteins) and to determine all interacting pro-
teins of AML1-ETO (the AML1-ETO multiprotein com-
plex), and to characterize those target and interacting proteins
of AML1-ETO functionally (functional proteomics). 
Proteome analysis has a number of advantages over RNA
expression studies using filter arrays or cDNA chips [14-16].
Protein and mRNA levels are only indirectly related and show
a correlation coefficient of < 0.5 in a number of studies. Since
the proteome reflects the sum of all levels of regulation
including transcriptional, translational and post-translational
regulation (protein modification), it represents the best bio-
chemical description of a cell or specific condition of a cell
(e.g., plus/minus AML1-ETO expression). Moreover, by
using 32P-labelled samples, it is possible to identify proteins
that are differentially phosphorylated between wild type cells
and cells overexpressing the protein of interest (in this case
AML1-ETO).
The proteomic studies of the authors use a Zn-inducible
AML1-ETO-U937 cell line as model system (Figure 2).
AML1-ETO is expressed under the control of the metal-
lothionin promoter and AML1-ETO expression can be
switched on by adding Zn to the culture medium. Upon Zn-
induction of inducible AML1-ETO expression in U937 cells
(or any other protein of interest), cells are labelled with 35S-
methionine and/or 32P. 35S-labelling is useful for quantifica-
tion of spot intensity and 32P-labelling is performed to iden-
tify phosphorylation changes in proteins.
After 6 hours, protein lysates are prepared for further pro-
teome analysis. Induction or repression of protein expression
is determined by proteome analysis combining 2D gel electro-
phoresis, MS and protein and expressed sequence tag (EST)
database searches. The 2D system used consists of immobi-
Figure 1. PU.1 and C/EBPα transcription factor interactions
in myeloid differentiation and leukaemia. The transcription
factor PU.1 (which drives monocytic differentiation and can be
mutated in AML [3]) is activated by the co-activator c-Jun [4], a
protein-protein interaction which can be disturbed by GATA-1 [5]
(leading to erythrocytic differentiation), by C/EBPα [6] (resulting in
granulocytic differentiation) or the leukemic fusion protein AML1-
ETO [7] (contributing to AML). 
AML: Acute myeloid leukaemia; C/EBPα: CCAAT/enhancer
binding protein alpha; PMN: Polymorphonucleocyte; SC: Stem
cell.
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lised pH gradients first in 1D and then SDS-PAGE in 2D. To
cover a wide range of proteins and obtain a resolution  suffi-
ciently high enough to detect low abundance proteins, six dif-
ferent gels in 2D are run of each sample: pH 3 – 10, 4 – 7 or
6 – 11 for isoelectric focusing in 1D with 14% and 7% SDS-
PAGE gels in 2D. Proteins are detected by silver staining and
autoradiography. Proteins with an isoelectric point between
pH 3 and pH 10 and ranging in size from 8 kDa to
~ 100 kDa can be reliably analysed. To exclude gel to gel dif-
ferences, each sample type has to be repeated at least 3 times.
Differential patterns of proteins obtained from 2D gels can
be analysed by Proteomweaver software, a new 2DGE image
analysis software developed by Definiens AG based on cogni-
tion network technology originally used in satellite image
classification. This software detects spots in a fully automated
manner with high precision and speed in a context-sensitive
way. Manual adjustments, such as background subtraction or
parameter settings, are unnecessary – even normalisation is
fully automated. Also spot matching can be performed with-
out manual interference. The results of Proteomweaver can be
investigated with advanced statistics tools. The most interest-
ing spots in terms of expression levels change simultaneously
with high statistical significance and can be displayed and/or
saved easily. Proteomweaver software seems to be faster, more
precise and easier to use than to older software available on
the market.
After the determination of reproducible protein spots
upregulated or downregulated by AML1-ETO, these proteins
are identified by MS (MALDI-TOF, tandem MS (MS/MS))
(Figure 2). For relatively abundant proteins, it is enough to
scale up the sample load in the analytical gel system and stain
proteins by coomassie blue to obtain enough material for fur-
ther analysis. For less abundant proteins, narrow pH gradients
(covering 1 – 2 pH units in 20 cm) are used in 1D allowing
higher loading of the gels. If the amount of the protein of
interest is too low to be detected by coomassie blue, the cells
can be labelled metabolically with 35S-methionine to detect
proteins by autoradiography and material from several gels
run in parallel can be combined. Finally, low abundant pro-
teins can be detected by MS/MS, rather than MALDI-TOF
MS.
In-gel digestion of proteins with trypsin ensures that there
is almost no loss of protein and the resulting eluted peptides
are analysed directly by MALDI-TOF MS, which generates
peptide mass fingerprints. This enables known proteins in
DNA or protein databases to be identified with the appropri-
ate search programs (e.g., PeptIdent, PeptideSearch,
MOWSE). From small amounts of starting material (< 0.1
pMol), a dual capacity MALDI-TOF MS instrument can
identify a mass range of 50 – 10000 amu, effective flight path
= 2.3 M, as well as > 500000 amu, effective flight path = 1.0
M. The current protocol allows up to 30 proteins to be proc-
essed within three working days. In the few cases where the
protein is not present in EST databases, de novo sequencing of
several peptides per protein has to be performed. For peptides
of low concentration not identified via the current annotated
databases after MALDI-TOF analysis, a high sensitivity liquid
chromatography ion-trap MS/MS system would be used.
Currently, there are some limitations to the very powerful
MALDI-TOF technology. Firstly, the database must contain
adequate stretches of protein sequence to enable comparison
with the experimentally derived mass map derived from the
unknown protein. This is not yet the case for the genomic
database due to incomplete coding information for all genes
[13,20,21]. For mass maps not matched in databases, other MS
technologies, such as use of the MS/MS proposed, can be
used to reanalyse and identify these unknown proteins present
in the fusion protein complex. The use of MS/MS allows
Figure 2. Proteomic analysis of transcription factor interactions: 2DGE and MALDI-TOF MS.
AML: Acute myeloid leukaemia; MALDI-TOF: Matrix assisted laser desorption/ionisation-time-of-flight; MS: Mass spectrometry; 
PMF: Peptide mass fingerprint.
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microsequencing by causing predictable fragmentations of
amino acid bands in peptides, allowing the determination of
individual mass differences in the mass spectrum, which then
can be used to infer at which position an amino acid was lost
from the peptide under analysis. The resulting MS/MS data
can be interpreted using programmes, such as SE-QUEST,
which compare the experimental data obtained with predicted
spectra from database sequences [22].
Due to the progress of the human genome project, EST
clones are already available for most of the proteins identified
using the method described. For those not yet available as
ESTs, the genes can be cloned with the aid of synthetic degen-
erated deoxyoligonucleotides deduced from peptide
sequences. For proteins with known sequences, clones can be
retrieved from the laboratories that cloned the genes.
After target proteins of AML1-ETO (or of any other pro-
tein of interest) have been identified in myeloid cells, whether
the promoters of these genes have functional AML1B protein
binding sites can be investigated. A search for AML1B con-
sensus DNA binding sites in the respective promoters can be
performed using transfac software [101] and by performing gel
shift assays with in vitro translated AML1B [1,2]. Luciferase
assays of promoter constructs with mutated AML1B sites
(which are generated by polymerase chain reaction mutagene-
sis) can be performed in myeloid U937 or nonmyeloid CV-1
cells [1,2]. Finally, a gene whose expression is downregulated by
AML1-ETO can be subcloned into the Zn-inducible vector
pPC18 to generate stable cell lines and to ask whether induci-
ble overexpression of this protein can induce myeloid differ-
entiation. This would indicate that the downregulation of this
protein by AML1-ETO might have a biological significance.
To determine a multi-protein complex (e.g., for AML1-
ETO), proteomic studies can be performed as outlined above
for target proteins. However, different starting material is used
for 2DGE and subsequent MS. AML1-ETO is expressed as a
fusion protein with a cleavable affinity tag, glutathion-S-
transferase (GST) to identify interacting proteins. In this case,
AML1-ETO protein is immobilised onto agarose beads using
a GST tag. Nuclear cell extracts are incubated with the beads
and the beads are then washed extensively. Thrombin is used
to cleave between the GST and the AML1-ETO protein,
resulting in the elution of all proteins that are specifically
bound to AML1-ETO. The advantage of this method is that
proteins that are nonspecifically bound to the matrix or the
tag itself are not eluted. The eluted proteins are resolved by
1D or 2DGE and compared to GST alone. The bands or
spots corresponding to proteins specifically bound to tagged
proteins are excised and analysed by MS as described for tar-
get proteins. Interacting proteins of AML1-ETO can be char-
acterised for functional relevance by performing GST pull-
down assays and luciferase assays of AML1-ETO responsive
promoters (such as the Bcl-2 promoter or a minimal thymi-
dine kinase  promoter driven by AML1B binding sites only).
3. Conclusion and expert opinion
Functional proteomics, the large-scale analysis of proteins and
their interactions, will contribute greatly to the understanding
of gene and protein function in the postgenomic era. The glo-
bal high-throughput functional proteomics approach
described will likely lead to new insights into the network of
protein–protein interactions and target proteins involved in
myelopoiesis and the development of leukaemia as well as
provide new targets for rational pathogenesis-based therapies
of leukaemia and cancer.
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Downregulation of c-Jun expression and cell cycle regulatory molecules
in acute myeloid leukemia cells upon CD44 ligation
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In the present study, we investigated the mechanism of
CD44 ligation with the anti-CD44 monoclonal antibody
A3D8 to inhibit the proliferation of human acute myeloid
leukemia (AML) cells. The effects of A3D8 on myeloid
cells were associated with speciﬁc disruption of cell cycle
events and induction of G0/G1 arrest. Induction of G0/G1
arrest was accompanied by an increase in the expression
of p21, attenuation of pRb phosphorylation and associated
with decreased Cdk2 and Cdk4 kinase activities. Since
c-Jun is an important regulator of proliferation and cell
cycle progression, we analysed its role in A3D8-mediated
growth arrest. We observed that A3D8 treatment of AML
patient blasts and HL60/U937 cells led to the down-
regulation of c-Jun expression at mRNA and protein level.
Transient transfection studies showed the inhibition of
c-jun promoter activity by A3D8, involving both AP-1
sites. Furthermore, A3D8 treatment caused a decrease in
JNK protein expression and a decrease in the level of
phosphorylated c-Jun. Ectopic overexpression of c-Jun in
HL60 cells was able to induce proliferation and prevent
the antiproliferative effects of A3D8. In summary, these
data identify an important functional role of c-Jun in the
induction of cell cycle arrest and proliferation arrest of
myeloid leukemia cells because of the ligation of the cell
surface adhesion receptor CD44 by anti-CD44 antibody.
Moreover, targeting of G1 regulatory proteins and the
resulting induction of G1 arrest by A3D8 may provide new
insights into antiproliferative and differentiation therapy
of AML.
Oncogene (2003) 22, 2296–2308. doi:10.1038/sj.onc.1206393
Keywords: CD44; c-Jun; AML; differentiation; prolif-
eration; cell cycle
Introduction
Acute myeloid leukemia (AML) is characterized by a
block in differentiation (Tenen et al., 1997). The
proliferative activity of leukemic blasts is maintained
leading to the accumulation of malignant cells and a
suppression of normal hematopoiesis (Tenen et al.,
1997; Lowenberg et al., 1999). In experimental systems,
and in speciﬁc clinical settings such as in acute
promyelocytic leukemia, the differentiation block can
be overcome and leukemic cells can terminally differ-
entiate after exposure to either chemical agents (Kan-
tarjian, 1999) or by use of monoclonal antibodies (both
conjugated and unconjugated) that target antigens on
leukemic blasts (Sievers, 2000; Waxman, 2000). Among
the various antigens that could serve as targets of
antibody-mediated differentiation, the adhesion recep-
tors, such as CD44, deserve considerable attention in
view of their role in transmitting signals that can
modulate cell proliferation, survival and differentiation
as well as their prevalence among leukemic cells (Reuss-
Borst et al., 1992; Liesveld et al., 1994; Moll et al., 1998;
Verfaillie, 1998).
A compelling body of evidence suggests outside-in
signaling through CD44 (Sanford et al., 1998; Lowell
and Berton, 1999) when ligated with its natural ligand,
hyaluronic acid (Aruffo et al., 1990; Miyake et al., 1990)
or with speciﬁc monoclonal antibodies (MoAbs). Recent
reports have suggested that ligation of CD44 by anti-
CD44 MoAbs (e.g. A3D8) has antiproliferative and
differentiation-inducing effects on myeloid cell lines and
AML patient blasts in all AML subtypes (Allouche
et al., 2000; Charrad et al., 1999). However, the
underlying molecular mechanisms remain largely un-
known. In this study, we assessed the ability of the anti-
CD44 MoAb A3D8 to modulate the expression of c-Jun
and cell cycle regulatory molecules in the human
myeloid leukemia cell lines HL60 and U937. We focused
our attention on c-Jun, since it is implicated in the
regulation of cell proliferation and cell cycle progression
(Kovary and Bravo, 1991; Smith and Prochownik, 1992;
Behre et al., 1999; Schreiber et al., 1999; Wisdom et al.,
1999; Bakiri et al., 2000; Shaulian and Karin, 2001).
Although the role c-Jun in myeloid cells has been largely
studied with respect to differentiation (Behre et al.,
2002; Rangatia et al., 2002; Vangala et al., 2002), the
role of c-Jun in A3D8-mediated growth arrest in human
myeloid leukemia cells has not been analysed before.
Moreover, at present there are only a few data regarding
the inﬂuence of c-Jun on cell proliferation and cell cycle
progression in myeloid cells. Consequently, it would be
of interest to investigate the role of c-Jun and cell cycle
regulatory molecules in parallel to further strengthening
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our knowledge on this ubiquitous transcription factor.
Our recent data (Elsa¨sser et al., 2002; Rangatia et al.,
2002) suggests that c-Jun expression might be a key
event in the decision of a myeloid cell to differentiate or
to proliferate. A mechanistic link between c-Jun and cell
cycle in ﬁbroblasts has been reported (Hilberg and
Wagner, 1992; Milde-Langosch et al., 2000).
The cell cycle machinery as such, is a highly
coordinated process in which cyclins, cyclin-dependent
kinases (Cdks) and their inhibitors (CDKIs) are
differentially regulated (Muller et al., 1993; Matsushime
et al., 1994; Sherr, 1994; Gitig and Koff, 2000). Each
cyclin can associate with one or more of the Cdk family,
of which at least Cdk2 and Cdk4 kinase activities have
been shown to operate in the G1 phase (Bates et al.,
1994; Meyerson and Harlow, 1994). The activity of G1
cyclin–Cdk complexes is regulated, at least in part, by
CDKIs. Evidence is accumulating that CDKIs are
targets of extracellular and intracellular signals that
regulate cell growth and differentiation (Harper et al.,
1993a, b; Hilberg et al., 1993; Nead et al., 1998;
Nishitani et al., 1999; Steinman et al., 1994). Based on
these data and in the present study, we provide evidence
that growth inhibition by CD44 ligation with A3D8 in
myeloid leukemia cells is mediated through its effect on
c-Jun expression. This is the ﬁrst report providing a link
between c-Jun and cell cycle in CD44-mediated growth
arrest of myeloid leukemia cells.
Results
CD44 ligation inhibits the proliferation and induces
terminal differentiation of myeloid leukemia cells
Treatment of HL60 (myeloblastic) and U937 (mono-
blastic) cells with the anti-CD44 MoAb antibody A3D8
for the time points as indicated in ﬁgure legends resulted
in a dramatic decrease of proliferation (Figure 1). We
performed the nonradioactive quantiﬁcation of cell
proliferation and cell viability (3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay)
for investigating the proliferation state of HL60
(Figure 1a) and U937 cells (Figure 1c). The decreased
proliferation of these myeloid cells also correlated with
decreased CD71 (transferrin receptor) expression (Fig-
ure 1b, d). CD71 is known to be a proliferation marker
(Theil, 1990; Kuhn, 1994; Trayner et al., 1998). Upon
CD44 ligation by A3D8 in HL60 and U937 cells, we
observed a drastic decrease in CD71 expression (47 and
7%, respectively) compared to the controls. It is
important to note that CD71 expression was higher in
HL60 cells (>90%, Figure 1b, upper left panel) as
compared to U937 cells (o20%, Figure 1d, upper left
panel). No inhibitory effect was observed with the
isotype-matched MoAb control. Our results are in
support of the recent observation that A3D8 has
antiproliferative effect on myeloid cell lines (Charrad
et al., 2002).
To rule out the possibility of a cytotoxic effect of
A3D8, we performed differentiation studies. Treat-
ment of human myeloid HL60 and U937 cells with
Figure 1 Decreased proliferation in myeloid leukemia cells upon
CD44 ligation. Effect of anti-CD44 MoAb (A3D8) on cellular
proliferation of HL60 and U937 myeloid leukemia cells as assessed
by MTT and FACS analysis. (a, c) MTT assay: cells were cultured
in 96-well plates with or without A3D8 and isotype control
antibody (20 mg/ml) for 1–4 days and then MTT incorporation was
measured. The absorbance at 575 nm (OD575), which is an
estimate of the proliferation state of cells, was measured using an
Elisa plate reader. Results are shown as mean7s.d. of three
independent experiments, each experiment in triplicate. (b, d)
FACS analysis: cells were cultured 1 105/200ml/well for 36 h in
the presence or absence of A3D8 (20mg/ml). They were then
analysed for their surface CD71 (transferrin receptor) expression
and the results were presented as scatter diagrams. The percentage
values (upper left panel) in each scatter diagram represents the
percentage positive cells of the marker (i.e. cells on upper left
quadrant)
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A3D8-induced striking changes in the morphology of
these cells characteristic of terminal differentiation
(Figure 2a, c). For example, A3D8-treated cells showed
decreased nucleus: cytoplasm ratios, segmented nuclei,
few nucleoli and chromatin condensation. The effects
like the formation of aggregates in culture and
adherence became visible only after 12–18 h of A3D8
treatment. We also analysed the expression of the cell
differentiation marker CD11b in HL60 and U937 cells
(Figure 2b, d) and observed that its expression was
increased in both cell lines after CD44 ligation. The
expression of CD11b increased to B31% after A3D8
treatment compared to unstimulated (B7%) and
isotype control (B9.6%) in HL60 cells (Figure 2b,
upper left panels). Corresponding to this, the D-value
(calculated as described in the Materials and methods)
was found to be 57 after A3D8 treatment in HL60 cells
compared to +30 for the control (Table 1). In U937
cells, the expression of CD11b increased toB22% after
A3D8 treatment compared to unstimulated (B6%) and
isotype control (B7%) (Figure 2d, upper left panels).
Corresponding to this, the D-value was found to be 78
after A3D8 treatment in U937 cells compared to +30
for the control (Table 1).
CD44 ligation with A3D8 induces a G0/G1 arrest in
myeloid leukemia cell lines
Cell cycle arrest is a common feature of cells undergoing
terminal differentiation and defective proliferation.
Based on the growth inhibitory and differentiation-
inducing effects of A3D8 on myeloid leukemia cell lines,
we investigated their cell cycle progression in response to
A3D8. The DNA content analysis showed that the
myeloid cells underwent a G0/G1 arrest (Figure 3).
Surprisingly, we observed a change in cell cycle
distribution at 6 h of A3D8 treatment in HL60 cells as
compared to untreated cells or cells treated with the
isotype antibody. The proportion of cells in G0/
G1 phase increased from 54% (controls) to 67% in
A3D8-treated cells after 24 h (Figure 3a). This was
mirrored by a decrease in the proportion of cells in the S
Figure 2 Differentiation induction in myeloid leukemia cells
upon CD44 ligation. Morphological analysis of HL60 and U937
myeloid leukemia cells: Cytospin preparations of cells stained
with May–Gru¨nwald–Giemsa after in vitro treatment for 36 h with
medium alone, with isotype antibody (20mg/ml) and A3D8 (20mg/
ml). (a, c) Representative data from HL60 and U937 cells,
respectively. (b, d) Changes in the differentiation marker (CD11b)
in HL60 and U937 cells before and after CD44 ligation with A3D8,
respectively. Cells were cultured 1 105/200 ml/well for 24–36 h
in the presence or absence of A3D8 (20 mg/ml). They were
then analysed for their surface CD11b expression and the results
were presented as scatter diagrams. The percentage values
(upper left quadrant) in each scatter diagram represents the
percentage positive cells of the marker (i.e. cells on upper left
quadrant)
Table 1 CD44 ligation decreases proliferation and induces differentiation in myeloid leukemia cells
Marker MFI ratio D-value (%)
Unstimulated Isotype A3D8 Unstimulated Isotype A3D8
HL 60
CD11b 1.11 1.03 1.41 30.00 +23.00 57.00
CD71 4.47 3.10 1.35 30.00 +25.00 +12.00
U937
CD11b 1.07 1.02 1.32 30.00 +20.00 78.00
CD71 1.00 1.03 0.98 30.00 36.00 +24.00
(+) Indicates decreased expression, () indicates increased expression.
Expression of CD71 and CD11b in HL60 and U937 cells in response to inducers with their MFI ratio and D-values, calculated as: MFI ratio of
unstimulated sampleMFI ratio of induced sample/MFI of unstimulated sample) 100.
The D-value for unstimulated control was arbitrarily chosen 30. The () sign indicates more MFI ratio of induced sample compared to
unstimulated sample and hence, increased expression of the marker
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and G2 phase from 13% (controls) to 2% in A3D8-
treated cells and from 23% (controls) to 4% in A3D8-
treated cells, respectively. The effect of A3D8 on cell
cycle was dose dependent (Figure 3b). In accordance
with the induction of terminal differentiation by A3D8,
we observed 14–27% of dead cells after 36 h. These data
suggest that the growth inhibitory effect of A3D8 on
myeloid cells is, in part, because of its effect on cell cycle
progression.
CD44 ligation with A3D8 induces the expression of p21
and downregulates the expression of major G1 regulatory
proteins
Based on the effects of A3D8 on G1phase accumula-
tion, we hypothesized the role of major G1 regulatory
proteins. We examined the effect of A3D8 on p21, pRb,
cyclin D1, cyclin D2, Cdk2, Cdk4 and Cdk6 protein
expression. Our results show that A3D8 treatment of
HL60 cells caused marked upregulation of p21 protein
expression after 6 h (Figure 4a, lane 3). The increased
p21 protein level persisted for 12 h and was undetectable
thereafter. The p21 level was undetectable in untreated
or isotype-treated cells (Figure 4a, lanes 1 and 2). Since
HL60 cells are p53 negative because of homozygous
deletions (Steinman et al., 1998), it is conceivable that
p21 induction by A3D8 is p53 independent. Our results
also show that treatment of HL60 cells with A3D8 for
12 and 24 h markedly decreases the expression of pRb
(Figure 4e). It is important to note the presence of a slow
migrating band (upper band) and a faster migrating
band (lower band) when the blot was probed with anti-
Rb antibody. The upper band corresponds to the
hyperphosphorylated (*) form, while the lower band
corresponds to the hypophosphorylated form (Slack
et al., 1993; Savatier et al., 1994). Inhibition of pRb
correlated with decreased levels of Cdk2 and Cdk4
(Figure 4b, c). There was no effect on Cdk6 expression
(Figure 4d), a little downregulation effect on cyclin D1
expression and no effect on the expression on cyclin D2
(data not shown).
CD44 ligation with A3D8 inhibits Cdk4 and Cdk2
activities
Cdk4 and Cdk2 kinase activities have been shown to
operate in the G1 phase. G0/G1 arrest by A3D8 led us
to analyse the kinase activities associated with these
Cdks. Antibodies against Cdk4 and Cdk2 were used to
perform immunocomplex kinase assays using recombi-
nant Rb fusion protein and puriﬁed histone H1 protein
as substrates, respectively. Consistent with its effect on
cell cycle progression, A3D8 treatment inhibited Cdk4
and Cdk2 kinase activities (Figure 4g, h). The densito-
metry analysis showed that A3D8 treatment after 24 h
caused greater than fourfold inhibition of Cdk4 kinase
activity. Interestingly, Cdk2 kinase activity showed
similar results. To normalize for the immunoprecipita-
tion (IP) efﬁciency, a Western blot for respective Cdks
was also performed after IP. IgG served as IP control.
The results (Figure 4g, h) clearly show the speciﬁcity of
our kinase reaction and that Cdk2 and Cdk4 were not
degraded during the kinase reaction. It is important to
note here that it might seem surprising to correlate Cdk
activity with Rb phosphorylation after A3D8 treatment
(Figure 4e) in which Rb IF8 (anti-mouse, sc-102) was
used. However, this is not the case. Western blot of the
lysates when probed with phospho-speciﬁc Rb antibody
(pRb Ser-780, sc-12901, Santa Cruz) gave the expected
results. Our results show that treatment of the cells with
A3D8 led to decreased Rb phosphorylation (Figure 4f),
thereby correlating with decreased Cdk activity. The
difference in the two results could thus, be attributed to
antibody speciﬁcities. These data suggest that induction
of G0/G1 arrest by A3D8 in myeloid cells may involve
p21 induction and/or inhibition of Cdk activity.
Figure 3 CD44 ligation arrests myeloid leukemia cells in the
G1phase of cell cycle. The ﬁgure represents cell cycle distribution
of HL60 cells before and after A3D8 treatment for different time
points. At the indicated time, cells were washed with PBS, and
stained for DNA with propidium iodide as described in Materials
and methods. Cell cycle distribution was then determined by FACS
analysis. (a) Cell cycle distribution at indicated times of treatment
with A3D8. (b) Cell cycle distribution showing different phases in a
dose response of A3D8. Lines: 1, A particular phase at 6 h of A3D8
treatment. 2, At 24 h A3D8 treatment and 3, at 36 h of A3D8
treatment
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CD44 ligation downregulates c-jun mRNA and c-Jun
protein expression
The AP-1 transcription factor c-Jun functions as a
proliferation-promoting gene and is involved in cell
cycle progression. Consequently, the expression of c-Jun
would be expected to change in response to decreased
proliferation and cell cycle arrest of HL60 and U937
cells upon CD44 ligation with A3D8. Our results show
that there is a drastic decrease in c-jun mRNA
expression (Figure 5a, b) upon A3D8 treatment of the
myeloid cells, c-jun expression was also downregulated
in AML patient blasts after 6 and 12 h of A3D8
treatment in vitro (Figure 5c). We also observed a
dramatic decrease in c-Jun protein expression upon
CD44 ligation (Figure 5d,e). It is important to note that
there is a higher basal level of c-Jun expression in HL60
cells than in U937 cells (Figure 5d, e, unstimulated
lanes). The amount of protein loaded in U937 blot
(Figure 5e) was at least three times that of HL60 cells
(Figure 5d). To rule out a general toxic effect, we show
that the expression of c-Fos (Figure 5f) is not altered in
a similar fashion. These data suggest that the down-
regulation of c-Jun contributes to A3D8-mediated
growth arrest in myeloid cells.
CD44 ligation downregulates human c-jun promoter
activity via AP-1 sites
To elucidate the molecular mechanisms underlying the
downregulation of c-Jun expression by CD44 ligation, we
performed promoter studies. U937 and HL60 cells were
transiently transfected with different c-jun promoter/
luciferase constructs and then subjected to A3D8
treatment. Our results show that the full-length c-jun
promoter (bp 1780/+731) activity was downregulated
14-fold after A3D8 treatment (Figure 6). It was not a
vector effect since A3D8 had no effect on pGL3, in which
c-jun promoter constructs were subcloned. As a positive
control for our promoter studies, we also show that TPA
increases the c-jun promoter activity (data not shown). To
map site(s) in the c-jun promoter responsible for the
downregulation, a series of c-jun promoter deletion
mutant-luciferase gene chimeric plasmids with variable
ends (from bp 1780 to 63), (Wei et al., 1998) was also
transiently transfected into the cells. The promoter
activity of each construct (without any treatment) with
respect to the full-length promoter activity is shown
(Table 2). The results show that the downregulation of c-
jun promoter activity is lost after deletion of the region
between bp 1780 and 63 (with 63/+731 construct),
where two AP-1 sites (bp 64 and 182) are located
(Figure 6a, c). The presence of the two AP-1 sites in the c-
jun promoter, a proximal (bp 64) and a distal (bp 182)
Figure 4 CD44 ligation induces the expression of p21 and down-
regulates the expression of major cell cycle regulatory proteins as well
as inhibits Cdk activity. The ﬁgure shows immunoblot analysis from
whole cell lysates of HL60 cells (p53 negative), for (a) p21, a cyclin-
dependent kinase inhibitor probed with anti-p21 antibody (SC); (b)
Cdk2; (c) Cdk4; (d) Cdk6; (e) pRb; (f) phospho-Rb. Lanes: 1, 2,
Unstimulated and isotype control, 3–5, A3D8 stimulated (6, 12, 24 h,
respectively). The numbers underneath the blot indicate protein/
respective b-tubulin ratios after densitometric analysis (Aida 2.1
software program). (g and h) In vitro kinase assay for Cdk2 and
Cdk4, respectively: HL60 cells were treated with 20mg/ml A3D8 or
isotype antibody for different time points. Whole cell lysates were then
prepared and immunoprecipitated with Cdk2 (g) and Cdk4 (h)
antibodies as described under Materials and methods section. Histone
H1 was used as substrate for Cdk2- and Rb-fusion protein as substrate
for Cdk4 in the in vitro kinase assay. Also shown (in the right panel) is
a Western blot of Cdk2 and Cdk4 after IP of the respective kinases
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one led us to further map the AP-1 site responsible for
the downregulation. Upon deletion of the proximal
(delpAP-1) or the distal (deldAP-1) AP-1 sites in the c-
jun promoter, we observed a similar downregulating
effect, while the effect was lost upon deletion of both AP-
1 sites (Figure 6b). The loss of repression effect cannot be
a simple activation because the promoter activity in the
presence of A3D8 is the same as that of the promoter
alone (Figure 6b, last two bars), although in the presence
of A3D8 antibody the activity of the promoter with two
mutant AP-1 sites has a higher activity than either of the
singly mutated constructs (Figure 6b, compare bars with
A3D8 treatment). These results show that both AP-1 sites
are important for the downregulation of c-jun promoter
activity upon CD44 ligation with A3D8.
A3D8 treatment decreases c-Jun phosphorylation and
JNK expression
The decreased transactivation property of c-Jun by A3D8
could be mediated through a change in the phosphoryla-
tion status of c-Jun. To investigate if A3D8 treatment of
the cells caused decreased c-Jun phosphorylation, we
performed immunoblot analyses of cell lysates from
HL60 cells using a phospho-speciﬁc (Ser63) anti-c-Jun
antibody (Figure 7). No phosphorylated c-Jun was
detected at 12 or 24h after A3D8 treatment (Figure 7,
lanes 4 and 5), although c-Jun phosphorylation was
detected at 6 h and in the controls (Figure 7, lanes 1–3).
Furthermore, our results showed that A3D8 treatment
drastically decreased the expression of JNK1, ahead of
Figure 5 CD44 ligation downregulates c-jun mRNA and protein expression in myeloid leukemia cells and AML patient samples.
Negative gel image showing c-junmRNA transcript ampliﬁed with speciﬁc c-jun primers and immunoblot analysis of whole cell extract
probed with anti-c-Jun and anti-c-Fos antibodies (Santa Cruz Biotechnologies) was performed as described in Materials and methods.
b-tubulin served as loading control. (a) HL60 cells: Lanes: 1, Marker, 2, unstimulated control, 3–5, A3D8 stimulated (6, 12, 24 h,
respectively), 6, isotype control, (b) U937 cells: Lanes: 1, Marker, 2, unstimulated control, 3–5, A3D8 stimulated (6, 12, 24 h,
respectively), 6, isotype control. (c) In AML patient samples the expression of c-jun was measured by quantitative Real-time PCR. The
bars represent the mean ratio of c-jun to G6PD of four AML patient samples. (d) c-Jun expression from whole cell lysates of HL60 cells
and (e) data from U937 cells. Lanes: 1, In vitro-translated c-Jun, 2, reticulocyte lysate, 3–4, unstimulated and isotype control, 5–7,
A3D8 stimulated (6, 12, 24 h, respectively). (f) Immunoblot analysis for c-Fos from whole cell lysates of HL60 cells. Lanes: 1, 2,
Unstimulated and isotype control, 3–5, A3D8 stimulated (6, 12, 24 h, respectively). The numbers underneath the blot indicate the
c-Jun/b-tubulin ratios after densitometric analysis (Aida 2.1 software program)
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decreased c-Jun phosphorylation (Figure 7b). The effect
seems to be JNK-speciﬁc since only an insigniﬁcant effect
on ERK1 expression could be detected (Figure 7c). These
data suggest that inhibition of c-Jun expression by A3D8
results from inhibition of c-Jun phosphorylation via the
JNK pathway. Taken together, our data indicate that
inhibition of c-Jun/AP-1 activity may be the mechanism
by which A3D8 inhibits the proliferation and causes cell
cycle arrest in myeloid cells.
Overexpression of c-Jun in HL60 cells overcomes the
proliferation-inhibiting effects of A3D8
To further characterize the role of c-Jun biologically,
we overexpressed c-Jun in HL60 cells to investigate if
the effects of proliferation inhibition and differentiation
induction by A3D8 can be overcome. HL60 cells were
transfected with pMV7-c-jun retroviral construct as
described in the Materials and methods section. After
selection of the cells in G418, they were kept in G418-
free media with and without A3D8. We observed that
the expression of CD71 was markedly increased in
pMV7-c-jun-transfected cells as compared to vector
alone (Figure 8a). Moreover, c-Jun overexpressing
HL60 cells showed increased cell numbers (Trypan blue
cell counting) as compared to cells containing vector
alone over a period of 3 days (Figure 8b). We could
clearly observe a slow growth in vector (pMV7)-
transfected cells under constant selection pressure,
whereas pMV7-c-jun-transfected cells showed a higher
growth rate under similar conditions. As a more direct
measure of cell proliferation, we also performed
bromodeoxyuridine (BrdU) incorporation assay.
Our results clearly show that pMV7-c-jun-transfected
cells incorporate more BrdU than pMV7-transfected
cells and hence, the former have more proliferation
potential than the latter (Figure 8c). After 24 h post-
transfection, the percentage of pMV7-c-jun-transfected
cells showed >50% BrdU incorporation as compared
to o10% in the control. It is important to mention
here that c-Jun overexpression in HL60 cells did
not lead to any cell death as determined by propidium
iodide staining (data not shown). Thus, c-Jun expression
and cell proliferation in fact, do correlate in myeloid
leukemia HL60 cells. The expression of c-Jun was
25-fold higher in pMV7-c-jun-transfected cells as
compared to the controls (Figure 8d, e). Further-
more, we observed that A3D8 treatment of untrans-
fected HL60 cells and the cells transfected with vector
alone (pMV7) caused decreased proliferation and
hence, decreased CD71 expression as compared to the
isotype control (Figures 1 and 8e, panels i, ii). On the
contrary, in HL60 cells overexpressing c-Jun (pMV7-
c-jun), A3D8 treatment did not lead to any changes
in CD71 expression as compared to the isotype control
(Figure 8e, panel iii). A similar pattern was observed
with CD11b expression (Figure 8f), although the
differentiation-inducing ability of c-Jun in c-Jun over-
expressing HL60 cells is not of the same extent as
the proliferation-inducing ability. These results clearly
indicate that downregulation of the proliferation
promoting transcription factor c-Jun is a prerequisite
for A3D8-mediated proliferation-inhibition in our
settings.
Figure 6 CD44 ligation downregulates c-jun promoter activity via
AP-1 sites. The ﬁgure represents a series of c-jun promoter deletion
mutants-luciferase gene chimeric plasmids with variable ends (from
bp 1780 to 63) (Wei et al., 1998). Each construct was transiently
transfected into HL60 and U937 cells. Transfected cells were then
treated with A3D8, 6 h before measurement of luciferase activity.
Promoter activity is normalized for transfection efﬁciency by
dividing ﬁreﬂy luciferase activity by renilla luciferase activity of a
cotransfected reporter plasmid pRL-0. Results are presented as
mean7s.d. of at least three independent experiments. pc-jun
represents the promoter constructs and pGL3 is the vector in
which the promoter constructs were subcloned. (a) Deletion
analysis of c-jun promoter. (b) Mutagenesis analysis of the AP-1
sites in the c-jun promoter. (c) A model of c-jun promoter showing
AP-1 sites
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Discussion
In the present study, we investigated the effect of CD44
ligation by anti-CD44 MoAb A3D8 on the proliferation
of myeloid leukemia cells and the underlying molecular
mechanisms involved. Our results demonstrate that
ligation of CD44 with A3D8 causes growth arrest and
induces terminal differentiation of human myeloid
leukemia cell lines HL60 and U937 through the down-
regulation of c-Jun expression via AP-1 sites (Figures 5
and 6). Furthermore, decreased JNK expression and a
consequent decrease in c-Jun phosphorylation may be
involved in A3D8-mediated downregulation of the c-Jun
promoter activity (Figure 7). The downregulation of c-
Jun expression is a prerequisite for growth inhibitory
effects of A3D8 since overexpression of c-Jun is able to
prevent A3D8-mediated effects (Figure 8). We also show
an induction of G0/G1 arrest by A3D8 (Figure 3), which
is accompanied by induction of p21 and inhibition of
pRb, Cdk2 and Cdk4 protein expression and Cdk
activity (Figure 4). Although our results show c-Jun
inactivation as an important mechanism of A3D8-
mediated growth arrest, we do not rule out other
mechanisms by which A3D8 can block proliferation of
myeloid leukemia cells.
Our results revealed that CD44 ligation with
A3D8 decreases the proliferation and leads to the
induction of terminal differentiation of HL60 and
U937 cells (Figures 1 and 2). These results are consistent
with previous reports (Charrad et al., 2002). A G0/G1
arrest upon A3D8 treatment of HL60 cells (Figure 3)
could be explained considering that an exit from the cell
cycle is a prerequisite for growth arrest and cell
differentiation. Consistent with this and other reports
(Danova et al., 1990; Hunter and Pines, 1994; Hor-
iguchi-Yamada et al., 1994; Jiang et al., 1994; Lieber-
mann et al., 1995; Steinman et al., 1998) A3D8
treatment led to the induction of p21 and inhibition of
Cdk4 and Cdk2 kinase activities (Figure 4). Thus,
increase of p21 and/or the decrease of Cdk2 and Cdk4
expression in HL60 upon A3D8 treatment are sufﬁcient
to inhibit kinase activity required for G0/G1 progression
into the S phase. In correlation with decreased Cdk
activity, the phosphorylation of Rb was also decreased
upon A3D8 treatment suggesting a role of Cdk/Rb
pathway in cell cycle arrest by CD44 signaling
(Figure 4f).
CD44 ligation with A3D8 markedly downregulated
the expression of c-Jun both at mRNA and protein
level (Figure 5). The downregulation of c-Jun could
be expected because of the decreased proliferation of
these cells. The downregulation of c-jun upon A3D8
treatment was also observed in AML patient blasts
(Figure 5). However, the effect of CD44 ligation on c-jun
expression in AML patients is less prominent than
in myeloid cell lines. This could be because of
the difference in cytogenetic set up in different
AML patients. Moreover, the requirement of c-Jun
could differ in normal versus transformed cells, in tumor
cells of different cell lineages, or in cells having
undergone transformation via different mechanisms.
Table 2 Activity of different c-jun promoter/luciferase constructs
DNA constructs (promoter/LUC) Basal promoter activity (% of full-length c-jun)
1780- - - - - - - - - - - - - - -//- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -//- - - - - - - - -+731 100
952- - - - - - - - - - -//- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -//- - - - -+731 115717
716- - - - -//- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -//- - - - -+731 483739
345- - - - -//- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -//- - - - -+731 48712
180- - - - - - - - - - - - - - - - - - - - - - - - - - - - -//- - - - -+731 1474
63- - - - - - - - - - - - -//- - - - -+731 4579
The values represent the promoter activity of different c-jun promoter constructs used in this study with respect to the full-length c-jun promoter
(1780/+731) chosen as 100. The transfection efﬁciency was corrected by dividing the promoter luciferase activity by renilla luciferase activity
Figure 7 CD44 ligation decreases c-Jun phosphorylation and
JNK expression. The ﬁgure represents immunoblot analysis of
whole cell extract of HL60 cells probed with anti-phospho c-Jun
(Ser 63), anti-JNK1 and anti-ERK1 antibodies (Santa Cruz
Biotechnologies). (a) Phospho c-Jun, (b) JNK1, and (c) ERK1.
Lanes: 1, 2, Unstimulated and isotype control, 3–5, A3D8
stimulated (6, 12, 24 h, respectively). The numbers underneath the
blot indicate the protein/respective b-tubulin ratios after densito-
metric analysis (Aida 2.1 software program)
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To rule out the downregulating effects on c-Jun as a
consequence of A3D8 toxicity, we also show that A3D8
treatment does not downregulate the expression of c-
Fos nonspeciﬁcally. Transient transfections of c-jun
promoter/luciferase constructs in myeloid cells revealed
that both AP-1 sites are responsible for the down-
regulation of c-jun promoter activity by CD44 signaling
(Figure 6). Our results also show that the expression of
JNK is decreased upon A3D8 treatment, with a
consequent decrease in the level of c-Jun phosphoryla-
tion, which is consistent with published reports
(Figure 7) (Binetruy et al., 1991; Minden et al., 1994;
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Smeal et al., 1991). We used JNK1 since it has been
shown to preferentially bind c-Jun and phosphorylate
c-Jun (Kallunki et al., 1994). The role of other
JNKs remains to be determined. The effect of A3D8 is
JNK-speciﬁc because ERK expression is not changed
under similar conditions. It is important to note here
that c-Fos expression did not change upon A3D8
treatment (Figure 5f). Fos is known to be regulated by
the ERK pathway (Chou et al., 1992; Deng and Karin,
1994). The decreased JNK expression and hence, c-Jun
phosphorylation could in turn be because of the positive
effect of A3D8 treatment on p21 protein level
(Figure 4a). It has been reported that interaction of
p21 with JNK inhibits JNK activity (Shim et al., 1996;
Patel et al., 1998). Thus, it is conceivable that the
inhibition of JNK by p21 may be the mechanism for the
downregulation of c-Jun phosphorylation and hence,
the transactivation potential of c-jun.
A3D8-mediated proliferation-inhibition in HL60 cells
was prevented by c-Jun overexpression (Figure 8e),
suggesting that c-Jun/AP-1 activity is one of the
molecular targets downstream of CD44 signaling. BrdU
incorporation, CD71 expression (Theil, 1990; Kuhn,
1994; Trayner et al., 1998) and Trypan blue cell counting
were used as a measure of cell proliferation and clearly
demonstrate that c-Jun in fact, increases the prolifera-
tion of myeloid cells. c-Jun overexpression had little
effect on CD11b expression (Figure 8f). In the context of
the role of c-Jun in myeloid cell differentiation, this
might seem surprising. However, the role of c-Jun in
differentiation could be time limiting. It is important to
mention here that the downregulation of c-Jun expres-
sion upon CD44 ligation is in accordance with our
recent ﬁndings in which the transcription factor C/EBPa
was shown to downregulate c-Jun expression to induce
myeloid differentiation (Rangatia et al., 2002). In
summary, it is thus, conceivable to propose a model
(Figure 9) which shows that the downregulation of c-Jun
expression along a pathway which involves inhibition of
JNK by p21 resulting in decreased c-Jun phosphoryla-
tion and hence, decreased promoter activity concomi-
tant with decreased cell cycle proteins may be an
important mechanism for regulating CD44-mediated
differentiation-induction and proliferation-arrest with
A3D8. Our results provide a framework for further
investigations and suggest that clariﬁcation of the
mechanisms of regulation may reveal novel targets for
antiproliferative and/or differentiation therapy in AML.
Materials and methods
AML patient samples
Peripheral blood or bone marrow specimens containing at least
80% leukemic blasts were collected on the occasion of initial
diagnosis. The fresh samples were seeded at 1 106 cells/ml and
stimulated with 20mg/ml A3D8. RNA isolation was performed
using RNeasy Mini kit (Qiagen) at time points indicated in the
ﬁgure legends and real-time PCR was performed for c-jun
expression as described below. Control samples were either
unstimulated or stimulated with isotype matched antibody
(IgG1, Sigma and/or J173, Immunotech). Cytospin was also
performed to investigate the differentiation inducing ability of
A3D8 as previously reported (Charrad et al., 1999).
Cell lines, antibodies and treatments
Human myeloid cell lines HL60 and U937 were obtained from
DMSZ (Germany) and cultured in RPMI-1640 medium (PAN
Figure 8 Ectopic overexpression of c-Jun in HL60 cells increases their proliferation and prevents A3D8-mediated downregulation of proliferation.
The ﬁgure represents an overlay of different peaks from FACS analysis for CD71 and CD11b expression of HL60 cells. (a) Overexpression of c-Jun
in HL60 cells increases their proliferation. HL60 cells were electroporated with pMV7-c-jun and pMV7 and selected in G418. The cells were then
analysed for CD71 expression as described in Materials and methods. In addition to empty vector control, untransfected HL60 cells also served as
control. The overlay of the peaks was carried out with WinMDI 2.8 software program. (b) Trypan blue cell counting of cells transfected with pMV7
and pMV7-c-jun when the cells were under selection pressure. (c) pMV7 and pMV7-c-jun-transfected cells were incubated with BrdU for 1 h and
subsequently stained for BrdU-incorporation as described. The ﬁgure represents a scatter plot at days 1 and 4 post-transfection. (d) This ﬁgure
represents Real time PCR for c-jun expression in c-Jun overexpressing HL60 cells. The bars represent c-jun/G6PD ratio of untransfected HL60
cells, transfected with empty vector, pMV7 and with pMV7-c-jun. (e) This represents Western blot analysis for c-Jun expression in c-Jun
overexpressing HL60 cells. Lanes: 1, In vitro-translated c-Jun, 2, reticulocyte lysate, 3, untransfected HL60 cells, 4, pMV7-transfected cells and 5,
pMV7-c-jun-transfected cells. (f, g) Overexpression of c-Jun in HL60 cells prevents A3D8-mediated growth inhibition and differentiation induction.
The ﬁgure represents overlay from FACS analysis for CD71 and CD11b expression in c-Jun overexpressing HL60 cells before and after treatment
with A3D8. After selection in G418 for 1 week, HL60 cells were stimulated with A3D8 at ﬁnal concentration of 20mg/ml for further 36 h and the
cells were analysed for CD71 and CD11b expression by ﬂow cytometry
Figure 9 Model of how CD44 ligation inhibits proliferation and
blocks cell cycle of myeloid leukemia cells by downregulating c-Jun
expression. The ﬁgure shows a possible mechanism for the growth
inhibitory effect of anti-CD44 antibody A3D8 in myeloid cells. The
growth arrest involves decreased c-Jun expression along a pathway,
which involves inhibition of JNK by p21 resulting in decreased c-
Jun phosphorylation and hence decreased promoter activity
concomitant with decreased cell cycle proteins
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Biotech GMBH) supplemented with 2mm glutamine, 100U/ml
penicillin and 100mg/ml streptomycin and 10% FBS (GIBCO-
BRL, Eragny, France) at 371C with 5% CO2 enrichment. The
cells were suspended at 3 105 cells/ml in 96-well tissue culture
plates (Nunc) with 200 ml/well. Monoclonal anti-CD44 anti-
body, A3D8 (Sigma) was added at the ﬁnal concentration of
20 mg/ml. All the control samples were either untreated or
treated with 20mg/ml isotype-matched antibody (IgG1, Sigma
or J173, Immunotech). For direct immunoﬂuorescence stain-
ing, ﬂuorescein isothiocyanate (FITC) MoAbs to CD11b
(FITC, immunotech, IgG1) and CD71 (FITC, DAKO,
IgG1) were used.
Proliferation assay
To assess the proliferation state of cells after various
treatments, MTT proliferation assay kit (Boehringer Man-
nheim, Germany) was used according to the manufacturer’s
instructions. Brieﬂy, cells were incubated with or without
A3D8 for 1–4 days in 96-well plates. A volume of 10 ml MTT
labeling reagent (5mg/ml) was added every day to each well
and the plates were incubated at 371C for 4 h. The resulting
formazon crystals were solubilized by adding 100ml of
solubilization buffer (10% SDS in 0.01m HCl) per well and
the plates were incubated at 371C overnight. The absorbance
of the formazon measured at 575 nm was used to account for
the proliferation state of cells. Trypan blue cell exclusion was
also used to assess the cell viability and the cell number.
Morphological analysis of cellular differentiation
After various cell treatments, HL60 and U937 cells were cyto-
centrifuged on glass slides using a cytospin device (Shandon-
Elliot, Paris, France). May–Gru¨nwald–Giemsa-stained cytos-
pin smears were then analysed under light microscopy. The
analysis was performed on 200–300 cells.
Cell cycle analysis and flow cytometry
To investigate the surface expression of myeloid differentiation
and proliferation markers, FACS analysis was performed.
HL60 and U937 cells (3 105 cells/ml) were stimulated
for 36h with A3D8 (20mg/ml) and then stained with FITC or
PE labeled antibodies at a concentration of 10mg/ml at
41C for 30min and washed twice with FACS buffer (PBS, 3%
FCS, 0.01% NaN3). Fluorescence was then analysed on Coulter
EPICS XL/XL-MCL SystemII Software. Data were collected
after 5000 cell analysis (per sample) and the results shown as
scatter diagrams or expressed as D-value which is calculated as
Mean fluorescence intensity ðMFIÞ ratio
¼Meanof sample stainedwithMoAb=
mean of isotype controlMoAb
Then, the percentage of difference between MFI ratio of
sample incubated with or without A3D8 was calculated, giving
a D-value (Pisani et al., 1997) for each sample. The D-value for
unstimulated control was arbitrarily chosen and that of
stimulated sample expressed relative to it. Negative D-values
indicate more MFI of stimulated sample than unstimulated
and hence, implies increased expression of the particular
marker. Similarly, positive D-values imply decreased expres-
sion of the marker. For the cell cycle analysis, cells with or
without A3D8 treatment were centrifuged at 1500 r.p.m. for
3min, washed with PBS and then the DNA was stained with
100 mg/ml propidium iodide for 30min at 41C protected from
light. The cells were then analysed with the FACScan
(Beckton-Dickinson) for different cell populations.
RNA isolation and semiquantitative RT–PCR
Total RNA was isolated from 7 105 cells before and after
treatment with A3D8 (20 mg/ml) and IgG1 (20 mg/ml) using
RNeasy Mini kit (Qiagen). RNA of 100 ng was used for ﬁrst-
strand cDNA synthesis in a 20 ml reaction with 10RT buffer,
dNTP (5mm), RNasin (1U/ml), oligo dT (1 mm) and the
reaction was incubated at 371C for 90min. Equal amounts of
cDNA were taken for c-jun PCR ampliﬁcation using a Qiagen
kit. Aldolase was used as an internal control. Primers used for
PCR ampliﬁcation were for c-jun (Gene Bank Acc. no.
J04111): forward primer 50-ACTGCAAAGA TGGAAAC-
GAC-30 (bp 1264–1283) and reverse primer 50-AAAATGTTT
GCAACTGCTGC-30 (bp 2235–2254); and for aldolase:
forward primer 50-AGCTGTCTG ACATCG CTCACCG-30
and reverse primer 50-CACATA CTGG CAGCGC
TTCAAG-30. The PCR cycling program consisted of 30 cycles
of 941C for 2min, 551C for 1min and 721C for 80 s using DNA
thermal cycler (Perkin-Elmer). PCR products of B971 bp (c-
jun) and B580 bp (Aldolase) were separated by 1.2% agarose
gel electrophoresis and visualized by ethidium bromide
staining with UV irradiation.
Quantitative Real-time PCR in AML patient samples
Real-time PCR for c-jun and for the housekeeping gene
glucose-6-phosphate dehydrogenase (G6PD) was performed
using the Light Cycler Technology (Roche Diagnostics,
Mannheim, Germany). For ampliﬁcation of G6PD, primers
were used according to Emig et al. (1999): G6PD-1 forward
primer 50-CCGGATCGACCACTACCTGGGCAAG-30 and
G6PD-2 reverse primer 50-GTTCCCCACGTACTGGC-
CCAGGACCA-30. c-jun was ampliﬁed using the primer
set according to Kiaris et al (1999). c-jun-1 forward primer
50-GCATGAGGAACC GCATCGCTGCCTCCAAGT-30
and c-jun-2 reverse primer 50-GCGACCAAGTCCTT
CCCACTCGTGCACACT-30. G6PD plasmid: pGdBBX,
kindly provided by A Hochhaus, University of Mannheim
was serially diluted to 10 000, 1000 and 100 fg and used as a
standard curve. The procedure for Real-time PCR was
essentially the same as described previously (Reddy et al., 2002).
Immunoblot analysis
Total cellular protein was extracted from HL60 and U937
cells before and after A3D8 treatment and subjected to
electrophoresis on 10% SDS–PAGE gels. The Western
blotting procedure was performed and the blots detected
with the ECL system as described previously (Behre et al.,
1999). Anti-b-tubulin antibody (Boehringer, Mannheim)
was used as internal loading control on the same blot after
stripping. Immunoblot analysis was performed for c-Jun
(anti-rabbit, sc-45), c-Fos (anti-rabbit polyclonal, sc-52), JunB
(anti-mouse monoclonal IgG1, sc-8051), Cdk2 (anti-rabbit,
sc-163), Cdk4 (anti-rabbit, sc-260), Cdk6 (anti-rabbit, sc-177),
cyclin D1 (anti-rabbit, sc-718), p21 (anti-mouse, sc-817), pRb
(anti-mouse monoclonal, sc-102) and phospho-speciﬁc
Rb (anti-goat, pRb-Ser780, sc-12901). The other antibodies
used for the Immunoblot analysis were JNK1 (anti-rabbit,
sc-474), ERK1 (anti-rabbit, sc-94 Santa Cruz), phospho-
c-Jun (anti-mouse monoclonal, sc-822 Santa Cruz) and
b-tubulin (anti-rabbit, sc-9104). All the blots were quantiﬁed
by densitometry (Aida 2.1 software program) and the
results reported in relation to b-tubulin. Comparison of the
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differences in expression was done between isotype control and
A3D8-treated samples. Unstimulated samples served as a
reference for the basal level of expression.
Immunocomplex kinase assay
After the described treatments, HL60 cells were washed
with cold PBS and RIPA lysates prepared at different time
points. Lysates were collected by centrifugation for 30min
and protein concentrations were quantiﬁed by the Bradford
assay (Bio-Rad Laboratories, Germany). Protein of 200 mg
was incubated with 2 mg of anti-Cdk2 or anti-Cdk4 antibody at
41C for 2 h with rotation. Protein A agarose beads (20 ml)
were then added and the incubation continued for another 2 h.
Immunocomplex beads were washed twice with PBS buffer
and three times with kinase buffer (150mm NaCl; 1mm
EDTA; 50mm Tris-HCl, pH 7.5; 10mm MgCl2; and 10mm
DTT). Kinase activity was assayed by incubating the beads
at 371C for 30min with 25 ml kinase buffer, 3mg histone H1
(Upsdate, Germany; Cdk2) or Rb-fusion protein (Santa Cruz;
Cdk4), 10mm ATP, and 4 mCi [g-32P]ATP (3000Ci/mmol).
Samples were then boiled for 5min in 2 sample buffer,
electrophoresed through a 12% SDS–PAGE, dried, and
phosphorylated histone H1 and Rb proteins were visualized
by autoradiography and quantiﬁed by Aida 2.1 software
program.
Reporter constructs and transient transfections
The human full-length c-jun promoter plus 731 bp of down-
stream sequences (1780/+731) subcloned into the ﬁreﬂy
luciferase vector pGL3, and deletion mutants in the proximal
and distal AP-1 sites of the same construct used in this study
were kindly provided by Wayne Vedeckis (Wei et al., 1998). As
an internal control plasmid for cotransfection assays, the pRL-
0 construct driving the Renilla luciferase gene (Promega) was
used as described (Behre et al., 1999). Transient transfections
were performed with these constructs by using Effectene
transfection reagent (Qiagen) in myeloid cells. Effectene allows
transfections in the absence of serum, which was important to
rule out any serum-induced ﬂuctuations in c-jun promoter
activity. The cells were transiently transfected with 1mg c-jun
promoter/luciferase constructs and pRL-0 plasmid per well of
the six-well plates. At 18 h after transfection, A3D8 was added
to the wells to a ﬁnal concentration of 20 mg/ml for additional
6 h. Promoter activities were determined by measuring the
luciferase activity with the Dual Luciferase Assay System
(Promega). Fireﬂy luciferase activities of different c-jun
promoter constructs in pGL3 were normalized to the Renilla
luciferase values of pRL-0 (Behre et al., 1999). Results are
given as mean7s.d. of at least three different independent
experiments.
Stable cell lines overexpressing c-Jun and BrdU incorporation
To generate cell lines overexpressing c-Jun, the retrovirus-
derived cDNA expression vector was used for the study.
This vector, designated pMV7-c-jun was kindly provided by
Dr Yaniv. The vectors are described elsewhere (Kirschmeier
et al., 1988). pMV7-c-jun and the empty vector pMV7 (lacking
the c-Jun cDNA insert) were transfected into HL60 cells by
electroporation (300V/975 mF). After 24–48 h, the cells were
transferred into selective medium containing 1mg/ml G418
and analysed for CD71 expression and BrdU incorporation
by ﬂow cytometry. Trypan blue cell counting and PI staining
was also performed at different time points. In addition to
CD71 expression and cell counting, BrdU, a thymidine
analogue which gets incorporated into cellular DNA was
also used as a measure of cell proliferation in c-Jun over-
expressing HL60 cells. The assay was performed by using in
situ cell proliferation kit, FLUOS (Roche, Mannheim,
Germany, cat. no. 1810740) according to the manufacturer’s
instructions. Brieﬂy, after transfer into selection medium,
HL60 cells (3 105 cells/ml previously transfected with
pMV7 and pMV7-c-jun) were incubated with 10 mm BrdU for
1 h at 371C in 5% CO2. The cells were then ﬁxed in 70%
ethanol in 50mm glycine buffer, pH 2.0, washed in PBS,
acid denatured (4m HCl) and incubated with anti-BrdU-
FLUOS antibody solution for 45min at 371C in 5% CO2.
The cells were then analysed by ﬂow cytometry and the data
presented as scatter diagrams. In a similar experiment, after 1
week in the selection medium, the cells transfected with pMV7
or pMV7-c-jun were then stimulated with A3D8 or IgG with a
ﬁnal concentration of 20 mg/ml. At 36 h after treatment with
A3D8, the cells were analysed for CD11b and CD71
expression. The expression of c-Jun in c-Jun overexpressing
HL60 cells was measured by Real-time PCR and Western blot
analysis.
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Elevated c-Jun expression in acute myeloid leukemias inhibits C/EBPa
DNA binding via leucine zipper domain interaction
Janki Rangatia1, Rajani K Vangala1, Sheo M Singh1, Abdul A Peer Zada1, Annika Elsa¨sser1,
Alexander Kohlmann1, Torsten Haferlach1, Daniel G Tenen2, Wolfgang Hiddemann1,
Gerhard Behre*,1
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Transcription factor C/EBPa induces normal myeloid
differentiation, inactivation of C/EBPa leads to a
differentiation block in acute myeloid leukemias (AML),
and overexpression of C/EBPa results in AML growth
arrest and differentiation. Recent reports suggest that
C/EBPa is activated or inactivated via protein–protein
interactions. We previously reported that C/EBPa needs
to inactivate the proto-oncogene c-Jun via leucine zipper
domain interaction in order to induce granulocytic
differentiation. We, therefore, hypothesized that c-Jun
expression might be elevated in AML and subsequently
inactivate C/EBPa. In fact, compared to normal bone
marrow mononuclear cells, c-Jun expression is increased
in AML patient samples (Affymetrix expression micro-
array analysis, n¼ 166). c-Jun binds to C/EBPa via the
leucine zipper domains and prevents C/EBPa from DNA
binding. Inactivation of C/EBPa by c-Jun is necessary for
c-Jun to induce proliferation because c-Jun-induced
proliferation can be prevented by ectopic overexpression
of C/EBPa. The dominant-negative 30-kDa C/EBPa
protein, found in AML, fails to downregulate c-Jun
mRNA expression in AML patient samples. Thus, our
data suggest a model for AML in which c-Jun promotes
proliferation and prevents differentiation by inhibiting
C/EBPa DNA binding via leucine zipper domain interac-
tion. It might depend on the expression levels of C/EBPa
and c-Jun, if inhibition of C/EBPa by c-Jun or if
inhibition of c-Jun by C/EBPa is more predominant:
proliferation versus differentiation; AML versus normal
myeloid development.
Oncogene (2003) 22, 4760–4764. doi:10.1038/sj.onc.1206664
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Acute myeloid leukemias (AML) are characterized by
the outgrowth of immature myeloid cells which are
blocked in differentiation (Tenen, 2003). Recently, a
concept is arising in which for AML to develop the
activity of the transcription factors C/EBPa and PU.1,
which are both pivotal for normal myeloid differentia-
tion, must be impaired by either mutations (Pabst et al.,
2001b; Mueller et al., 2002) or by antagonistic protein–
protein interactions (Pabst et al., 2001a; Vangala et al.,
2003). Thus, we previously reported that C/EBPa (Pabst
et al., 2001b) and PU.1 (Mueller et al., 2002) are
mutated in AML, and that AML1-ETO in t(8;21)-AML
binds to C/EBPa (Pabst et al., 2001b) and PU.1
(Vangala et al., 2003) and blocks their activity via direct
protein–protein interactions. Furthermore, the fusion
protein BCR-ABL in chronic myeloid leukemia (Per-
rotti et al., 2002; Schuster et al., 2003) and AML-speciﬁc
Flt3 mutations (Mizuki et al., 2002) downregulate
C/EBPa expression. Thus, inactivation of C/EBPa and
PU.1 by direct protein–protein interactions is an arising
new mechanism in the pathogenesis of myeloid leuke-
mias. Most interestingly, protein–protein interactions
are not only responsible for inactivation of C/EBPa in
AML, but also C/EBPa itself seems to function via
protein–protein interactions (McKnight, 2001). Thus,
C/EBPa arrests cell proliferation through direct inhibi-
tion of Cdk2 and Cdk4 (Wang et al., 2001, 2002), E2F
repression by C/EBPa is required for adipogenesis and
granulopoiesis (Porse et al., 2001), and C/EBPa binds to
and leads to phosphorylation of p300 (Schwartz et al.,
2003).
The proto-oncogene c-Jun, a member of the AP-1
transcription factor family, can induce proliferation by
repression of tumor suppressors, as well as upregulation
of positive cell cycle regulators, and c-Jun expression is
elevated in many types of cancers (Shaulian and Karin,
2002). In contrast, the transcription factor C/EBPa is
necessary for normal myeloid differentiation (Zhang
et al., 1997; Porse et al., 2001), inactivation of C/EBPa
can lead to myeloid leukemia (Pabst et al., 2001a,b;
Perrotti et al., 2002; Schuster et al., 2002), and
overexpression of C/EBPa in AML leads to growth
arrest and partial differentiation (Radomska et al., 1998;
Truong et al., 2003). We previously reported that C/
EBPa is functionally activated by the Ras signal
transduction pathway via phosphorylation on serine
248 (Behre et al., 2002). After being activated, C/EBPa
inactivates the transcription factor PU.1 via direct
protein–protein interaction to prevent dendritic and
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monocytic cell differentiation (Iwama et al., 2002;
Reddy et al., 2002). Furthermore, C/EBPa needs to
inactivate the proto-oncogene c-Jun via leucine zipper
domain interaction in order to prevent proliferation and
to induce granulocytic differentiation (Rangatia et al.,
2002). We therefore hypothesized that c-Jun expression
might be elevated in AML and inactivate C/EBPa.
Elevated c-Jun expression in AML
The proto-oncogene c-Jun can induce proliferation
(Peer Zada et al., 2003) and c-Jun expression is elevated
in many types of neoplasia (Shaulian and Karin, 2002).
The leukemic fusion proteins BCR-ABL (Burgess et al.,
1998) and AML1-ETO (Elsaesser et al., 2003) upregu-
late c-Jun expression, and differentiation induction of
AML blasts with antibodies inducing CD44-signaling
downregulates c-Jun expression (Peer Zada et al., 2003).
Furthermore, we previously reported that C/EBPa needs
to downregulate c-Jun expression in order to induce
granulocytic differentiation (Rangatia et al., 2002). We
therefore hypothesized that c-Jun expression might be
elevated in AML. Total RNA from AML patient
samples was isolated, and gene expression analysis was
performed (Affymetrix HG-U133A microarray). As
seen in Figure 1a, c-Jun, c-Jun mRNA expression level
in normal bone marrow mononuclear cells from healthy
volunteers is lower in comparison with c-Jun expression
Figure 1 Elevated c-Jun expression in AML; c-Jun inhibits C/EBPa
DNA binding via leucine zipper domain interaction. (a) c-Jun mRNA
expression is increased in AML patient samples (n¼ 166) in
comparison with normal bone marrow (nBM) mononuclear cells
(n¼ 9). Total RNA was isolated and processed as described before
(Schoch et al., 2002). Standard Affymetrix software (Microarray Suite,
Version 5.0) and the HG-U133A set of normalization controls were
used for data analysis (mask ﬁle online available, www.affymetrix.-
com). As recommended by the manufacturer, 100 human maintenance
genes served as a tool to normalize and scale the data prior to
performing data comparisons. Expression signal intensities are given as
absolute numbers (Schoch et al., 2002). The error bars indicate the
s.e.m. n indicates the number of patient samples analysed in each
subgroup. AML patient samples included translocation t(8;21),
t(15;17), t(11q23)/MLL, inv(16) positive cases, as well as cases with
complex aberrant and normal karyotypes. (b) C/EBPa and c-Jun
colocalize in the nucleus: Confocal image of c-Jun and C/EBPa
cotransfected HeLa cells. FITC and Cy3 staining show nuclear
localization of C/EBPa and c-Jun, respectively. Overlay of the
confocal images in the right panel indicates the colocalization of these
two proteins. HeLa cells were plated on glass coverslips and
transfected with the respective DNA plasmids using a lipofectamine
transfection protocol. At 24-h post transfection, the cells were washed
in PBS and ﬁxed with 3% paraformaldehyde for 10min followed by
incubation in 2% glycine for 15min. Cells were permeablized with
0.2% Triton X-100 for 10min. Cells were blocked in 0.2% BSA for
15min followed by incubation in the primary antibody (1 : 100
dilution) for 1 h. At 1 : 100 dilution for FITC and 1 : 500 dilution for
Cy3 was used for secondary antibody. After incubation of the cells
with secondary antibody for 1 h, cells were washed, dried and mounted
on coverslip. Fluorescence for the respective secondary antibody was
observed using Leica confocal microscope. (c) c-Jun inhibits C/EBPa
DNA binding via the c-Jun leucine zipper domain. Electromobility
shift assays (EMSA) were performed as described earlier (Rangatia
et al., 2002; Vangala et al., 2003). A G-CSF receptor C/EBP consensus
site oligo was used as the probe for C/EBPa (Rangatia et al., 2002). In
vitro translated C/EBPa, c-Jun, c-JunDRK (deletion of the DNA
binding domain), and c-JunDLZ (deletion of the leucine zipper
dimerization domain) were generated using Promega in vitro transla-
tion kit (Behre et al., 1999; Rangatia et al., 2002). C/EBPa (SC-61X)
antibody and normal rabbit IgG (SC-2027) from Santa Cruz were used
for supershift experiments
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in AML patient samples. Various subtypes of AML are
depicted with the patient number analysed (n¼ 166).
These data suggest that c-Jun expression is elevated in
AML. Whereas cytogenetics accomplished the subclas-
siﬁcation of AML in many subgroups, many of those
genetic events might target common mechanisms to
induce proliferation and block differentiation, such as
inducing c-Jun expression as potential common theme in
AML.
c-Jun inhibits C/EBPa DNA binding via the c-Jun leucine
zipper domain
Since C/EBPa is inactivated by BCR-ABL (Perrotti
et al., 2002; Schuster et al., 2003), AML1-ETO (Pabst
et al., 2001a), PML-RARa (Truong et al., 2003), and
through mutation (Pabst et al., 2001b), thus being a
common target in myeloid leukemias, we hypothesized
that elevated c-Jun expression in AML might inactivate
C/EBPa function. We have earlier shown using co-
immunoprecipitation and GST pulldown assays that C/
EBPa and c-Jun interact through their leucine zipper
domains (Rangatia et al., 2002). Moreover, we could
demonstrate that C/EBPa can prevent c-Jun from
binding to an AP-1 site through this leucine zipper
domain interaction (Rangatia et al., 2002). Finally, we
could demonstrate that c-Jun and C/EBPa colocalize in
the nucleus (Figure 1b). Therefore, we speculated that c-
Jun binds to C/EBPa with a leucine zipper domain
interaction and pulls C/EBPa away from C/EBP sites in
target promoters. In fact, EMSA experiments using a G-
Figure 2 Inactivation of C/EBPa by c-Jun is necessary for c-Jun to
induce proliferation in AML; 30-kDa C/EBPa protein in AML fails to
downregulate c-Jun mRNA expression. (a) c-Jun-induced proliferation
in AML cell lines is inhibited by ectopic overexpression of C/EBPa
U937 and HL60 cells were transduced with pMV7-neo, pMV7-neo-c-
jun and pMSCV-C/EBPa-IRES-GFP vectors. FACS analysis for
CD71-PE (clone M-A712, BD Biosciences) and its isotype control
IgG2ak PE (clone G155-178, BD Biosciences) was performed as
described before (Rangatia et al., 2002; Vangala et al., 2003). (b) 30-
kDa C/EBPa protein in AML fails to downregulate c-Jun mRNA
expression. Real-time PCR reactions for c-Jun and G6PD from AML
FAB M2 patient samples without translocation t(8;21) and with or
without reported 30-kDa C/EBPa mutations were carried out. The
error bars indicate the s.e.m. from three experiments. n indicates the
number of patient samples analysed in each subgroup. Real-time
quantitative PCR was performed using the light cycler technology
(Roche Diagnostic) as described before (Vangala et al., 2003). The
primers for c-Jun: forward 50GCA TGA GGA AAC GCA TCG CTG
CCT CCA AGT 30 and reverse 50GCG ACC AAG TCC TTC CCA
CTC GTG CAC ACT 30. G6PD primers were forward 50CCG GAT
CGA CCA CTA CCT GGG CAA C 30 and reverse 50GTT CCC CAC
GTA CTG GCC CAG GAC CA 30. In all, 35 cycles of c-Jun and
G6PD ampliﬁcation conditions were: 951C for 10min; 951C for 0.5 s;
641C for 10 s; 721C for 25 s. Running the samples on 1.2% agarose gel,
the PCR fragment size of 400 bps for c-Jun and 340bps for G6PD were
observed. (c) Model for AML in which c-Jun promotes proliferation
and prevents differentiation by inhibiting C/EBPa DNA binding via
leucine zipper domain interaction. c-Jun expression is increased in
AML patient samples. c-Jun binds to C/EBPa via the leucine zipper
domains and prevents C/EBPa from DNA binding. Inactivation of C/
EBPa by c-Jun is necessary for c-Jun to induce proliferation because c-
Jun-induced proliferation can be prevented by ectopic overexpression
of C/EBPa. The dominant-negative 30-kDa C/EBPa protein, found in
AML, fails to downregulate c-Jun mRNA expression in AML patient
samples. Thus, our data suggest a model for AML in which c-Jun
promotes proliferation and prevents differentiation by inhibiting C/
EBPa DNA binding via leucine zipper domain interaction. It might
depend on the expression levels of C/EBPa and c-Jun, if inhibition of
C/EBPa by c-Jun or if inhibition of c-Jun by C/EBPa is more
predominant: proliferation versus differentiation; AML versus normal
myeloid development
b
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CSF receptor C/EBP binding site oligo and in vitro
translated C/EBPa, c-Jun, c-JunDLZ and c-JunDRK
demonstrate that wild-type c-Jun as well as c-JunDRK
(basic domain mutant) prevent C/EBPa from binding to
the DNA, whereas c-JunDLZ (leucine zipper domain
mutant) does not prevent C/EBPa DNA binding
(Figure 1c). The inactivation of C/EBPa by c-Jun might
depend on very few amino acids of C/EBPa targeted by
interaction with c-Jun, because it has been recently
reported that DNA binding of C/EBPa primarily
depends on Arg289 and its interacting partners Tyr285
and Asn293 (Miller et al., 2003). In conclusion, c-Jun
binds to C/EBPa via the leucine zipper domains and
prevents C/EBPa DNA binding. In one model, it could
simply depend on the relative concentrations of c-Jun
and C/EBPa, whether the C/EBPa–c-Jun leucine zipper
domain interaction leads to granulocytic differentiation
or to a block in differentiation. Interestingly, competing
concentration-dependent protein–protein interactions
have not only been described before in the case of
AML, such as AML1-ETO–PU.1 interaction (Vangala
et al., 2003), AML1-ETO–C/EBPa interaction (Pabst
et al., 2001a), or PML-RARa–C/EBPa interaction
(Truong et al., 2003), but also as a driving force in the
context of lineage commitment and normal differentia-
tion, such as PU.1–c-Jun interaction (Behre et al., 1999),
PU.1–C/EBPa interaction (Reddy et al., 2002), or
GATA1–PU.1 interaction (Zhang et al., 1999). Agonis-
tic and antagonistic protein–protein interactions, there-
fore, might play a major role in stem cell development
and leukemogenesis.
Inactivation of C/EBPa by c-Jun is necessary for c-Jun to
induce proliferation in AML
As shown before, c-Jun is highly expressed in AML and
inactivates C/EBPa via leucine zipper domain interac-
tion. We, therefore, asked the question whether inacti-
vation of C/EBPa by c-Jun is absolutely recessary for
c-Jun to induce proliferation in AML, or whether
inactivation of C/EBPa by c-Jun is a mechanistically
interesting, but biologically not important phenomenon.
In fact, overexpression of c-Jun induced proliferation in
AML cell lines, measured by Trypan blue cell counting
(Peer Zada et al., 2003), brdU assay (Peer Zada et al.,
2003), and CD71 FACS analysis (Figure 2a). Most
importantly, ectopic overexpression of C/EBPa pre-
vented c-Jun-induced proliferation (Figure 2a). These
data conﬁrm that C/EBPa function needs to be down-
regulated by c-Jun in order for c-Jun to be able to induce
proliferation. It might depend on the expression levels of
C/EBPa and c-Jun, if inhibition of C/EBPa by c-Jun or
if inhibition of c-Jun by C/EBPa is more predominant:
proliferation versus differentiation.
30-KDa C/EBPa protein in AML fails to downregulate
c-Jun MRNA expression
C/EBPa mutants, mostly encoding a 30-kDa form that
acts dominant negative to wild-type 42-kDa C/EBPa on
the second allele, have been described before in around
13% of AML (Pabst et al. , 2001b; Gombart et al., 2002;
Preudhomme et al., 2002; Waalwijk Van Doorn-
Khosravani et al., 2002). Interestingly, in AML FAB
M2 patient samples with the 30-kDa C/EBPa protein,
c-Jun mRNA expression measured by real-time PCR is
much higher than in AML patient samples of the FAB
M2 subtype without C/EBPa mutants and normal
karyotype (Figure 2b). This is expected because intact
and functional C/EBPa downregulates c-Jun expression
as we have described before (Rangatia et al., 2002). One
mechanism for the upregulation of c-Jun expression in
AML might be the downregulation of C/EBPa activity
by the dominant-negative 30-kDa C/EBPa protein
found in AML. Once upregulated, c-Jun further down-
regulates C/EBPa activity by inhibiting C/EBPa DNA
binding as shown in the present report. Thereby, c-Jun
is, in fact, downstream of C/EBPa (Rangatia et al.,
2002), but also upstream of C/EBPa, as shown here.
This way in AML a deadly inactivation circle for
C/EBPa might be happening. In summary (Figure 2c),
our data suggest a model for AML in which c-Jun
promotes proliferation and prevents differentiation by
inhibiting C/EBPa DNA binding via leucine zipper
domain interaction.
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Elevated c-Jun expression in AML inactivates C/EBPa
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The myeloid master regulator transcription factor PU.1 is inactivated by
AML1-ETO in t(8;21) myeloid leukemia
Rajani K. Vangala, Marion S. Heiss-Neumann, Janki S. Rangatia, Sheo M. Singh, Claudia Schoch,
Daniel G. Tenen, Wolfgang Hiddemann, and Gerhard Behre
The transcription factor PU.1 plays a piv-
otal role in normal myeloid differentia-
tion. PU.1/mice exhibit a complete block
in myeloid differentiation. Heterozygous
PU.1 mutations were reported in some
patients with acute myeloid leukemia
(AML), but not in AML with translocation
t(8;21), which gives rise to the fusion
gene AML1-ETO. Here we report a nega-
tive functional impact of AML1-ETO on
the transcriptional activity of PU.1. AML1-
ETO physically binds to PU.1 in t(8;21)
Kasumi-1 cells. AML1-ETO binds to the
34 region in the DNA-binding domain of
PU.1 and displaces the coactivator c-Jun
from PU.1, thus down-regulating the tran-
scriptional activity of PU.1. This physical
interaction of AML1-ETO and PU.1 did not
abolish the DNA-binding capacity of PU.1.
AML1-ETO down-regulates the transacti-
vation capacity of PU.1 in myeloid U937
cells, and the expression levels of PU.1
target genes in AML French-American-
British (FAB) subtype M2 patients with
t(8;21) were lower than in patients without
t(8;21). Conditional expression of AML1-
ETO causes proliferation in mouse bone
marrow cells and inhibits antiproliferative
function of PU.1. Overexpression of PU.1,
however, differentiates AML1-ETO–ex-
pressing Kasumi-1 cells to the monocytic
lineage. Thus, the function of PU.1 is
down-regulated by AML1-ETO in t(8;21)
myeloid leukemia, whereas overexpres-
sion of PU.1 restores normal differentia-
tion. (Blood. 2003;101:000-000)
© 2003 by The American Society of Hematology
Introduction
The Ets family of transcription factors plays a key role in the
growth, survival, differentiation, and activation of hematopoietic
cells. This family of proteins is characterized by presence of an
85-amino acid,1 winged helix-turn-helix DNA-binding domain.
PU.1 is one of the most important Ets transcription factors.2 Its
expression is limited to hematopoietic cells, including primitive
CD34 cells, macrophages, B lymphocytes, neutrophils, mast
cells, and early erythroblasts.2,3 In vitro studies suggest that PU.1
regulates the activity of a number of myeloid- and lymphoid-
specific promoters and enhancers.4-10 PU.1 is a key transcription
factor for normal myeloid development as demonstrated by a
complete block of myeloid development in PU.1/ mice.11,12 Fetal
or newborn PU.1/ mice have no detectable monocytes/
macrophages or neutrophils.11,12 We have recently shown that PU.1
is mutated in patients with acute myeloid leukemia (AML).13 These
studies all point to the crucial role of PU.1 in both normal myeloid
differentiation and leukemogenesis.
AML1 is a member of the Runt-like transcription factors
(Runx-1, -2, and -3) named after the Runt protein that regulates
segmentation during Drosophila embryogenesis.14-16 AML1 ap-
pears to act as an “organizing” factor for many promoters and
enhancers by interacting with various coactivators and DNA-
binding transcription factors.17-22 The AML1 gene is one of the most
frequently translocated or mutated genes in human cancer.23-25 The
t(8;21)(q22;q22) translocation fuses residues 1-177 of AML1
(including the DNA-binding domain) to nearly all of ETO (also
known as CBF2T1).26 ETO is the human homolog of Drosophila
NERVY protein.27-29 The t(8;21) belongs to the most common
chromosomal abnormalities in AML, accounting for 10% of all
AML cases and 40% of the AML French-American-British (FAB)
M2 phenotype.30-33 AML1 activates transcription from enhancer
core motifs (TGT/cGGY), which are present in a number of genes
relevant to myeloid development, including the macrophage colony-
stimulating factor (M-CSF) receptor, granulocyte-macrophage
colony-stimulating factor (GM-CSF), myeloperoxidase, and neutro-
phil elastase.34-39 Like AML1, AML1-ETO can act as a tran-
scriptional activator,40-43 but it is also a transcriptional repressor in
other contexts.44 Only one allele of AML1 is altered in leukemia
cells expressing t(8;21), and AML1-ETO can efficiently repress
AML1-dependent transcriptional activation. Therefore, AML1-
ETO has been postulated to act as a dominant inhibitor of AML1
function.34,37,44
Recently, we have shown that AML1-ETO blocks CCAAT
enhancer-binding protein (C/EBP)–dependent activation of its
own promoter thus blocking normal granulocytic differentiation of
myeloid cells.36 Furthermore, AML1-ETO was shown to repress
AML1 and MEF-2–dependent gene activation.45 In our earlier
studies we demonstrated that c-Jun, a member of AP-1 transcrip-
tion factor family, can interact with PU.1 at the 34 domain in
PU.1 and coactivate the transcriptional activity of PU.1.46 Here we
show that AML1-ETO blocks the transcriptional activity of PU.1
by displacing its coactivator c-Jun.
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Materials and methods
Cell lines and cell culture
Human kidney 293T, mouse embryonal carcinoma F9, and ecotrophic
Phoenix cells were maintained in Dulbecco modified Eagle medium
(DMEM; Gibco, ) supplemented with 10% fetal bovine serum (FBS), 1%
glutamine, and 1% Penstrep ( all from Gibco). Human monoblastic U937
cells and t(8;21) Kasumi-1 cells were cultured in RPMI 1640 medium
supplemented with 10% FBS (both from Gibco).
Bone marrow cells were isolated from the femurs of Balb/C mice. The
femurs were removed and stripped of the soft tissue and crushed to release
cells within marrow cavity. The red blood cells were lysed with a
0.15-mol/L solution of ammonium chloride. The pelleted cells were
subjected to low-density mononuclear cell separation by incubating with
density gradient (Histopaque 1083; Sigma, St Louis, MO) for 10 minutes
and centrifuged at 600 rpm for 30 minutes, washed twice in phosphate-
buffered saline (PBS), followed by culturing in Iscove modified Dulbecco
medium (IMDM; Stem Cell Technologies, ) supplemented with 10% FBS
(Stem Cell Technologies), 50 ng/mL stem cell factor (R & D Systems,
Minneapolis, MN), 50 ng/mL interleukin 6 (IL-6; R & D Systems), and 50
ng/mL Flt-3 ligand (Flt-3L; R & D Systems).
Coimmunoprecipitation assay
Kasumi-1 cells (2  107) were lysed and 200 g protein was used to
perform immunoprecipitation as mentioned by Mao et al.45 The following
antibodies were used: rabbit IgG (Santa Cruz Biotechnologies, Santa Cruz,
CA; catalog no. sc2027), goat IgG (Santa Cruz Biotechnologies; catalog no.
2028), anti-AML1 antibody (Calbiochem, ; catalog no. PC284), anti-PU.1
(Santa Cruz Biotechnologies; catalog no. sc352), and protein-A agarose
beads (Santa Cruz Biotechnologies; catalog no. sc2001).
Western blot
After plating in 100-mm plates, 293T cells were transfected using the
LipofectAMINE Plus kit (Gibco) as per the manufacturer’s protocol. At 24
hours after transfection, cells were harvested and lysed in RIPA lysis buffer,
and immunoblot for PU.1 was performed with 100 g protein as described
earlier.46-48 To generate protein lysates, 1  106 F9, Kasumi-1, or 293T cells
were lysed and nuclear extracts were prepared and immunoblot was
performed with 100 g protein for c-Jun (Santa Cruz Biotechnologies;
catalog no. sc54). Mouse bone marrow cells transduced with PU.1,
AML1-ETO, or respective empty vectors were similarly lysed (RIPA lysis)
and 100 g protein was used for immunoblot analysis for PU.1 and
AML1-ETO (anti-ETO antibody, Santa Cruz Biotechnologies; catalog no.
sc9737). Mouse monoclonal anti–-tubulin purchased from Roche (; catalog
no. 1111876) was used for immunoblot assay as internal control. Protein
A-peroxidase–conjugated for antirabbit (Amersham Pharmacia, ; catalog
no. NA 9120), or antigoat peroxidase-conjugated immunoglobulins (Dako,
; code no. p0449) were used as secondary antibodies.
Reporter constructs and expression plasmids
The human monocyte–specific M-CSF receptor promoter with or without
AML1-binding site, p(PU.1)4TK, and p(mutPU.1)4TK (PU.1-binding sites
and mutated PU.1-binding sites subcloned into pTK61luciferase) were
described earlier.46 As an internal control plasmid for transient transfection
assay, we used the pRL-null construct driving a Renilla luciferase gene
(Promega, Madison, WI).49 Other vectors used were pECE-PU.1-murine,
pcDNA.1-PU.1, pGEX-2TK-PU.1 or 34, pS3H-c-Jun, and pSP6-c-Jun,
as described previously.46,50 AML1B-pCMV5 and CBF-pCMV5 were
described earlier.42 AML1-ETO-pcDNA3 was constructed by enzymatic
digestion of AML1-ETO-pCMV542 with XbaI and subcloning the resulting
2258-bp fragment into the XbaI site of pcDNA3 plasmid (Invitrogen, ).
Transfection assays
Transient transfections in 293T or F9 cells were carried out with Lipo-
fectAMINE transfection kit (Gibco) in 24-well plates as described ear-
lier.46,47,49 U937 cells were transiently transfected by electroporation in
RPMI medium at 980 F and 280 V. Firefly luciferase activities from the
constructs M-CSF receptor promoter luciferase, pXP2, p(PU.1)4TK,
p(mutPU.1)4TK, and Renilla luciferase activity from internal control
plasmid pRL-null were determined 24 hours after transfection using Dual
Luciferase Reporter Assay System (Promega). Results are given as
means SEMs from at least 3 independent experiments.
Protein interaction assays
c-Jun and AML1-ETO were transcribed in vitro and translated in the
presence of [35S]-methionine (Amersham Pharmacia, ) using the T7/SP6-
coupled reticulocyte system (Promega) in accordance with the manufac-
turer’s instruction. Glutathione-S-transferase (GST) precipitation assays
were performed as described earlier.46,48
EMSA
32P-adenosine triphosphate (ATP; Amersham Pharmacia)–labeled double-
stranded oligonucleotides of PU.1 DNA-binding site51 and AML1-binding
site52 for electrophoretic mobility shift assay (EMSA) were prepared. The
assay was performed with in vitro–translated proteins as mentioned
earlier.11,47 For supershift experiments 3 L of either anti-PU.1 or anti-ETO
antibodies were added to the reaction mixture.
Retroviral transduction assay
Ecotrophic Phoenix cells (5  106) were plated in 10-cm plates and
transfected with 5g PINCO-GFP, PINCO-AML1-ETO-GFP, pGsam-PU.1-
ires-NGFR, or pGsam-ires-NGFR vectors using LipofectAMINE transfec-
tion kit (Gibco). At 24 hours after transfection, the transfection medium was
replaced with IMDM (supplemented with 10% FBS, 50 ng/mL stem cell
factor, 50 ng/mL IL-6, and 50 ng/mL Flt-3L) for collection of the virus
particles. After the viral particle production, freshly isolated mouse bone
marrow cells were incubated with viral medium on fibronectin-coated
plates and centrifuged for 30 minutes at 1000g (this step was repeated every
12 hours).53 At 60 hours after first transduction, NGFR or enhanced green
fluorescence protein-positive (EGFP) cells were isolated by fluorescence-
activated cell sorting (FACS) analysis (Becton Dickinson, ). To detect the
expression of tNGFR on the cell surface, cells were stained with mouse
antihuman NGFR (Chemicon, ; catalog no. MAB5246) followed by
phycoerythrin (PE)–conjugated rabbit antimouse immunoglobulins (mouse
IgG RPE; Dako; catalog no. R0439). Then, 1  104 transduced cells sorted
for NGFR positivity were plated in 1.2 mL mouse colony-forming medium
(Stem Cell Technologies). After 3, 6, and 12 days of plating live cells were
counted by trypan blue staining.
Patient material and FACS analysis
Bone marrow cells from AML-M2 patients with or without t(8;21) were
obtained after informed consent was given by the patients. Mononuclear
cells were isolated from the bone marrow by density gradient centrifugation
with Histopaque (Sigma). FACS analysis was performed with CD11b
(Pharmingen, ; catalog no. 555388), CD14 (Pharmingen; catalog no.
555397), and CD64 (Pharmingen; catalog no. 555527).
Transfection of Kasumi-1 cells and FACS analysis
Kasumi-1 cells were electroporated as mentioned above with pGsam-PU.1-
ires-NGFR or pGsam-ires-NGFR vectors and sorted 24 hours after
transfection for NGFR positivity by FACS (with anti-NGFR antibody from
Chemicon, catalog no. MAB5246, and mouse IgG RPE from Dako, catalog
no. R0439). Five days after sorting for NGFR expression, morphologic
changes were observed by Wright-Giemsa staining of cells. Then, 1  106
NGFR Kasumi-1 cells were incubated with 10 L recombinant PE-
conjugated mouse monoclonal CD11b (Pharmingen; catalog no. 555388) or
fluorescein isothiocyanate (FITC)–conjugated mouse monoclonal CD14
(Pharmingen; catalog no. 555397) in 100 L PBS for 60 minutes on ice,
washed in PBS followed by analysis on a FACScan flow cytometer (Becton
Dickinson) using Cellquest software. The cells were also analyzed for the
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isotype controls, PE-conjugated mouse IgG1	 (Pharmingen, catalog no.
554680) for CD11b-PE– and CD11b-FITC–conjugated mouse IgG1	
(Pharmingen; catalog no. 555748) for CD14-FITC. At 24 hours after
transfection, 5  104 NGFR cells were plated in a 6-well plate and
passaged with fresh medium every 24 hours. Cell count for live cells was
performed by trypan blue staining every 24 hours.
Results
AML1-ETO interacts with PU.1 in vivo and inhibits its
transcriptional activity
To determine whether PU.1 interacts with AML1-ETO, coimmuno-
precipitation assays were performed in Kasumi-1 cells, a human
cell line containing t(8;21). PU.1 coprecipitated with both AML1
and ETO antibodies but not with IgG control, suggesting that PU.1
interacts with AML1-ETO in vivo (Figure 1A). A similar experi-
ment was performed using a PU.1-specific antibody: AML1-ETO
coprecipitated with PU.1, but not with rabbit IgG control
(Figure 1A).
To investigate the functional impact of this in vivo interaction,
we performed transient transfection assays in 293T cells. An
M-CSF receptor promoter luciferase reporter construct, which was
transactivated 12-fold by PU.1 and 28-fold by PU.1/c-Jun, is
completely down-regulated by AML1-ETO (Figure 1B). AML1-
ETO had no effects on serum response element (pSRE)/Ras
activity nor on the empty vector (pXP2) as negative controls. The
expression levels of cotransfected PU.1 did not change in the
presence of AML1-ETO indicating that the transactivating capac-
ity, but not the expression of cotransfected PU.1, was down-
regulated (Figure 1B).
AML1 does not affect transactivation capacity of PU.1
or PU.1/c-Jun
The M-CSF receptor promoter has adjacent AML1- and PU.1-
binding sites.45 AML1-ETO retains the 177 N-terminus amino
acids of AML1, suggesting that AML1 might also have an
influence on transactivation of PU.1 or PU.1/c-Jun. Therefore, we
addressed if AML1 had any functional impact on the transactiva-
tion capacity of PU.1 or PU.1/c-Jun using a promoter containing
only PU.1-binding sites (p(PU.1)4TK). Transient transfection
assays in 293T cells were performed with p(PU.1)4TK and
expression plasmids of PU.1, c-Jun, AML1, and core-binding
factor  (CBF). Results (Figure 1C) show that AML1 did not
affect the PU.1 or PU.1/c-Jun transactivation capacity. In the same
experiment AML1 could transactivate the M-CSF receptor pro-
moter 4-fold in the presence of CBF (data not shown). AML1,
PU.1, c-Jun, and CBF had no effects on control vectors
(p(mutPU.1)4TK and pXP2) in the experiments above (data
not shown).
AML1-ETO inhibits the coactivation of PU.1 by c-Jun
We have earlier shown that c-Jun can coactivate transactivation of
PU.1 in a JNK-independent manner.46 PU.1 induced strong transac-
tivation of p(PU.1)4TK in 293T cells (Figure 1C). This is possibly
due to high expression of its coactivator c-Jun in these cells.
Immunoblot assay for c-Jun indicated that 293T cells have high
amounts of c-Jun (Figure 2A, lane 1) comparable to Kasumi-1 cells
(Figure 2A, lane 3). However, F9 cells had no detectable c-Jun
protein (Figure 2A, lane 2). Therefore, further experiments were
carried out in F9 cells, which served as a model cell line for
understanding how AML1-ETO might interfere with the capacity
of c-Jun in coactivating PU.1. PU.1/c-Jun could transactivate
p(PU.1)4TK (Figure 2B) and also the M-CSF receptor promoter
(Figure 2C) in F9 cells as described earlier.46 In the presence of
AML1-ETO, the capacity of PU.1/c-Jun in transactivating the
target promoters (Figure 2B,C) was down-regulated. c-Jun up-
regulated the p(PU.1)4TK promoter in 293T cells (Figure 1B) and
F9 cells (Figure 2B,C), which might be due to presence of
noncanonical sites in the promoter construct or unknown factors in
these 2 cell lines collaborating with c-Jun. A similar effect was also
reported earlier.48 However, this does not influence the
final conclusion.
Figure 1. AML1-ETO binds to PU.1 and down-regulates transactivation capacity of PU.1. (A) AML1-ETO binds to PU.1 in vivo. (i) Kasumi-1 cell nuclear extracts (200 g)
were immunoprecipitated with rabbit IgG (lane 1), anti-AML1 antibody (lane 2), goat IgG (lane 3), or anti-ETO antibody (lane 4). The immunoprecipitates were subjected to
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) along with in vitro translated PU.1 (lane 6) and nuclear extracts (NE; lane 7) and further subjected to
immunoblotting with PU.1 antibody. (ii) Kasumi-1 nuclear extracts were immunoprecipitated with anti-PU.1 (lane 2) or IgG (lane 3) and subjected to SDS-PAGE along with
nuclear extracts of Kasumi-1 cells (lane 4) and blotted with anti-ETO antibody. (B) AML1-ETO inhibits transactivation capacity of PU.1. (i) 293T cells were transiently
transfected with human monocyte-specific M-CSF receptor promoter or promoterless vector pXP2 or pSRE (serum response element) and with expression plasmids of PU.1
(100 ng), c-Jun (50 ng), AML1-ETO (20 ng), and activated Ras (50 ng). Promoter activities (fold) were determined 24 hours after transfection and normalized to the activities of
the internal control plasmid pRL0. (ii) AML1-ETO does not change the expression of cotransfected PU.1. The 293T cells were transfected as above and whole cell lysates were
subjected to SDS-PAGE followed by immunoblot assay with PU.1-specific antibody. (C) AML1 does not affect transactivation capacity of PU.1. The 293T cells transfected with
p(PU.1)4TK-luc and expression plasmids of PU.1 (100 ng), c-Jun (50 ng), AML1 (50 ng), or CBF (50 ng), PU.1, c-Jun, AML1, and CBF had no effects on negative control
p(mut.PU.1)4TK (data not shown).
PU.1 IS INACTIVATED BY AML1-ETO 3BLOOD, 1 JANUARY 2003  VOLUME 101, NUMBER 1
AQ: 11
AQ: 18
F1
AQ: 21
AQ: 24
AQ: 29
AQ: 19
F2
tapraid4/h8-bloo/h8-bloo/h80103/h83591d03a mazzam S11 10/16/02 13:21 Art: 2002-04-1288
Not for distribution: this preliminary material is embargoed until publication.
AML1-ETO displaces c-Jun by binding to the 34 region
in PU.1
The results in F9 cells (Figure 2B,C) suggest that AML1-ETO
interferes with coactivation of PU.1 by c-Jun. To investigate this, in
vitro protein-protein interaction assays were performed. c-Jun and
AML1-ETO bind to the full-length PU.1 fused to GST (Figure 3A).
c-Jun was shown to interact at the 34 region of the DNA-binding
domain of PU.1.48 Therefore, we performed protein-protein interac-
tion assays using GST-34 and found that AML1-ETO also binds
to GST-34 (Figure 3B). In competitive protein-protein interac-
tion assays on increasing the AML1-ETO protein, c-Jun protein
bound to GST-34 was reduced (Figure 3B). These results indicate
that AML1-ETO competes c-Jun away from binding to the 34
domain of PU.1. Thus, the c-Jun coactivation function of PU.1 is
down-regulated and this in turn down-regulates transcriptional
activity of PU.1.
AML1-ETO does not change the DNA binding of PU.1
The protein-protein interactions described above demonstrate that
AML1-ETO directly interacts with PU.1. The physical interaction
of AML1-ETO/PU.1 might down-regulate the DNA-binding capac-
ity of PU.1. To address this possibility, we performed an EMSA
using in vitro–translated PU.1 and AML1-ETO and oligonucleo-
tide probes having respective DNA-binding sequences.51,52 In
vitro–translated PU.1 binds specifically to the PU.1-binding oligo-
nucleotide (Figure 4). Even in presence of AML1-ETO, no change
of DNA binding of PU.1 was observed (Figure 4), indicating that
AML1-ETO blocks the transactivation capacity, but not DNA
binding of PU.1. In the same experiment in vitro–translated
AML1-ETO was found to bind to the AML1 probe (data not shown).
AML1-ETO down-regulates PU.1 transcriptional activity
in myeloid cells
All the above transfections were performed in nonmyeloid 293T or
F9 cells. We asked whether the same effects were also observed in
myeloid cells. Therefore, we performed transient transfection
assays in myelomonocytic U937 cells. U937 cells were transfected
with wild type M-CSF receptor promoter, M-CSF receptor pro-
moter without AML1-binding site, minimal promoter having
PU.1-binding sites (p(PU.1)4TK), minimal promoter with mutated
PU.1-binding sites (p(mutPU.1)4TK) as control, and empty vector
Figure 2. AML1-ETO inhibits coactivation of PU.1 by c-Jun. (A) F9 cells do not express c-Jun. Nuclear extracts (100 g) of 293T, F9, and Kasumi-1 cells along with in
vitro–translated c-Jun were subjected to SDS-PAGE and immunoblotted for c-Jun. (B) AML1-ETO inhibits PU.1/c-Jun transactivation capacity. F9 cells were transfected with
p(PU.1)4TK, a minimal TK promoter driven by PU.1 DNA-binding sites only or control vector p(mut.PU.1)4TK along with expression plasmids of PU.1 (100 ng), c-Jun (50 ng),
and AML1-ETO (20 ng). (C) AML1-ETO down-regulates the PU.1-regulated M-CSF receptor promoter activity by inhibiting PU.1/c-Jun function. F9 cells were transfected with
M-CSF receptor promoter and PU.1 (100 ng), c-Jun (50 ng), and AML1-ETO (20 ng). PU.1, c-Jun, and AML1-ETO had no effects on control vector pXP2 (data not shown).
Figure 3. AML1-ETO displaces the coactivator c-Jun from PU.1 by binding to
the 34 region of PU.1. (A) AML1-ETO physically binds to PU.1 in vitro. GST
pull-down assay was performed using [35S]-methionine–labeled in vitro–translated
c-Jun (lane 1) or AML1-ETO (lane 4) incubated with equal amounts of bacterially
expressed GST-PU.1 (lanes 2 and 5) or GST plus beads (lanes 3 and 6). GST-PU.1
or GST was recovered using glutathione-agarose beads and separated by SDS-
PAGE prior to autoradiography. (B) AML1-ETO displaces c-Jun from binding to the
34 domain of PU.1. Saturating amounts of in vitro–translated c-Jun (20 L) were
incubated with GST-34 and increasing amounts (from lanes 7-13) of in vitro–
translated AML1-ETO (7.5-12.5 L) were incubated. Densitometric quantification
was also performed (given as percent input of the proteins).
Figure 4. AML1-ETO does not change the DNA binding of PU.1. The PU.1-binding
sequence from the CD11b promoter was chosen and labeled with 32p-dATP (lane 1),
incubated with in vitro–translated PU.1 (lane 2), or in vitro–translated PU.1 and
anti-PU.1 antibody (lane 3). As a competitor, unlabeled probe was used in 100 molar
excess with (lane 5) and without (lane 4) anti-PU.1 antibody. To investigate if this
binding and supershift is specific for PU.1, similar experiments were performed with
rabbit reticulocyte lysate (lanes 6-9). In presence of AML1-ETO, PU.1 still binds to its
DNA (lane 10) and supershifts with anti-PU.1 antibody (lane 11). To the left of blots, ss
indicates supershift; s, shift.
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with or without AML1-ETO expression plasmid. We observed that
all the promoters were down-regulated by AML1-ETO without any
effect on the empty vectors (Figure 5A). These data confirm that
AML1-ETO down-regulates the transcriptional activity of PU.1 in
myeloid cells also. U937 cells express high levels of PU.1 and
C/EBP; therefore AML1-ETO might not only down-regulate
PU.1 but also C/EBP. Therefore only 50% down-regulation of the
promoters transfected into U937 cells could be seen. Furthermore,
there might be proteins in myeloid cells (in contrast to 293T or F9
cells) that might interfere with the capacity of AML1-ETO to block
PU.1 function.
Low expression of PU.1 target genes in patients with t(8;21)
To further understand if the down-regulation of the PU.1/c-Jun
transactivation capacity by AML1-ETO leads to down-regulation
of the PU.1 target genes, we performed FACS analysis of PU.1
target cell surface markers.7,51 In AML-M2 patients with t(8;21),
CD14, CD11b, and CD64 were 4.6-, 5.4-, and 5.8-fold less
expressed in comparison to patients with normal M2 karyotype
(Figure 5B). Regulation of CD11b promoter by PU.1 has been
shown51 and further analysis (by TRANSFAC analysis to identify
potential transcription factor-binding sites in a promoter) of the
promoter revealed potential AML1-binding sites were present (data
not shown). Down-regulation of CD11b might also be due to
down-regulation of AML1 in addition to PU.1’s transactivation
capacity by AML1-ETO. Similar analysis of CD14 and CD64
promoters showed (data not shown) that these gene promoters have
PU.1-binding sites but no C/EBP-, AML1-, or MEF-binding sites.
Therefore, CD14 and CD64 down-regulation could be due to
specific down-regulation of PU.1’s transactivation capacity by
AML1-ETO in these patients.
AML1-ETO causes proliferation of mouse bone marrow cells
by inhibiting PU.1
To investigate the functional consequences of AML1-ETO down-
regulating the transactivation capacity of PU.1, we transduced
mouse bone marrow cells with PU.1 (pGsam-NGFR-PU.1) and
AML1-ETO (PINCO-AML1-ETO-GFP). The cells transduced
with AML1-ETO rapidly increased in number over 12 days, as did
the cells overexpressed with AML1-ETO and PU.1 (Figure 6A).
The cells transduced with PU.1 showed no increase in cell number
(Figure 6A). Furthermore, transduction of AML1-ETO blocks
PU.1-induced monocytic differentiation in mouse bone marrow
cells (data not shown). The expression of transduced genes is
shown in Figure 6, panels B and C. Densitometric quantification of
the PU.1 protein expression in the same experiment revealed
down-regulation of endogenous PU.1 expression on overexpres-
sion of AML1-ETO (Figure 6B). This could be due to AML1-ETO
preventing the autoregulation of PU.1.54 The expression of AML1-
ETO was also quantified (data not shown).
Overexpression of PU.1 initiates differentiation in t(8;21)
Kasumi-1 cells
Our data so far shows that AML1-ETO interacts with PU.1 at the
34 region in the DNA-binding domain of PU.1 and displaces
c-Jun from binding and coactivating PU.1 (Figures 2 and 3).
Moreover, overexpression of AML1-ETO down-regulated the
PU.1 expression in mouse bone marrow cells (Figure 6B). It is
important to note that Kasumi-1 cells shows high levels of c-Jun
protein expression (Figure 2A). Hence, we asked whether overex-
pression of PU.1 could overcome the functional block of PU.1 by
AML1-ETO. Transient overexpression of PU.1 (pGsam-NGFR-
PU.1) in t(8;21)–bearing Kasumi-1 cells was performed. FACS
Figure 5. AML1-ETO down-regulates transactivation
capacity of PU.1 in myeloid cells and the expression
of the PU.1 target genes in AML patients with t(8;21).
(A) AML1-ETO down-regulates transactivation of PU.1 in
myeloid cells. U937 cells were electroporated with wild-
type M-CSF receptor promoter, M-CSF receptor pro-
moter without (w/o) AML1-binding site, p(PU.1)4TK,
p(mutPU.1)4TK, or pXP2 with and without AML1-ETO.
(B) Low expression of PU.1 target genes in patients with
t(8;21). AML patients (n  number of patients) with t(8;
21) have less positive cells for cell surface markers
regulated by PU.1 as compared to patients without
t(8;21). CD14 and CD64 promoters have PU.1-binding sites,
but no putative C/EPB-,AML1-, or MEF-binding sites.
Figure 6. The antiproliferative effect of PU.1 is down-regulated by AML1-ETO in mouse bone marrow cells. (A) AML1-ETO causes proliferation in mouse bone marrow
cells. Live transduced mouse bone marrow cells with PU.1, AML1-ETO, or PU.1 and AML1-ETO were counted on days 3, 6, and 12 after trypan blue staining. Because both the
empty vectors gave the same cell count, only one vector (PINCO) has been represented as mock. (B) Expression of PU.1 in mouse bone marrow cells. The cells of the
transduction described in the legend to Panel A were lysed and immunoblot assays were performed for PU.1 and -tubulin. NGFR (N; lysate of empty vector of PU.1), N-PU.1
(NGFR-PU.1–transduced cells), PINCO (P; lysate of empty vector of AML1-ETO–transduced cells), P-AML1-ETO (lysate of PINCO-AML1-ETO–transduced cells), and
P-AML1-ETON-PU.1 (lysate of PINCO-AML1-ETO– and NGFR-PU.1–transduced cells) were analyzed. The ratio of PU.1/-tubulin was calculated after densitometric
quantification of the bands.
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sorting (for NGFR) of the transfected cells showed the PU.1
expression, which was further shown by immunoblot analysis of
sorted cells for PU.1 expression (Figure 7B). Fourfold overexpres-
sion was observed after transfection (Figure 7B).
Five days after transfection of PU.1, morphologic changes
(Figure 7A) were observed by Wright-Giemsa staining of cells.
PU.1-transfected cells differentiated to the monocyte like cells,
whereas the empty vector (pGsam-NGFR) transfected cells showed
no morphologic change. The PU.1-transfected Kasumi-1 cells also
showed an increase in cell surface markers CD11b (Figure 7C;
marker for myeloid differentiation) and CD14 (Figure 7D; marker
for the monocytic lineage). At 24 hours after transfection, the
NGFR-sorted cells were further plated and counted for live cells
every 24 hours. In PU.1-transfected cells a decrease in cell number
was observed (Figure 7E).
Discussion
The importance of PU.1 in myeloid differentiation is well estab-
lished. Recently we have reported that PU.1 is mutated in patients
with AML13 similar to C/EBP,55 suggesting that PU.1 also plays a
major role in leukemogenesis. However, PU.1 was not found to be
mutated in AML patients with t(8;21), which suggests that distinct
pathways of inactivation of PU.1 might be occurring in t(8;21)
leukemia. We show here that PU.1 plays a major role in leukemo-
genesis in t(8;21) leukemia because it interacts with fusion protein
AML1-ETO (Figure 1A). We have previously reported a similar
phenomenon for C/EBP,36 an important transcription factor in
granulocytic differentiation. The physical interaction of PU.1 and
AML1-ETO results in inactivation of the transactivation activity of
PU.1 by displacing PU.1’s coactivator c-Jun (Figures 1B, 2B, 2C,
and 5A). AML1B was shown to interact with PU.1 and synergize
on M-CSF receptor promoter.10,56 In contrast, AML1B does not
influence PU.1’s transactivation capacity on a promoter driven by
PU.1-binding sites only (Figure 1C). These data taken together
suggest that AML1B and PU.1 synergy is possible in the promoters
having the respective binding sites in near proximity for physical
interaction, like the M-CSF receptor promoter.
We observed that AML1-ETO down-regulates the transcrip-
tional activity of PU.1 in myeloid cells (Figure 5A) and physically
interacts at the 34 region in the DNA-binding domain of PU.1
(Figure 3B). Our earlier data show that c-Jun, an AP-1 transcription
factor complex member, binds to the 34 region and coactivates
PU.1 in a JNK-independent manner.46 The competitive protein-
protein interaction experiments with in vitro–translated proteins
indicate that AML1-ETO disrupted PU.1/c-Jun interaction in a
Figure 7. Transient overexpression of PU.1 induces
differentiation toward the monocytic lineage in AML1-
ETO Kasumi-1 cells. (A) PU.1 induces differentiation in
t(8;21) Kasumi-1 cells. Kasumi-1 cells were transiently
transfected with PU.1 (pGsam-PU.1-ires-NGFR) or the
empty vector (pGsam-ires-NGFR) and morphologic
changes were observed on day 5. Arrows indicate the
differentiating cells. (B) PU.1 overexpression in Kasumi-1
cells. Western blot shows PU.1 expression and -tubulin
in transfected Kasumi-1 cells after day 5. (C) PU.1
induces CD11b expression in Kasumi-1 cells. FACS
analysis was performed for the cell surface expression of
CD11b in Kasumi-1 cells transfected with empty vector or
PU.1. (D) PU.1 induces CD14 expression in Kasumi-1
cells. In the same experiment FACS analysis was per-
formed for the cell surface expression of CD14 in Ka-
sumi-1 cells transfected with empty vector or PU.1. (E)
Kasumi-1 cell number decreases in PU.1-transfected
cells. The transfected cells described in the legend to
Panel D were counted by trypan blue staining on days 1,
2, 3, 4, and 5 after transfection. (F) Model of AML1-ETO
blocking PU.1 function. Model is of AML1-ETO interacting
with PU.1 and displacing its coactivator c-Jun. This
down-regulation of the PU.1 transcriptional activity by
AML1-ETO results in down-regulation of PU.1 target
genes important for myeloid differentiation.
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competitive manner (Figure 3B), thus blocking c-Jun from coacti-
vating PU.1. We have described a similar mechanism for GATA-150
and C/EBP.48 The role of c-Jun in myeloid differentiation was
shown to be rather important, because it could enhance the extent
of differentiation in U937 cells.57 In other studies AP-1 and
C/EBP were shown to cooperate in regulation of common target
genes, including the human TSG-6,58 collagenase-1 gene,59 and
tumor necrosis factor  (TNF-).60 These data suggest that the
capacity of c-Jun to coactivate PU.1 is also a very important
mechanism, which is down-regulated by AML1-ETO.
We observed that physical interaction between AML1-ETO and
PU.1 did not abolish the DNA- binding capacity of PU.1 (Figure
4A), although AML1-ETO interacted with the PU.1 DNA-binding
domain. Interestingly, in PU.1’s crystal structure,1 the 34 domain
does not interact with DNA, but is exposed to the solvent. This
structural ability allows PU.1 to retain its DNA binding though
being functionally repressed. We show here that the normal
interaction between coactivators and transcription factors are
altered in presence of AML1-ETO, which could be one of the
important mechanisms for disrupted myelopoiesis in t(8;21)
leukemia (Figure 7F).
AML1B and AML1-ETO have been shown to transactivate the
M-CSF receptor,42 suggesting that interaction between AML1B
and AML1-ETO could be important for leukemogenesis. To
investigate the importance of AML1-ETO/PU.1 interaction in
leukemogenesis, transactivation, proliferation, and differentiation
assays were performed in cells expressing wild-type AML1B
protein. In the presence of AML1-ETO, the M-CSF receptor
promoter was down-regulated and similarly the AML1 site mutated
M-CSF receptor promoter and minimal promoter containing only
PU.1-binding sites in U937 cells (Figure 5A). This could be
explained by a dual function of AML1-ETO in regulation of the
M-CSF receptor expression. During normal myeloid differentia-
tion, M-CSF receptor expression is required for G1-to-S phase
transition, which could be down-regulated by AML1-ETO through
the functional interaction with PU.1, and then AML1-ETO cooper-
ates with AML1B to up-regulate the M-CSF receptor expression
for transformation and proliferation of abnormal progenitor cells.
In patients with t(8;21), expression of the cell surface markers
CD11b, CD14, and CD64 was less in comparison to patients
without t(8;21) (Figure 5B). CD14 and CD64 promoters have
putative PU.1 binding sites but not AML1-, C/EBP-, or MEF-
binding sites suggesting that down-regulation of the function of
PU.1 by AML1-ETO could possibly be an important step in
progression toward leukemia. CD11b, another marker for differen-
tiation, was also less expressed in patients with t(8;21) in compari-
son to patients without t(8;21) (Figure 5B). CD11b is regulated by
PU.1 and its promoter contains putative binding sites of AML1. In
this case AML1-ETO interaction and down-regulation of important
myeloid transcription factors like PU.1 and AML1 could explain
the lower CD11b expression. The phenotype of PU.1/ mice
suggests that PU.1 is critical for myeloid differentiation and
development.4,11,12 Interaction of PU.1 with AML1-ETO and
subsequent suppression of PU.1 target genes (Figure 5B) might
contribute to the phenotypic changes seen in t(8;21). Furthermore,
PU.1 is a self-regulatory protein54 and AML1-ETO overexpression
in mouse bone marrow cells down-regulated the endogenous PU.1
expression (Figure 6B).
Because AML1/ mice lack PU.1 expression,61 AML1-ETO
could down-regulate PU.1 expression through repressing AML1
function. However, in a diseased condition or in presence of
AML1-ETO, like in Kasumi-1 cells, the expression of AML1 and
PU.1 genes was still observed. Furthermore, AML1 does not have a
down-regulatory effect on PU.1 (Figure 1C). Therefore, the
presence of AML1-ETO does not completely repress the expres-
sion levels of these genes, but may block their functions by
protein-protein interactions. To analyze the functional impact of
AML1-ETO on PU.1 in the presence of wild-type AML1B protein,
we performed experiments in cells expressing endogenous AML1B
protein. Overexpression of PU.1 in mouse bone marrow cells leads
to a block in proliferation, but in presence of AML1-ETO this
function of PU.1 was abrogated (Figure 6A). Recently, it was
shown that AML1-ETO expression in human progenitor cells leads
to expansion of human hematopoietic stem cells.62 Therefore, the
block of differentiation and increase in abnormal proliferation of
hematopoietic stem cells could be due to down-regulation of the
activity of PU.1 in t(8;21) leukemia.
Overexpression of PU.1 in t(8;21) Kasumi-1 cells differenti-
ates them toward the monocytic lineage (Figure 7). Morphologi-
cally, cells did not appear to be terminally differentiated even
though the cell surface markers CD11b and CD14 were increased
in expression. It has been earlier shown that short-term activation
of PU.1 in multipotent hematopoietic cells leads to immature
eosinophils.63 However, stable overexpression of PU.1 could lead
to myeloid lineage in hematopoietic progenitor cells.63 Therefore,
higher and stable expression of PU.1 in Kasumi-1 cells might be
needed to terminally differentiate toward the monocytic lineage.
The cell number of PU.1-transfected Kasumi-1 cells decreased
over a course of time (Figure 7E) showing that PU.1 functions as
an antiproliferative factor on overexpression in Kasumi-1 cells.
However, this mechanism needs to be further elucidated. Our
data suggest that the ectopic expression of PU.1 in Kasumi-1
cells overcomes the functional block by AML1-ETO. PU.1 and
C/EBP are important factors for myeloid differentiation and
AML1-ETO down-regulating these 2 factors could be an important
step toward leukemia. This also suggests the possibility of using
these 2 factors independently or in combination for therapy of
t(8;21) myeloid leukemias.
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